
<html lang="en"     class="pb-page"  data-request-id="60903c1b-0ff5-4af3-9142-6c764d63a02b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01663;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor" /></meta><meta name="dc.Creator" content="Chuan-Fei  Jin" /></meta><meta name="dc.Creator" content="Zhi-Zheng  Wang" /></meta><meta name="dc.Creator" content="Kang-Zhi  Chen" /></meta><meta name="dc.Creator" content="Teng-Fei  Xu" /></meta><meta name="dc.Creator" content="Ge-Fei  Hao" /></meta><meta name="dc.Description" content="Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. Inhibition of monoamine oxidase-B (MAO-B), which is mainly found in the glial cells of the brain, may lead..." /></meta><meta name="Description" content="Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. Inhibition of monoamine oxidase-B (MAO-B), which is mainly found in the glial cells of the brain, may lead..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 19, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01663" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01663" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01663" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01663" /></link>
        
    
    

<title>Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01663" /></meta><meta property="og:title" content="Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0016.jpeg" /></meta><meta property="og:description" content="Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. Inhibition of monoamine oxidase-B (MAO-B), which is mainly found in the glial cells of the brain, may lead to an elevated level of dopamine (DA) in patients. MAO-B inhibitors have been used extensively for patients with PD. However, the discovery of the selective MAO-B inhibitor is still a challenge. In this study, a computational strategy was designed for the rapid discovery of selective MAO-B inhibitors. A series of (S)-2-(benzylamino)propanamide derivatives were designed. In vitro biological evaluations revealed that (S)-1-(4-((3-fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (C3) was more potent and selective than safinamide, a promising drug for regulating MAO-B. Further studies revealed that the selectivity mechanism of C3 was due to the steric clash caused by the residue difference of Phe208 (MAO-A) and Ile199 (MAO-B). Animal studies showed that compound C3 could inhibit cerebral MAO-B activity and alleviate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuronal loss." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01663"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01663">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01663&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01663&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01663&amp;href=/doi/10.1021/acs.jmedchem.0c01663" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 15021-15036</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01607" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01514" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chuan-Fei Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chuan-Fei Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sunshine Lake Pharma Co. Ltd., Shenzhen 518000; HEC Pharm Group, HEC Research and Development Center, Dongguan 523871, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chuan-Fei++Jin">Chuan-Fei Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhi-Zheng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhi-Zheng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhi-Zheng++Wang">Zhi-Zheng Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kang-Zhi Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kang-Zhi Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sunshine Lake Pharma Co. Ltd., Shenzhen 518000; HEC Pharm Group, HEC Research and Development Center, Dongguan 523871, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kang-Zhi++Chen">Kang-Zhi Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teng-Fei Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teng-Fei Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sunshine Lake Pharma Co. Ltd., Shenzhen 518000; HEC Pharm Group, HEC Research and Development Center, Dongguan 523871, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teng-Fei++Xu">Teng-Fei Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ge-Fei Hao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ge-Fei Hao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Research and Development Center for Fine Chemicals, Guizhou University, Guiyang 550025, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#fd9a989b9894a2959c92bd9b9285909c9491d39e9290"><span class="__cf_email__" data-cfemail="74131112111d2b1c151b34121b0c19151d185a171b19">[email protected]</span></a>. Phone: +86085183620521.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ge-Fei++Hao">Ge-Fei Hao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4090-8411" title="Orcid link">http://orcid.org/0000-0003-4090-8411</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01663&amp;href=/doi/10.1021%2Facs.jmedchem.0c01663" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 15021–15036</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 19, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 September 2020</li><li><span class="item_label"><b>Published</b> online</span>19 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01663" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01663</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15021%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChuan-Fei%2BJin%252C%2BZhi-Zheng%2BWang%252C%2BKang-Zhi%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01663%26title%3DComputational%2BFragment-Based%2BDesign%2BFacilitates%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BMonoamine%2BOxidase-B%2B%2528MAO-B%2529%2BInhibitor%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15036%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01663"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1000</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01663" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chuan-Fei&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Zhi-Zheng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kang-Zhi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Teng-Fei&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Ge-Fei&quot;,&quot;last_name&quot;:&quot;Hao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15021-15036&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01663&quot;},&quot;abstract&quot;:&quot;Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. Inhibition of monoamine oxidase-B (MAO-B), which is mainly found in the glial cells of the brain, may lead to an elevated level of dopamine (DA) in patients. MAO-B inhibitors have been used extensively for patients with PD. However, the discovery of the selective MAO-B inhibitor is still a challenge. In this study, a computational strategy was designed for the rapid discovery of selective MAO-B inhibitors. A series of (S)-2-(benzylamino)propanamide derivatives were designed. In vitro biological evaluations revealed that (S)-1-(4-((3-fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (C3) was more potent and selective than safinamide, a promising drug for regulating MAO-B. Further studies revealed that the selectivity mechanism of C3 was due to the steric clash caused by the residue difference of Phe208 (MAO-A) and Ile199 (MAO-B). Animal studies showed that compound C3 could inhibit cerebral MAO-B activity and alleviate 1-m&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01663&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01663" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01663&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01663" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01663&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01663" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01663&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01663&amp;href=/doi/10.1021/acs.jmedchem.0c01663" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01663" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01663" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01663%26sid%3Dliteratum%253Aachs%26pmid%3D33210537%26genre%3Darticle%26aulast%3DJin%26date%3D2020%26atitle%3DComputational%2BFragment-Based%2BDesign%2BFacilitates%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BMonoamine%2BOxidase-B%2B%2528MAO-B%2529%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D15021%26epage%3D15036%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. Inhibition of monoamine oxidase-B (MAO-B), which is mainly found in the glial cells of the brain, may lead to an elevated level of dopamine (DA) in patients. MAO-B inhibitors have been used extensively for patients with PD. However, the discovery of the selective MAO-B inhibitor is still a challenge. In this study, a computational strategy was designed for the rapid discovery of selective MAO-B inhibitors. A series of (<i>S</i>)-2-(benzylamino)propanamide derivatives were designed. <i>In vitro</i> biological evaluations revealed that (<i>S</i>)-1-(4-((3-fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (<b>C3</b>) was more potent and selective than safinamide, a promising drug for regulating MAO-B. Further studies revealed that the selectivity mechanism of <b>C3</b> was due to the steric clash caused by the residue difference of Phe208 (MAO-A) and Ile199 (MAO-B). Animal studies showed that compound <b>C3</b> could inhibit cerebral MAO-B activity and alleviate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuronal loss.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is a serious prevalent progressive neurodegenerative motor disorder, and it affects around six million people worldwide over the age of 65. According to current estimates for the United States, the combined direct and indirect costs of PD are $25 billion per year, representing a heavy burden on patients, families, caregivers, and society.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In most cases, the existing therapies are palliative, which makes the development of effective drugs against PD a meaningful search.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Inhibition of monoamine oxidase-B (MAO-B) is involved in the pathogenesis of PD. MAO-B has been a pharmacological target for the treatment of PD since its inhibition boosts dopamine (DA) levels and is found to decrease in the striatum of PD patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Dopaminergic loss is considered a pathological hallmark of PD, and current therapeutic strategies have been focused on enhancing the levels of DA in the brain. Though various drugs for alleviating the symptoms of PD have been developed and used in clinics, MAO-B inhibitors have shown a more favorable safety profile.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">MAO-B inhibitors have drawn considerable attention, and a variety of MAO-B inhibitors are developed.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Selegiline, rasagiline, and safinamide are often used alone or in combination with levodopa for the treatment of PD in clinics.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, recent examples have disclosed a variety of new MAO-B inhibitors, such as chromone,<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9−15)</a> coumarin,<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> chalcone,<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25">(20−25)</a> and <i>N</i>-containing heterocyclic compounds<a onclick="showRef(event, 'ref11 ref16 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref11 ref16 ref26 ref27 ref28 ref29 ref30 ref31">(11,16,26−31)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In Borges’ studies, chromone derivatives were discovered as potential therapeutic compounds for relieving Parkinsonism, and these inhibitors exhibited promising activity against MAO-B.<a onclick="showRef(event, 'ref12 ref32'); return false;" href="javascript:void(0);" class="ref ref12 ref32">(12,32)</a> Gobec et al. found that geometric isomers of <i>cis</i>- and <i>trans</i>-1-propargyl-4-styrylpiperidines were potent MAO-B inhibitors and revealed the importance of their chirality for bioactivity.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Carradori et al. discovered flavonoid derivatives as reversible and competitive MAO inhibitors and characterized their inhibition model by Lineweaver–Burk plots.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, the nonselective irreversible inhibition of MAOs could lead to the accumulation of tyramine and is associated with a serious hypertensive crisis called the “cheese effect” triggered by the consumption of tyramine-rich food.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Meanwhile, the morbidity of PD is drastically increasing. Hence, there is still a pressing need to develop MAO-B inhibitors with good potency and high selectivity.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Known MAO-B inhibitors in clinical use and several research chemical scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fragment-based drug design (FBDD) is an effective method in modern medicinal research, especially for the identification of lead compounds.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Compared with high-throughput screening (HTS), the FBDD method had a higher hit rate because it may explore a larger chemical space.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Moreover, the hit compounds usually have a low molecular weight and high ligand efficiency. Therefore, hit compounds are more likely to act as a starting point for structural optimization to obtain high-quality leads.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> We have developed a computational FBDD method named pharmacophore-linked fragment virtual screening (PFVS), which has been used to discover the first <i>bc</i>1 complex inhibitor with picomolar activity.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We further optimized PFVS and developed a web server named Auto Core Fragment In Silico Screening (ACFIS).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These methods may supply a solution for discovering selective inhibitors of MAO-B.</div><div class="NLM_p last">In this study, we developed a computational strategy named steric clash-induced binding allostery (SCIBA) that led to the rapid discovery of highly potent and selective inhibitors targeting MAO-B. In the SCIBA strategy, the fragment that had a steric clash with a nontarget protein was regarded as the selective pharmacophore fragment. The linking fragments toward the unoccupied subpocket of the target protein were obtained through pharmacophore fragment-based virtual screening. The more the linking fragment match with the subpocket of the target protein, the more the pharmacophore fragment may induce binding allostery for the linking fragment in the subpocket of the nontarget protein. This allostery may weaken the binding affinity with nontarget and therefore produce better selectivity. The SCIBA strategy was conducted as the following steps: (1) safinamide was cut into two fragments according to the subpockets of MAO-A/MAO-B, (2) the binding free energy between fragments and MAO-A/MAO-B were calculated, (3) the fragment, steric clashed with MAO-A, had the highest binding free energy difference between MAO-A and MAO-B and, thus, was chosen as the pharmacophore, (4) fragment-based virtual screening on the unoccupied subpocket of MAO-B was performed to obtain a new linking fragment. A set of (<i>S</i>)-2-(benzylamino)propanamide derivatives was next designed and synthesized, and the bioactivities of the new compounds were evaluated. Among these new compounds, compound <b>C3</b>, which has an azetidine moiety, exhibited a much higher potency and selectivity than safinamide, a promising drug for regulating MAO-B. To the best of our knowledge, this strategy may be effective in extensively guiding the tuning of the selectivity of MAO-B, and (<i>S</i>)-2-(benzylamino)propanamide derivatives represent promising agents for the treatment of PD.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Selectivity Mechanism of Safinamide</h3><div class="NLM_p">We first compared the binding pockets of MAO-A and MAO-B.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The alignment showed that MAO-A and MAO-B share highly conserved protein sequences in their binding sites, and most of the residues, except for a pair of residues (Phe208 for MAO-A and Ile199 for MAO-B), do not exhibit an obvious effect on the binding pocket. The binding pockets in MAO-A and MAO-B could be divided into two subpockets, S1 and S2 for MAO-A and S1 and S2′ for MAO-B (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). MAO-B has a straight binding pocket, and the S1 and S2′ subpockets are divided by Ile199. However, for MAO-A, the residue change from Ile199 to Phe208 would change the shape of the binding pocket. The gatekeeper of the subpockets is Phe208, which is located in the center region of the binding pocket, and its bulkier side chain narrowed S1 in MAO-A (59 Å<sup>3</sup>) compared with MAO-B (76 Å<sup>3</sup>). Meanwhile, the S2 position was also changed compared with S2′ because the cleft was blocked by Phe208, leading to the curved shape of the binding pocket in MAO-A. Overall, the residue difference (Phe208 for MAO-A and Ile199 for MAO-B) was the main difference between the two binding pockets and led to a change in the shape of the binding pocket.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding pocket of MAO-A and MAO-B. (A) Docking result of MAO-A with safinamide. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y">2Z5Y</a> was used as docking receptor. (B) Crystal structure of MAO-B with safinamide (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>). The subpocket size of S1 was narrowed for MAO-A (59 Å<sup>3</sup>) compared with MAO-B (76 Å<sup>3</sup>) because of Phe208 of MAO-A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Then, we analyzed the binding mode of safinamide to understand the selectivity mechanism, which may inspire a design strategy. The binding mode of safinamide with MAO-A was predicted using molecular docking. The crystal structure of safinamide with MAO-B was retrieved from the RCSB Protein Data Bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>). For MAO-B, safinamide forms hydrophobic interactions with these residues, including Phe103, Leu164, Leu167, Leu171, Ile199, and Tyr398, and forms a hydrogen bond with Gln206. However, for MAO-A, the linear-type safinamide is not suitable for the curved binding site. The steric clash with Phe208 will make the 1-fluoro-3-phenoxymethylbenzene group bind to S2, which may change the binding conformation of safinamide. Therefore, safinamide cannot form a hydrogen bond with Gln215. Safinamide may have only hydrophobic interactions with Phe112 and Phe208. The residue difference from Ile199 (MAO-B) to Phe208 (MAO-A) caused a steric clash between safinamide and MAO-A, which would lead to the conformational change of safinamide and, therefore, weaken the binding affinity. The steric clash between MAO-A and the 1-fluoro-3-phenoxymethylbenzene group of safinamide may be the reason that safinamide has a selective index of 279 toward MAO-B compared to MAO-A.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Steric Clash-Induced Binding Allostery (SCIBA) Strategy</h3><div class="NLM_p">Based on the selectivity mechanism of safinamide, we designed a computational strategy for the discovery of selective MAO-B inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The selective mechanism of safinamide revealed that subpocket S2/S2′ played a key role because its steric clash with the 1-fluoro-3-phenoxymethylbenzene group of safinamide would change the conformation and was unfavorable for binding. Therefore, if we retained the 1-fluoro-3-phenoxymethylbenzene group and optimized the binding fragment near the flavin adenine dinucleotide (FAD) cofactor in subpocket S1 of MAO-B, we might obtain MAO-B inhibitors with higher activity and selectivity. Based on the predicted binding mode of MAO-A-safinamide and the crystal structure of MAO-B-safinamide, we first performed fragment deconstruction and calculated the binding free energy (Δ<i>G</i>) of each fragment. Meanwhile, the ligand efficiency (LE) value of each fragment was also calculated. LE could quantitatively evaluate the molecular properties, especially the size and lipophilicity, of small molecules that are required to enhance the binding affinity to a drug target.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> LE is defined as binding free energy (Δ<i>G</i>) divided by the nonhydrogen atom count (NHAC), LE = −Δ<i>G</i>/NHAC. There might be a series of fragments binding in subpocket A, and ΔLE (LE<sub>MAO-B</sub> – LE<sub>MAO-A</sub>) was used to judge the most selective fragment for the next virtual screening of fragments. This fragment would link with a fragment database built from FDA-approved drugs,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and the Δ<i>G</i> of generated compounds with MAO-A and MAO-B were calculated. The resulting compounds were sorted according to the Δ<i>G</i> values toward MAO-B, and the ΔΔ<i>G</i> (Δ<i>G</i><sub>MAO-B</sub> – Δ<i>G</i><sub>MAO-A</sub>) values were also calculated for the evaluation of selectivity. The SCIBA strategy could keep the fragment that caused the steric clash in a nontarget protein for selectivity and optimize the fragment into a lead compound through fragment virtual screening.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Workflow of the SCIBA strategy. Based on the binding mode of safinamide with MAO-A and MAO-B, fragment deconstruction and protein fragment Δ<i>G</i> calculations were performed. Then, the fragment with the highest ΔLE in complex with MAO-A and MAO-B was used for fragment screening. The newly generated compound with the lowest ΔΔ<i>G</i> value might be a selective inhibitor of MAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further investigate whether the 1-fluoro-3-phenoxymethylbenzene group could be used as the starting structure for fragment virtual screening, we performed a fragment deconstruction study on safinamide. The fragment deconstruction results are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf" class="ext-link">Table S1</a>. Notably, the 1-fluoro-3-phenoxymethylbenzene group (fragment <b>a</b>) had a Δ<i>G</i> of −21.76 kcal/mol toward MAO-B and the highest LE value of 1.36. We next analyzed the binding affinity of fragment <b>a</b> toward MAO-A. The Δ<i>G</i> of MAO-A:<b>a</b> was −9.28 kcal/mol, and the LE value was 0.58. The LE value was in a low stage among MAO-A and fragment complexes, and the ΔLE was the highest value of 0.78. Hence, fragment <b>a</b> could be regarded as a core fragment for subsequent fragment growth. The other generated fragments were also analyzed, and we found that fragments that contained 1-F-phenyl groups (fragments <b>a</b>, <b>b</b>, <b>g</b>, and <b>i</b>) had high ΔLE values. The fragment deconstruction analysis proved that the 1-fluoro-3-phenoxymethylbenzene group was important for the selectivity of safinamide and could be a good starting structure for fragment virtual screening.</div><div class="NLM_p last">Fragment virtual screening was performed based on fragment <b>a</b> in complex with MAO-A and MAO-B. We obtained ten hits with the most favorable Δ<i>G</i> values (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf" class="ext-link">Table S2</a>). Among these compounds, the compound with a chiral azacyclic amide had the best Δ<i>G</i> of −26.04 kcal/mol toward MAO-B, which was better than that of safinamide (−24.87 kcal/mol). Moreover, this compound had a Δ<i>G</i> of −12.41 kcal/mol toward MAO-A, and the ΔΔ<i>G</i> was −13.63 kcal/mol, which suggested that this compound might have a better selective index than safinamide (ΔΔ<i>G</i> = −8.66 kcal/mol).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> However, for other compounds, the bulky substituents would decrease the Δ<i>G</i> as there is a limited volume in subpocket S1 of MAO-B. We found that compounds containing pyrrolidine or morpholine moieties had worse Δ<i>G</i> values. However, the bulky substituents might contribute to the selective index, as most of these compounds had better ΔΔ<i>G</i> values than safinamide. The acylamino group of the compound with azetidine-3-carboxamide could not form a hydrogen bond with Gln206, and its Δ<i>G</i> (−23.47 kcal/mol) was higher than that of safinamide, which showed that the hydrogen bond with Gln206 was important. Based on these computational results and previous reports in this field, a series of (<i>S</i>)-2-(benzylamino)propanamide derivatives containing fragment <b>a</b> were synthesized.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">Based on the screening results above, we chose to prepare two chemical scaffolds. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> illustrates the synthetic pathways to derivatives <b>A1</b>–<b>A10</b> and <b>C1</b>–<b>C13</b>. Intermediates <b>a1</b>–<b>a5</b> were synthesized from material <b>1</b> by reacting with substituted 4-hydroxybenzaldehyde derivatives using K<sub>2</sub>CO<sub>3</sub> as the inorganic base. The target compounds <b>A1</b>–<b>A3</b> and <b>A9</b>–<b>A10</b> were prepared by reductive amination of intermediates <b>a</b> with the corresponding (<i>S</i>)-2-(benzylamino)propanamide derivatives. Then, the corresponding compound <b>A</b> reacted with 3-bromopropyne in the presence of K<sub>2</sub>CO<sub>3</sub> to obtain the corresponding target compounds <b>A5</b>–<b>A8</b>. In terms of compound <b>A4</b>, the coupling reaction of intermediate <b>a5</b> bearing -Br at R and cyclopropylboronic acid yielded <b>a6</b>, along with reductive amination with <span class="smallcaps smallerCapital">l</span>-alanine hydrochloride in the presence of NaBH<sub>3</sub>(CN) to produce the target compound <b>A4</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>A1</b>–<b>A10</b> and <b>C1</b>–<b>C13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (I) K<sub>2</sub>CO<sub>3</sub>, KI, EtOH, 85 °C, 12–18 h; (II and V) (<i>S</i>)-2-(benzylamino)propanamide derivatives, Et<sub>3</sub>N, AcOH, NaBH<sub>3</sub>(CN), MeOH, 0 °C-rt, 19 h; or <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), LiCl, MeOH, rt, 15 h, then KBH<sub>4</sub>, 0 °C, 2 h; (III) 3-bromopropyne, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), rt, 12 h; (IIII) cyclopropylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene/H<sub>2</sub>O, 100 °C, 4 h; (VI) NaBH<sub>4</sub>, MeOH, 0 °C-rt, 2–22 h; (VII) SOCl<sub>2</sub>, DMF, 0 °C, 2–5 h; and (VIII) (chiral) cyclic carboxamides, Et<sub>3</sub>N, DMF, rt, 6–17 h.</p></p></figure><div class="NLM_p last">For the preparation of <b>C1</b>–<b>C13</b>, compounds <b>a1</b>–<b>a4</b> were further reduced to intermediates <b>b1</b>–<b>b4</b> in the presence of NaBH<sub>4</sub>. Next, intermediates <b>b1</b>–<b>b4</b> were reacted with SOCl<sub>2</sub> to produce intermediates <b>c1</b>–<b>c4</b>. Finally, the target compounds <b>C1</b>–<b>C13</b> were obtained by the nucleophilic substitution reaction of <b>c1</b>–<b>c4</b> with (chiral) azetidine carboxamide, pyrrolidine-2-carboxamide, or morpholine-3-carboxamide derivatives.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> MAO Inhibitory Activity <i>In Vitro</i> and Structure–Activity Relationship (SAR) Studies</h3><div class="NLM_p">All of the synthesized (<i>S</i>)-2-(benzylamino)propanamide derivatives were evaluated for MAO-A and MAO-B inhibitory activities. The approved drugs, safinamide, selegiline, and clorgiline, were chosen as the MAO-B/MAO-A positive controls. The results from these <i>in vitro</i> assays are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Notably, all compounds had no inhibitory activity toward MAO-A at 2.1 μM, whereas compounds <b>A1</b>–<b>C3</b>, <b>A5</b>–<b>C8</b>, and <b>C2</b>–<b>C7</b> showed strong inhibitory activity toward MAO-B at this concentration. The simple halogen or alkyl modifications of safinamide on the phenyl ring at R achieved significantly more potent inhibitory activity against MAO-B (<b>A1</b>–<b>A3</b>); however, an exception to this is compound <b>A4</b>, which has a bulky cyclopropyl group, as it showed significantly diminished activity. When the propynyl group was introduced at R<sup>1</sup> of <b>A1</b>–<b>A3</b>, compounds with an electron-withdrawing -F (<b>A7</b>) or -Cl (<b>A8</b>) group displayed better MAO-B inhibitory potencies than the compound with an electron-donating methyl group (<b>A6</b>) at R<sup>1</sup>. Next, a series of compounds containing azacyclic amides were investigated (<b>C1</b>–<b>C13</b>). Replacement of the 3-position carboxamide by the 2-position carboxamide enhanced the potency (<b>C1</b> vs <b>C2</b>–<b>C6</b>). The MAO-B inhibitory activity of <b>C3</b> (IC<sub>50</sub> = 0.022 μM) was improved compared with compound <b>C2</b> (IC<sub>50</sub> = 0.046 μM), indicating that the chiral moiety is favorable for inhibiting MAO-B. Compound <b>C4</b>, bearing an electron-donating group (-Me), showed less inhibitory activity than <b>C3</b>, which is similar to selegiline (or safinamide). In comparison, compounds <b>C5</b>–<b>C6</b>, which bear electron-withdrawing groups (-F or -Cl), and compound <b>C3</b> showed fairly a potent inhibitory activity that was 6- and 10-fold more potent than that of selegiline (or safinamide), respectively. Of these azetidine moiety derivatives tested, compound <b>C3</b> provided the highest selectivity and activity. Then, the azetidine moiety was changed to a pyrrolidine or morpholine moiety to measure the activity against MAO-B. The results indicated that compound <b>C7</b> (IC<sub>50</sub> = 0.23 μM) displayed a similar potent inhibitory activity against MAO-B in comparison with safinamide. Nevertheless, none of these compounds (<b>C7</b>–<b>C13</b>) showed a more potent MAO-B inhibitory activity than compound <b>C3</b>. In general, these activities coincided with our computational results, which indicated that the ACFIS web server was quite reliable and that compound <b>C3</b> was a more potent and selective MAO-B inhibitor than safinamide.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values and Selectivity Indices of Compounds <b>A1–A10</b> for the Inhibition of MAO-A and MAO-B<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The results are expressed as the mean ± SD.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SI values for MAO-B were obtained by dividing the IC<sub>50</sub> values of MAO-A by those of MAO-B. “-” indicates no test.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values and Selectivity Indices of Compounds <b>C1–C13</b> for the Inhibition of MAO-A and MAO-B<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The results are expressed as the mean ± SD.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">SI values for MAO-B were obtained by dividing the IC<sub>50</sub> values of MAO-A by those of MAO-B. “-” indicates no test.</p></div></div><div></div></div><div class="NLM_p">Comparative molecular field analysis (CoMFA) was a straightforward tool to perform the 3D-QSAR study and has been used in the MAO-B inhibitors. Carradori et al. constructed a CoMFA model for a series of hydrazothiazole derivatives and provided useful guidelines for further structural optimization.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> We used the Cloud 3D-QSAR web server (<a href="http://cloud3dqsar.cn/" class="extLink">http://cloud3dqsar.cn/</a>) to construct our CoMFA model (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The cross-validation correlation coefficient (<i>q</i><sup>2</sup>) was 0.757, and the number of optimum components (NOC) was 6. Meanwhile, the noncross-validated correlation coefficient (<i>r</i><sup>2</sup>) was 0.988, the standard error of estimate (SEE) was 0.121, and F-statistic values (F) was 24018, while the predictive correlation coefficient (<i>r</i><sub>pred</sub><sup>2</sup>) value was 0.762 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). The high <i>q</i><sup>2</sup> and <i>r</i><sub>pred</sub><sup>2</sup> (>0.5) indicated that our model might be a reliable CoMFA model. The contributions of the steric and electrostatic fields were 40.8 and 59.2%, respectively. For the steric contour map, there was a green contour near the four-membered ring, which indicated that the bulky group would increase the activity; for example, compound <b>C3</b> has better activity than safinamide. But a yellow contour was surrounding the green contour map, which means adding substituent group in this region was unfavorable to activity, such as <b>C8</b>, <b>C9</b>, and <b>C10</b>. For the electrostatic contour map, there was a series contour near the acid amide group, which suggested its importance to the activity. From CoMFA analysis, we found and explained that the ring with suitable shape and acid amide derivation were significant groups to the MAO-B inhibition.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Result of CoMFA analysis. (A) Correlation between the experimental versus predicted activities of training and test set of MAO-B. (B) Contour maps of the CoMFA model, <b>C3</b> was used as the template compound. For the steric field, green contours and yellow contours represent favorable and unfavorable regions for bulky groups. For the electrostatic field, blue contours indicate the favorable region for positively charged groups, while red contours indicate the favorable region for negatively charged groups. (C) Statistical result of the CoMFA model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The chiral center was a structural feature for our MAO-B inhibitors; therefore, we investigate the effect of different stereoisomers on the bioactivity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). For compounds <b>A1–A10</b>, they shared a similar scaffold with safinamide and were in an (<i>S</i>) configuration. From the docking result, we could find that (<i>R</i>)-safinamide had almost the same interactions with MAO-B as (<i>S</i>)-safinamide. The only difference was the methyl group, which might have a steric clash with Tyr398. Hence, we also calculated the binding free energy of each compound. The result showed that (<i>S</i>)-safinamide had similar binding free energy (−24.87 kcal/mol) with (<i>R</i>)-safinamide (−23.47 kcal/mol). Inversely, the chiral centers of compounds <b>C3–C13</b> were located in a stereo ring structure. The configurational change may lead to the disappearance of the hydrogen bond with key residue Gln206. Hence, the binding free energy of (<i>R</i>)-<b>C3</b> (−22.63 kcal/mol) was significantly decreased compared with (<i>S</i>)-<b>C3</b> (−26.04 kcal/mol). It was noticed that (<i>S</i>)-<b>C3</b> (IC<sub>50</sub> = 0.021 μM) has better bioactivity against MAO-B than the raceme <b>C2</b> (IC<sub>50</sub> = 0.046 μM), which is consistent with our docking result. Hence, the chiral center will be more important for the activity when (<i>S</i>)-configurations of compounds <b>C3–C13</b> form hydrogen bonds with key residue Gln206.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of compounds in different configurations with MAO-B. The binding mode of (<i>S</i>)-safinamide with MAO-B (A) came from the crystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>), and (<i>S</i>)-safinamide is shown in the yellow stick. The binding mode of (<i>R</i>)-safinamide (B), (<i>S</i>)-<b>C3</b> (C), and (<i>R</i>)-<b>C3</b> (D) with MAO-B was predicted via molecular docking. <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a> was used as the docking receptor. (<i>R</i>)-safinamide, (<i>S</i>)-<b>C3</b>, and (<i>R</i>)-<b>C3</b> are shown in green, peach, and cyan stick, respectively. Hydrogen bonds are given in the black dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Measurement of Inhibitory Activity against MAOs in the Mouse Brain</h3><div class="NLM_p">To determine whether compound <b>C3</b> could inhibit MAOs <i>in vivo</i>, we measured the activity of MAOs in the mouse brain. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a, compound <b>C3</b> (In the current study, <b>C3</b> methanesulfonate was used in animal experiments, while <b>C3</b> was used in in vitro assay.) significantly inhibited MAO-B activity at 80 μg/kg (intraperitoneal; i.p.) and exhibited more potent MAO-B inhibitory activity at 400 μg/kg. Moreover, <b>C3</b> displayed much stronger MAO-B inhibitory activity than safinamide at the same dose (400 μg/kg), while no significant inhibition of MAO-A was observed (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). These results demonstrated that compound <b>C3</b> was a functional inhibitor of MAO-B in the brains of mice.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>C3</b> on MAO activity in the brains of mice. MAO-B (a) and MAO-A (b) inhibitory activities with Saf (400 μg/kg) as a positive control. Data are shown as the mean ± standard error of the mean (SEM): *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001 vs Ctrl, <i>N</i> = 6, Saf: Safinamide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Reversibility of MAO-B Inhibition</h3><div class="NLM_p">To explore the reversibility/irreversibility toward the MAO-B inhibitor, the most potent MAO-B inhibitor compound <b>C3</b> was selected to study by the time course of mice brain MAO-B inhibition. We found that 50% of MAO-B activity was recovered within 5 h after the administration of <b>C3</b> and 100% recovery was obtained 24 h later. These findings demonstrated that <b>C3</b> was a reversible MAO-B inhibitor (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of mice brain MAO-B inhibition <i>ex vivo</i> by a single dose of <b>C3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Effect of <b>C3</b> on Dopamine (DA) Levels in the Mouse Striatum</h3><div class="NLM_p">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the only known dopaminergic neurotoxin capable of causing a clinical picture in both humans and monkeys indistinguishable from PD. MPTP-induced neurochemical, behavioral, and histopathological alterations replicate the clinical symptoms of PD patients very closely. Moreover, MPTP produces a reliable and reproducible lesion of the nigrostriatal dopaminergic pathway after its systemic administration, which is often not the case for other documented poisons. Based on these reasons, the MPTP model has been the most commonly used. Many of the studies geared toward unraveling the mechanisms and underlying the demise of dopaminergic neurons have been performed in mice.<a onclick="showRef(event, 'ref47 ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49 ref50 ref51 ref52 ref53">(47−53)</a> MPTP is converted to 1-methyl-4-phenylpyridinium (MPP+) through MAO-B. The toxic metabolite MPP+ is translocated by the vesicular monoamine transporter to dopaminergic neurons and then damages these neurons. MAO-B inhibitors can protect against neurotoxicity by preventing the conversion of MPTP to MPP+, resulting in protection from the neuronal cell loss induced by MPP+ in mice.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">MAO-B is generally abundant in the brain and it is necessary to inhibit at least 80% of the enzyme to achieve a pharmacological effect.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> MAO-B inhibition of <b>C3</b> at 16, 80, and 400 μg/mg were 25.70, 53.35, and 93.23% <i>ex vivo</i>, respectively (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf" class="ext-link">Table S3</a> in the Supporting Information). Thus, the doses of <b>C3</b> in MPTP mice were determined. We selected 0.1, 1, and 3 mg/kg to inhibit >80% MAO-B in brain and 1 and 3 mg/kg were chosen to achieve pharmacological effects.</div><div class="NLM_p">DA level changes in the mouse striatum were analyzed to first investigate the protective activities against DA deficits after treatment with <b>C3</b>. The changes of DA levels in MPTP-treated C57BL/6 mice are shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a. MPTP (30 mg/kg) was administered i.p. to C57BL/6 mice, and <b>C3</b> (0.1, 1.0, 3.0 mg/kg) or safinamide (3.0 mg/kg) was administered i.p, 30 min before the administration of MPTP. The results showed that DA levels were significantly decreased in the striatal of MPTP-injected mice (<i>p</i> < 0.001 vs Ctrl) compared with that of the control animals. Administration of <b>C3</b> resulted in a significant increase in DA levels at 100 μg/kg (i.p.) compared with the MPTP-alone-injected group (<i>p</i> < 0.05 vs MPTP alone). Moreover, the DA levels in <b>C3</b>-treated mice were as high as those in safinamide-treated mice at the same dose (3.0 mg/kg), suggesting that compound <b>C3</b> has potential efficacy for alleviating DA deficits in the MPTP-induced PD mouse model.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Effects of <b>C3</b> pretreatment on MPTP-induced DA depletion in the striatum. (b) Effects of <b>C3</b> on the DA concentration in the striatum administered with LD/benserazide (50.0/12.5 mg/kg) in MPTP mice. Saf (3.0 mg/kg) is the positive control. Data are shown as the mean ± SEM: <sup>###</sup><i>P</i> < 0.001 vs Ctrl; *<i>P</i> < 0.05, **<i>P</i> < 0.01 vs MPTP alone; <sup>$</sup><i>P</i> < 0.05, <sup>$$</sup><i>P</i> < 0.01, <sup>$$$</sup><i>P</i> < 0.001 vs LD/benserazide, <i>N</i> = 8, Saf: Safinamide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><b>C3</b> inhibits MAO-B and prevents the formation of the toxic intermediate. To prove the effect of <b>C3</b> on PD, <b>C3</b> is administered after MPTP combined with <span class="smallcaps smallerCapital">l</span><b>-</b>dopa (LD) and benserazide. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b, DA levels were significantly decreased in the striatal area of MPTP-injected animals (<i>p</i> < 0.001 vs Ctrl) compared with that of the control animals. In the LD/benserazide--treated group, DA levels were increased compared with those in the MPTP-alone-treated group (<i>p</i> < 0.05 vs MPTP alone). After coadministration with <b>C3</b> and LD/benserazide, DA levels were significantly increased (<i>P</i> < 0.05, <i>P</i> < 0.01 vs LD/benserazide). These results showed that <b>C3</b> significantly increased the effect of levodopa on dopamine concentration in the striatum.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Selectivity Mechanism of <b>C3</b></h3><div class="NLM_p">To study the selectivity mechanism of <b>C3</b>, we analyzed the binding mode of <b>C3</b> with MAO-A and MAO-B using molecular docking (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Notably, for MAO-B, compound <b>C3</b> was in an extended conformation and could have hydrophobic interactions with surrounding residues as well as a hydrogen bond with Gln206. However, for MAO-A, compound <b>C3</b> had an unfavorable conformation. Because of the side chain of Phe208, <b>C3</b> could not form hydrogen bonds with MAO-A. Moreover, the steric clash caused by Phe208 causes <b>C3</b> to have a conformational flip and is located in subpocket S2, which is located away from the hydrophobic region that consists of Phe173, Leu176, and Ile180. Hence, the binding pocket difference caused by Phe208 for MAO-A and Ile199 for MAO-B might lead <b>C3</b> to have different binding affinities and be a highly selective MAO-B inhibitor.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Proposed binding mode of compound <b>C3</b> with MAO-A (A) and MAO-B (B) via molecular docking. Crystal structures of MAO-A (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y">2Z5Y</a>) and MAO-B (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>) were used in docking. Compound <b>C3</b> is shown as a peach stick model. The hydrogen bonds are shown as black dotted lines. (C) Δ<i>G</i> of <b>C3</b> with MAO-A and MAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further validate the binding mode by taking into account the flexibility of compound <b>C3</b>, we performed 20 ns molecular dynamics (MD) simulations and calculated the Δ<i>G</i> of compound <b>C3</b> with MAO-A and MAO-B. The Δ<i>G</i> of <b>C3</b> with MAO-A and MAO-B was −13.66 and −21.48 kcal/mol, respectively, which coincided with the observed activity and indicated that <b>C3</b> is a selective inhibitor of MAO-B. The Δ<i>E</i><sub>VDW</sub> and Δ<i>E</i><sub>ELE</sub> of MAO-B were −62.30 and −51.30 kcal/mol, respectively, which are much lower than those of MAO-A, and this might be due to the extensive interactions of <b>C3</b> with MAO-B. In addition, the binding conformation of <b>C3</b> in MAO-A had a higher potential energy, which was unfavorable to the binding affinity. Therefore, the difference in the binding pocket caused by Phe208 (MAO-A) and Ile199 (MAO-B) would lead to an increase in the Δ<i>G</i> and might be the key reason for the selectivity mechanism. This conclusion could explain the activity difference between MAO-A:<b>C3</b> and MAO-B:<b>C3</b>. The MD simulation and Δ<i>G</i> calculation results coincided well with the docking results and suggested that the steric clash between <b>C3</b> and MAO-A made <b>C3</b> exhibit a high selectivity toward MAO-B.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23726" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23726" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The discovery of selective MAO-B inhibitors is always a challenge for the treatment of PD. The present study aimed to explore an effective and widely used design strategy to rapidly discover selective MAO-B inhibitors. To this end, we designed a computational strategy, which keeps the group that caused a steric clash with MAO-A and optimizes this group into a lead compound of MAO-B through fragment virtual screening. We synthesized a series of (<i>S</i>)-2-(benzylamino)propanamide derivatives based on this strategy. Compound <b>C3</b>, containing a chiral azacyclic amide moiety, was found to have the highest <i>in vitro</i> activity and selectivity, and the experimental results were explained with molecular modeling. Compound <b>C3</b> exhibited a promising selectivity (the selectivity index between MAO-A and MAO-B was 1227-fold), which was much better than that of safinamide (the selective index was 268-fold). A molecular modeling study revealed the selectivity mechanism of <b>C3</b>, which was due to the steric clash caused by Phe208 of MAO-A. Moreover, <i>in vivo</i> biochemical assays revealed that compound C3 significantly inhibited MAO-B. Overall, our finding indicates that <b>C3</b> could be a promising selective inhibitor of MAO-B and serve as a lead compound for the treatment of PD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Procedures</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Molecular Docking Simulations</h3><div class="NLM_p last">The molecular docking was performed using AutoDock Vina.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> The PDB IDs of MAO-A and MAO-B were <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y">2Z5Y</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>, respectively. The proteins were retrieved from the RCSB Protein Data Bank and prepared by adding hydrogen atoms, repairing side chains, and removing water molecules. The cofactor FAD was retained as the receptor. The ligand was docked into the active site of MAO-A and MAO-B. Twenty poses were exported for further analysis.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Fragment Deconstruction Analysis</h3><div class="NLM_p last">The fragment deconstruction analysis was a three-step process. (1) The minimization procedure was first performed on the MAO-A:safinamide and MAO-B:safinamide complexes in Amber 16. (2) Safinamide binding in the pocket was deconstructed into a series of fragments. (3) The Δ<i>G</i> values were calculated for each protein-fragment complex using the MM-PBSA method.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The LE was defined as Δ<i>G</i> divided by the NHAC<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (LE = −ΔG/NHAC) and ΔLE (LE<sub>MAO-B</sub> – LE<sub>MAO-A</sub>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacophore-Linked Fragment Virtual Screening (PFVS)</h3><div class="NLM_p last">Fragment <b>a</b> in complex with MAO-A and MAO-B were selected as starting structures, and a database containing 2883 fragments from FDA-approved drugs were linked to fragment <b>a</b>. After a minimization procedure, the Δ<i>G</i> value of each newly generated compound was calculated using the MM-PBSA method.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p">Unless otherwise specified, all common reagents, solvents, and several (<i>S</i>)-2-(benzylamino)propanamide derivatives were obtained from commercial suppliers and used without purification. Column chromatography was carried out on silica gel (200–300 mesh). Melting points were determined on an MP70 melting point apparatus and were uncorrected. All new products were further characterized by high-resolution mass spectrometry (HRMS) obtained on a time-of-flight (TOF) liquid chromatography–mass spectrometry (LC/MS) mass spectrometer equipped with an electrospray ionization (ESI) source. <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 400 and III HD 600 spectrometer in DMSO-<i>d</i><sub>6</sub>, CDCl<sub>3</sub>, and chemical shifts were recorded in parts per million (ppm) with tetramethylsilane (TMS) as the internal standard. All target compounds were purified to ≥95% purity, as determined by an Agilent 1620 high-performance liquid chromatography (HPLC) System with a flow rate of 1 mL/min and a gradient of 10% MeCN/90% aqueous sodium perchlorate solution (pH = 2.5) to 80% MeCN/20% aqueous sodium perchlorate solution (pH = 2.5) in 30 min using a diode array detector. An Agilent Eclipse Plus C18 (4.6 mm × 100 mm, 3.5 μm) was used. The purity was based on the integrated ultraviolet (UV) chromatogram (230 or 270 nm).</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Procedure for Preparation of Intermediates <b>a1–a6</b></h4><div class="NLM_p">K<sub>2</sub>CO<sub>3</sub> (5.27 g, 38.19 mmol, 1.10 equiv) and KI (0.58 g, 3.47 mmol, 0.10 equiv) were added to a stirred suspension of 4-hydroxybenzaldehyde derivatives (36.46 mmol, 1.05 equiv) and 3-fluorobenzyl chloride (5.00 g, 34.72 mmol, 1.00 equiv) in EtOH (30 mL). The reaction mixture was refluxed at 85 °C for 12–18 h, and then the solvent was removed under vacuum. Water (30 mL) was added and the mixture was stirred for 3 h. Subsequently, a filtration operation was conducted to obtain a white solid, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The mixture was washed with water (10 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under vacuum after filtration to afford the products <b>a1, a3</b>–<b>a5</b>. For 4-hydroxybenzaldehyde bearing 2-Me, after the reaction was finished, the solvent was then removed under vacuum and the residue was purified by chromatography on silica gel, eluting with (EA/PE 1:5 (v/v)) to afford compound <b>a2</b>.</div><div class="NLM_p last">To a solution of <b>a5</b> (309 mg, 1.00 mmol, 1 equiv) in toluene/H<sub>2</sub>O (5.00 mL, 4:1) were added Pd(PPh<sub>3</sub>)<sub>4</sub> (116 mg, 0.10 mmol, 0.10 equiv), cyclopropylboronic acid (103 mg, 1.20 mmol, 1.20 equiv), and K<sub>3</sub>PO<sub>4</sub> (656 mg, 3.00 mmol, 3.00 equiv). The resulting mixture was stirred at 100 °C for 4 h under N<sub>2</sub> and concentrated under vacuum. The residue was then purified by flash column chromatography on silica gel, eluting with (EA/PE 1:10 (v/v)) to give <b>a6</b>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-((3-Fluorobenzyl)oxy)benzaldehyde (<b>a1</b>)</h4><div class="NLM_p last">White solid, yield: 92%, mp 46–47 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.89 (s, 1H), 7.85–7.83 (m, 2H), 7.39–7.34 (m, 1H), 7.20 (d, <i>J</i> = 4.0 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.08–7.01 (m, 3H), 5.14 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.6, 163.4, 163.0 (d, <i>J</i> = 245.0 Hz), 138.5 (d, <i>J</i> = 7.0 Hz), 132.0, 130.4, 130.3 (d, <i>J</i> = 8.0 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 115.1, 114.2 (d, <i>J</i> = 22.0 Hz), 69.4 (d, <i>J</i> = 2.0 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>12</sub>FO<sub>2</sub> ([M + H]<sup>+</sup>): 231.0816, found 231.0805.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-((3-Fluorobenzyl)oxy)-2-methylbenzaldehyde (<b>a2</b>)</h4><div class="NLM_p last">Yellow oil, yield: 96%; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 10.11 (s, 1H), 7.75 (d, <i>J</i> = 12.0 Hz, 1H), 7.37–7.34 (m, 1H), 7.19 (d, <i>J</i> = 6.0 Hz, 1H), 7.14 (d, <i>J</i> = 12.0 Hz, 1H), 7.03 (td, <i>J</i> = 12.0, 6.0 Hz, 1H), 6.89 (dd, <i>J</i> = 12.0, 6.0 Hz, 1H), 6.82 (d, <i>J</i> = 6.0 Hz, 1H), 5.11 (s, 2H), 2.64 (s, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 191.1, 162.9 (d, <i>J</i> = 246.0 Hz), 162.4, 143.3, 138.6 (d, <i>J</i> = 7.5 Hz), 134.7, 130.2 (d, <i>J</i> = 7.5 Hz), 128.3, 122.7 (d, <i>J</i> = 3.0 Hz), 117.8, 115.1 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 112.1, 69.13 (d, <i>J</i> = 1.5 Hz), 19.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>15</sub>H<sub>14</sub>FO<sub>2</sub> ([M + H]<sup>+</sup>): 245.0972, found 245.0975.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Fluoro-4-((3-fluorobenzyl)oxy)benzaldehyde (<b>a3</b>)</h4><div class="NLM_p last">White solid, yield: 97%, mp 89–91 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.20 (s, 1H), 7.82 (t, <i>J</i> = 8.0 Hz, 1H), 7.40–7.34 (m, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.05 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.84 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.70 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 5.12 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 185.8 (d, <i>J</i> = 4.5 Hz), 166.1 (d, <i>J</i> = 258.0 Hz), 164.8 (d, <i>J</i> = 10.5 Hz), 163.0 (d, <i>J</i> = 246.0 Hz), 137.9 (d, <i>J</i> = 7.5 Hz), 130.4 (d, <i>J</i> = 9.0 Hz), 130.2 (d, <i>J</i> = 3.0 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 118.3 (d, <i>J</i> = 9.0 Hz), 115.4 (d, <i>J</i> = 21.0 Hz), 114.3 (d, <i>J</i> = 22.5 Hz), 111.8 (d, <i>J</i> = 3.0 Hz), 102.4 (d, <i>J</i> = 24.0 Hz), 69.8 (d, <i>J</i> = 3.0 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>F<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 249.0722, found 249.0718.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Chloro-4-((3-fluorobenzyl)oxy)benzaldehyde (<b>a4</b>)</h4><div class="NLM_p last">White solid, yield: 96%, mp 92–93 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.35 (d, <i>J</i> = 0.8 Hz, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.42–7.37 (m, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.07 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 7.03 (d, <i>J</i> = 4.0 Hz, 1H), 6.97 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 5.14 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 188.4, 163.0 (d, <i>J</i> = 245.0 Hz), 163.3, 139.6, 137.9 (d, <i>J</i> = 7.0 Hz), 131.1, 130.4 (d, <i>J</i> = 8.0 Hz), 126.4, 122.7 (d, <i>J</i> = 3.0 Hz), 116.2, 115.3 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 114.1, 69.7 (d, <i>J</i> = 2.0 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>ClFO<sub>2</sub> ([M + H]<sup>+</sup>): 265.0426, found 265.0428.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Bromo-4-((3-fluorobenzyl)oxy)benzaldehyde (<b>a5</b>)</h4><div class="NLM_p last">White solid, yield: 90%, mp 80–82 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.21 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.44–7.34 (m, 1H), 7.21 (d, <i>J</i> = 4.0 Hz, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.04 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 5.12 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.4, 163.3, 163.0 (d, <i>J</i> = 246.0 Hz), 138.0 (d, <i>J</i> = 7.0 Hz), 131.5, 130.41 (d, <i>J</i> = 9.0 Hz), 128.6, 127.5, 122.8 (d, <i>J</i> = 3.0 Hz), 119.5, 115.4 (d, <i>J</i> = 21.0 Hz), 114.7, 114.3 (d, <i>J</i> = 22.0 Hz), 69.7 (d, <i>J</i> = 2.0 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>BrFO<sub>2</sub> ([M + H]<sup>+</sup>): 308.9921, found 308.9933.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Cyclopropyl-4-((3-fluorobenzyl)oxy)benzaldehyde (<b>a6</b>)</h4><div class="NLM_p last">Yellow oil, yield: 77%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.42 (s, 1H), 7.79 (d, <i>J</i> = 8.0 Hz, 1H), 7.38–7.33 (m, 1H), 7.19–7.13 (m, 2H), 7.03 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.85 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.66 (d, <i>J</i> = 0.6 Hz, 1H), 5.09 (s, 2H) 2.68–2.64 (m, 1H), 1.09–1.04 (m, 2H), 0.77–0.73 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 191.2, 163.0 (d, <i>J</i> = 246.0 Hz), 163.0, 149.0, 138.7 (d, <i>J</i> = 6.0 Hz), 133.1, 130.3 (d, <i>J</i> = 7.5 Hz), 129.0, 122.8 (d, <i>J</i> = 3.0 Hz), 115.2 (d, <i>J</i> = 21.0 Hz), 114.3 (d, <i>J</i> = 22.5 Hz), 112.9, 111.8, 69.24 (d, <i>J</i> = 3.0 Hz), 11.9, 8.7. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>17</sub>H<sub>16</sub>FO<sub>2</sub> ([M + H]<sup>+</sup>): 271.1129, found 271.1129.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure for Preparation of Target Compounds <b>A0–A4</b></h4><div class="NLM_p last">The corresponding intermediate <b>a</b> (2.20 mmol, 1.00 equiv), <span class="smallcaps smallerCapital">l</span>-alaninamide hydrochloride (0.27 g, 2.20 mmol, 1.00 equiv), Et<sub>3</sub>N (0.20 mL, 2.20 mmol, 1.00 equiv), and AcOH (0.25 mL, 4.40 mmol, 2.00 equiv) in MeOH (20 mL) were stirred at room temperature for 3 h and then cooled to 0 °C, followed by the addition of NaBH<sub>3</sub>(CN) (0.21g, 3.29 mmol, 1.50 equiv). The resultant solution was stirred for 19 h at room temperature and then evaporated under vacuum. The crude residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed with aqueous NaHCO<sub>3</sub> (10 mL) and H<sub>2</sub>O, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The residue was purified by chromatography on silica gel, eluting with (MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1:10 (v/v)) to afford the compounds <b>A0</b>–<b>A4</b>.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide (<b>A0</b>)<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></h4><div class="NLM_p last">White solid, yield: 51%, mp 117–118 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 1H), 7.23 (s, 1H), 7.21 (s, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.15–7.10 (m, 2H), 7.00 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.92 (d, <i>J</i> = 8.0 Hz, 2H), 5.04 (s, 2H), 3.71 (dd, <i>J</i> = 20.0, 12.0 Hz, 2H), 3.26 (q, <i>J</i> = 8.0 Hz, 1H), 1.33 (d, <i>J</i> = 4.0 Hz, 3H). HPLC purity: 97.73%.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)-2-methylbenzyl)amino)propanamide (<b>A1</b>)</h4><div class="NLM_p last">White solid, yield: 48%, mp 89–90 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.30 (m, 1H), 7.23–7.11 (m, 3H), 7.07 (s, 1H), 7.02–6.97 (m, 1H), 6.80 (s, 1H), 6.75 (d, <i>J</i> = 8.0 Hz, 1H), 6.24 (s, 1H), 5.02 (s, 2H), 3.72–3.65 (m, 2H), 3.25 (q, <i>J</i> = 8.0 Hz, 1H), 2.32 (s, 3H), 1.34 (d, <i>J</i> = 4.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ178.4, 163.0 (d, <i>J</i> = 245.0 Hz), 157.7, 139.8 (d, <i>J</i> = 8.0 Hz), 137.8, 130.4, 130.1 (d, <i>J</i> = 8.0 Hz), 129.8, 122.7 (d, <i>J</i> = 3.0 Hz), 117.2, 114.7 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 111.9, 69.1 (d, <i>J</i> = 2.0 Hz), 58.1, 49.9, 19.7, 19.2. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 317.1660, found 317.1660. HPLC purity: 96.32%.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-2-((2-Fluoro-4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide (<b>A2</b>)</h4><div class="NLM_p last">White solid, yield: 33%, mp 112–113 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.31 (m, 1H), 7.17 (d, <i>J</i> = 8.0 Hz, 2H), 7.13 (d, <i>J</i> = 12.0 Hz, 1H), 7.01 (td, <i>J</i> = 8.0, 2.0 Hz, 1H), 6.71–6.66 (m, 2H), 5.03 (s, 2H), 3.73 (dd, <i>J</i> = 36.0, 12.0 Hz, 2H), 3.21 (q, <i>J</i> = 8.0 Hz, 1H), 1.31 (d, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 178.1, 163.0 (d, <i>J</i> = 246.0 Hz), 161.8 (d, <i>J</i> = 244.5 Hz), 159.1 (d, <i>J</i> = 10.5 Hz), 138.9 (d, <i>J</i> = 7.5 Hz), 131.0 (d, <i>J</i> = 6.0 Hz), 130.2 (d, <i>J</i> = 7.5 Hz), 122.6 (d, <i>J</i> = 3.0 Hz), 118.9 (d, <i>J</i> = 16.5 Hz), 115.0 (d, <i>J</i> = 21.0 Hz), 114.1 (d, <i>J</i> = 21.0 Hz), 110.4 (d, <i>J</i> = 3.0 Hz), 102.8 (d, <i>J</i> = 24.0 Hz), 69.4 (d, <i>J</i> = 1.5 Hz), 57.5, 46.1 (d, <i>J</i> = 1.5 Hz), 19.7. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>17</sub>H<sub>19</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 321.1409, found 321.1409. HPLC purity: 97.57%.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-2-((2-Chloro-4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide (<b>A3</b>)</h4><div class="NLM_p last">White solid, yield: 53%, mp 129–130 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.32 (m, 1H), 7.23–7.12 (m, 4H), 7.04–7.00 (m, 2H), 6.85 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 5.59 (s, 1H), 5.06 (s, 2H), 3.81 (dd, <i>J</i> = 40.0, 12.0 Hz, 2H), 3.24 (q, <i>J</i> = 8.0 Hz, 1H), 1.35 (d, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 178.0, 163.0 (d, <i>J</i> = 244.5 Hz), 158.4, 139.0 (d, <i>J</i> = 7.5 Hz), 134.5, 131.3, 130.2 (d, <i>J</i> = 7.5 Hz), 129.4, 122.7 (d, <i>J</i> = 3.0 Hz), 116.3, 115.0 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 113.5, 69.5 (d, <i>J</i> = 1.5 Hz), 57.5, 49.9, 19.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>17</sub>H<sub>19</sub>FClN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 337.1114, found 337.1112. HPLC purity: 98.03%.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-2-((2-Cyclopropyl-4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide (<b>A4</b>)</h4><div class="NLM_p last">White solid, yield: 46%, mp 98–99 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 1H), 7.19–7.13 (m, 4H), 7.02–6.98 (m, 1H), 6.73 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 6.60 (d, <i>J</i> = 4.0 Hz, 1H), 5.96 (s, 1H), 5.01 (s, 2H), 3.92–3.85 (m, 2H), 3.28 (q, <i>J</i> = 8.0 Hz, 1H), 2.01–1.94 (m, 1H), 1.35 (d, <i>J</i> = 8.0 Hz, 3H), 0.96–0.94 (m, 2H), 0.67 (d, <i>J</i> = 4.0 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.3, 163.0 (d, <i>J</i> = 245.0 Hz), 158.1, 142.9, 139.7 (d, <i>J</i> = 7.0 Hz), 131.4, 130.1 (d, <i>J</i> = 8.0 Hz), 129.9, 122.7 (d, <i>J</i> = 3.0 Hz), 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 112.8, 111.3, 69.2 (d, <i>J</i> = 1.0 Hz), 58.0, 49.8, 19.7, 12.7, 7.7, 7.7. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>20</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 343.1816, found 343.1791. HPLC purity: 98.64%.</div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure for Preparation of Target Compounds <b>A5–A8</b></h4><div class="NLM_p last">The mixture of corresponding <b>A</b> (0.57 mmol, 1.00 equiv), 3-Bromopropyne (0.06 mL, 0.70 mmol, 1.20 equiv), K<sub>2</sub>CO<sub>3</sub> (0.94 g, 6.84 mmol, 12 equiv), and DMF (10 mL) was stirred at room temperature for 12 h. After this, H<sub>2</sub>O (30 mL) was added to the mixture and extracted with AcOEt (30 mL × 2). The combined organic layer was washed with H<sub>2</sub>O (20 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was purified by chromatography on silica gel, eluting with (EA/PE 1:2 (v/v)) to afford the compounds <b>A5</b>–<b>A8</b>.</div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)benzyl)(prop-2-yn-1-yl)amino)propanamide (<b>A5</b>)</h4><div class="NLM_p last">White solid, yield: 40%, mp 87–88 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28–7.09 (m, 4H), 7.04–6.84 (m, 4H), 5.03 (s, 2H), 3.71 (d, <i>J</i> = 16.0 Hz, 1H), 3.54 (d, <i>J</i> = 12.0 Hz, 1H), 3.46–3.41 (m, 1H), 3.28 (s, 2H), 2.26 (s, 1H), 1.36 (d, <i>J</i> = 4.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.3, 162.9 (d, <i>J</i> = 245.0 Hz), 157.9, 139. 5 (d, <i>J</i> = 7.0 Hz), 130.2, 130. 1 (d, <i>J</i> = 8.0 Hz), 130.0, 122.6 (d, <i>J</i> = 2.0 Hz), 114.9, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 78.7 (d, <i>J</i> = 15.0 Hz), 73.4 (d, <i>J</i> = 17.0 Hz), 69.2 (d, <i>J</i> = 2.0 Hz), 60.9, 54.3, 40.0, 38.6, 12.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>20</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 341.1660, found 341.1666. HPLC purity: 99.63%.</div></div><div id="sec4_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)-2-methylbenzyl)(prop-2-yn-1-yl)amino)propanamide (<b>A6</b>)</h4><div class="NLM_p last">White solid, yield: 90%, mp 98–100 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 1H), 7.23–7.13 (m, 3H), 7.03 (t, <i>J</i> = 8.0 Hz, 1H), 6.83–6.74 (m, 3H), 5.03 (s, 2H), 3.84 (d, <i>J</i> = 12.0 Hz, 1H), 3.52 (d, <i>J</i> = 16.0 Hz, 1H), 3.43–3.38 (m, 1H), 3.32 (s, 2H), 2.35 (s, 3H), 1.37 (d, <i>J</i> = 4.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 177.3, 162.9 (d, <i>J</i> = 244.5 Hz), 157.7, 139.6 (d, <i>J</i> = 7.5 Hz), 138.7, 130. 7, 130.0 (d, <i>J</i> = 9.0 Hz), 128.2, 122.6, 117.1, 114.7 (d, <i>J</i> = 21.0 Hz), 114.1(d, <i>J</i> = 22.5 Hz), 111.7, 79.1, 73.4, 69.0, 60.3, 52.2, 38.9, 19.5, 12.2. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>21</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 355.1816, found 355.1816. HPLC purity: 98.97%.</div></div><div id="sec4_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-2-((2-Fluoro-4-((3-fluorobenzyl)oxy)benzyl)(prop-2-yn-1-yl)amino)propanamide (<b>A7</b>)</h4><div class="NLM_p last">White solid, yield: 71%, mp 89–91 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.33 (m, 1H), 7.28 (s, 1H), 7.19–7.12 (m, 2H), 7.04–7.02 (m, 1H), 6.73–6.66 (m, 2H), 5.04 (s, 2H), 3.69 (s, 2H), 3.40–3.23 (m, 3H), 2.29 (s, 1H), 1.40 (d, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 177.1, 162.9 (d, <i>J</i> = 246.0 Hz), 162.2 (d, <i>J</i> = 246.0 Hz), 159.4 (d, <i>J</i> = 10.5 Hz), 138.9 (d, <i>J</i> = 7.5 Hz), 132.2, 130.2 (d, <i>J</i> = 7.5 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 116.8, 115.0 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 110.5, 102.9 (d, <i>J</i> = 27.0 Hz), 78.5, 73.7, 69.4, 61.3, 48.9, 38.6, 13.4. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>20</sub>H<sub>21</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 359.1566, found 359.1570. HPLC purity: 99.57%.</div></div><div id="sec4_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-2-((2-Chloro-4-((3-fluorobenzyl)oxy)benzyl)(prop-2-yn-1-yl)amino)propanamide (<b>A8</b>)</h4><div class="NLM_p last">White solid, yield: 67%, mp 117–118 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.31 (m, 2H), 7.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.04–7.00 (m, 2H), 6.84 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 5.03 (s, 2H), 3.78 (dd, <i>J</i> = 72.0, 12.0 Hz, 2H), 3.43 (q, <i>J</i> = 8.0 Hz, 1H), 3.34–3.23 (m, 2H), 1.39 (d, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.9, 163.0 (d, <i>J</i> = 245.0 Hz), 158.5, 138.9 (d, <i>J</i> = 7.0 Hz), 135.2, 132.0, 130.2 (d, <i>J</i> = 8.0 Hz), 127.7, 122.7 (d, <i>J</i> = 3.0 Hz), 116.4, 115.0 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 113.6, 79.1, 73.7, 69.5 (d, <i>J</i> = 2.0 Hz), 60.7, 52.2, 39.1, 12.4. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>20</sub>H<sub>21</sub>ClFN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 375.1270, found 375.1271. HPLC purity: 98.71%.</div></div><div id="sec4_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Procedure for Preparation of Target Compounds <b>A9–A10</b></h4><div class="NLM_p last">The corresponding intermediate <b>a</b> (1.78 mmol, 1.00 equiv), (<i>S</i>)-2-aminopropanamide derivatives (1.78 mmol, 1.00 equiv), DIPEA (0.15 mL, 0.89 mmol, 0.50 equiv), and LiCl (0.04 g, 0.89 mmol, 0.50 equiv) in MeOH (10 mL) were stirred at room temperature for 15 h and then cooled to 0 °C, followed by addition of KBH<sub>4</sub> (0.096 g, 1.78 mmol, 1.00 equiv). The resultant solution was stirred for 2 h at the same temperature and then evaporated under vacuum. The residue was purified by chromatography on silica gel, eluting with (MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1:30 (v/v)) to afford the compounds <b>A9</b>–<b>A10</b>.</div></div><div id="sec4_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)-<i>N</i>-methyl-<i>N</i>-(prop-2-yn-1-yl)propanamide (<b>A9</b>)</h4><div class="NLM_p last">Colorless oil, yield: 72%;<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.32 (m, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.16 (d, <i>J</i> = 12.0 Hz, 1H), 7.01 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.93 (s, 1H), 6.91 (s, 1H), 5.06 (s, 2H), 4.33–4.21 (m, 1H), 3.74–3.68 (m, 1H), 3.65–3.50 (m, 2H), 3.05–3.01 (m, 3H), 2.19 (s, 2H), 1.29–1.23 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.2, 163.0 (d, <i>J</i> = 245.0 Hz), 157.6, 139.8 (d, <i>J</i> = 7.0 Hz), 132.5, 130.1 (d, <i>J</i> = 8.0 Hz), 129.7, 122.7 (d, <i>J</i> = 3.0 Hz), 114.8, 114.7 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 78.6, 72.0, 69.2 (d, <i>J</i> = 2.0 Hz), 52.2, 51.3, 36.6, 33.8, 18.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>21</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 355.1816, found 355.1815. HPLC purity: 99.07%.</div></div><div id="sec4_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)-<i>N</i>-(2-morpholinoethyl)propanamide (<b>A10</b>)</h4><div class="NLM_p last">Colorless oil, yield: 56%;<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H),7.36–7.30 (m, 1H), 7.27 (d, <i>J</i> = 8.0 Hz, 2H), 7.19–7.13 (m, 2H), 7.00 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.91 (d, <i>J</i> = 8.0 Hz, 2H), 5.04 (s, 2H), 3.71–3.63 (m, 6H), 3.47–3.39 (m, 1H), 3.34–3.21 (m, 2H), 2.49–2.44 (m, 6H), 1.30 (d, <i>J</i> = 4.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.8, 162.9 (d, <i>J</i> = 244.0 Hz), 157.7, 139.6 (d, <i>J</i> = 8.0 Hz), 132.3, 130.1 (d, <i>J</i> = 8.0 Hz), 129.2, 122.6 (d, <i>J</i> = 3.0 Hz), 114.8, 114.7 (d, <i>J</i> = 22.0 Hz), 114.0 (d, <i>J</i> = 22.0 Hz), 69.2 (d, <i>J</i> = 1.8 Hz), 66.9, 57.9, 57.4, 53.4, 51.9, 35.2, 19.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>23</sub>H<sub>30</sub>FN<sub>3</sub>NaO<sub>3</sub> ([M + Na]<sup>+</sup>): 438.2163, found 438.2151. HPLC purity: 98.43%.</div></div><div id="sec4_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure for Preparation of Intermediates <b>b1–b4</b></h4><div class="NLM_p last">To a solution of the intermediate <b>a</b> (17.39 mmol, 1.00 equiv) in MeOH (20 mL) was added NaBH<sub>4</sub> (0.99 g, 26.09 mmol, 1.50 equiv) at 0 °C slowly. After this, the mixture was stirred at room temperature for 2–22 h and then evaporated under vacuum. The resulting residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and was washed with brine and then dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under vacuum after filtration to obtain intermediates <b>b1</b>–<b>b4</b>.</div></div><div id="sec4_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (4-((3-Fluorobenzyl)oxy)phenyl)methanol (<b>b1</b>)</h4><div class="NLM_p last">White solid, yield: 94%, mp 69–70 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.32 (m, 1H), 7.30 (s, 1H), 7.27 (s, 1H), 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.16 (d, <i>J</i> = 12.0 Hz, 1H), 7.01 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.96 (s, 1H), 6.94 (s, 1H), 5.06 (s, 2H), 4.60 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 244.0 Hz), 158.0, 139.6 (d, <i>J</i> = 7.0 Hz), 133.7, 130.1 (d, <i>J</i> = 8.0 Hz), 128.6, 122.6 (d, <i>J</i> = 3.0 Hz), 114.9, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 69.2 (d, <i>J</i> = 2.0 Hz), 64.8. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>12</sub>FO ([M – OH]<sup>+</sup>): 215.0867, found 215.0859.</div></div><div id="sec4_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (4-((3-Fluorobenzyl)oxy)-2-methylphenyl)methanol (<b>b2</b>)</h4><div class="NLM_p last">Yellow oil, yield: 98%; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.36–7.32 (m, 1H), 7.23 (d, <i>J</i> = 6.0 Hz, 1H), 7.19 (d, <i>J</i> = 6.0 Hz, 1H), 7.16 (d, <i>J</i> = 6.0 Hz, 1H), 7.01 (td, <i>J</i> = 12.0, 6.0 Hz, 1H), 6.82 (d, <i>J</i> = 6.0 Hz, 1H), 6.77 (dd, <i>J</i> = 12.0, 6.0 Hz, 1H), 5.05 (s, 2H), 4.62 (s, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 244.5 Hz), 158.1, 139.7 (d, <i>J</i> = 7.5 Hz), 138.2, 131.7, 130.1 (d, <i>J</i> = 7.5 Hz), 129.5, 122.7 (d, <i>J</i> = 3.0 Hz), 117.2, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 111.7, 69.1 (d, <i>J</i> = 1.5 Hz), 63.2, 18.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>15</sub>H<sub>14</sub>FO ([M – OH]<sup>+</sup>): 229.1023, found 229.1029.</div></div><div id="sec4_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (2-Fluoro-4-((3-fluorobenzyl)oxy)phenyl)methanol (<b>b3</b>)</h4><div class="NLM_p last">Yellow oil, yield: 90%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.34 (m, 1H), 7.31 (t, <i>J</i> = 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.04 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 6.76 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 6.69 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 5.05 (s, 2H), 4.66 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 246.0 Hz), 161.3 (d, <i>J</i> = 246.0 Hz), 159.4 (d, <i>J</i> = 10.5 Hz), 139.0 (d, <i>J</i> = 7.5 Hz), 130.4 (d, <i>J</i> = 6.0 Hz), 130.2 (d, <i>J</i> = 7.5 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 120.5 (d, <i>J</i> = 16.5 Hz), 115.0 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 21.0 Hz), 110.6 (d, <i>J</i> = 3.0 Hz), 102.7 (d, <i>J</i> = 25.5 Hz), 69.5 (d, <i>J</i> = 1.5 Hz), 59.0 (d, <i>J</i> = 4.5 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>F<sub>2</sub>O ([M – OH]<sup>+</sup>): 233.0772, found 233.0779.</div></div><div id="sec4_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (2-Chloro-4-((3-fluorobenzyl)oxy)phenyl)methanol (<b>b4</b>)</h4><div class="NLM_p last">White solid, yield: 70%, mp 73–74 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.32 (m, 2H), 7.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 12.0 Hz, 1H), 7.03 (d, <i>J</i> = 8.0 Hz, 1H), 6.99 (d, <i>J</i> = 4.0 Hz, 1H), 6.86 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 5.03 (s, 2H), 4.69 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 162.9 (d, <i>J</i> = 244.5 Hz), 158.5, 138.9 (d, <i>J</i> = 7.5 Hz), 133.6, 130.8, 130.2 (d, <i>J</i> = 7.5 Hz), 130.0, 122.6 (d, <i>J</i> = 1.5 Hz), 115.9, 115.0 (d, <i>J</i> = 21.0 Hz), 114.1 (d, <i>J</i> = 22.5 Hz), 113.5, 69.4 (d, <i>J</i> = 1.5 Hz), 62.4. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>ClFO ([M – OH]<sup>+</sup>): 249.0477, found 249.0472.</div></div><div id="sec4_4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> General Procedure for Preparation of Intermediates <b>c1–c4</b></h4><div class="NLM_p last">SOCl<sub>2</sub> (0.92 g, 7.75 mmol, 1.20 equiv) was dropped slowly into a solution of the corresponding intermediates <b>b1</b>–<b>b4</b> (6.46 mmol, 1.00 equiv) in DMF (5 mL) at 0 °C. The solution was stirred for 2–5 h, and then water (20 mL) was added to this mixture. The mixture was stirred at room temperature for 0.5 h. After extraction by CH<sub>2</sub>Cl<sub>2</sub> (20 mL), the combined organic solvent was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum after filtration to give intermediates <b>c1</b>–<b>c4</b>.</div></div><div id="sec4_4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-((4-(Chloromethyl)phenoxy)methyl)-3-fluorobenzene (<b>c1</b>)</h4><div class="NLM_p last">White solid, yield: 93%, mp 54–55 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.35 (m, 1H), 7.34 (s, 1H), 7.32 (s, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 12.0 Hz, 1H), 7.03 (td, <i>J</i> = 8.0, 2.4 Hz, 1H), 6.97 (s, 1H), 6.95 (s, 1H), 5.07 (s, 2H), 4.58 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 244.5 Hz), 158.6, 139.4 (d, <i>J</i> = 7.5 Hz), 130.3 (d, <i>J</i> = 6.0 Hz), 130.2, 130.1, 122.7 (d, <i>J</i> = 3.0 Hz), 115.1, 114.9 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 69.2 (d, <i>J</i> = 1.8 Hz), 46.2. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>12</sub>FO ([M – Cl]<sup>+</sup>): 215.0867, found 215.0869.</div></div><div id="sec4_4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-(Chloromethyl)-4-((3-fluorobenzyl)oxy)-2-methylbenzene (<b>c2</b>)</h4><div class="NLM_p last">Colorless oil, yield: 55%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38–7.33 (m, 1H), 7.25–7.15 (m, 3H), 7.03 (td, <i>J</i> = 8.0, 2.0 Hz, 1H), 6.85 (d, <i>J</i> = 4.0 Hz, 1H), 6.78 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 5.05 (s, 2H), 4.61 (s, 2H), 2.43 (s, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 244.5 Hz), 158.9, 139.56 (d, <i>J</i> = 7.5 Hz), 139.2, 131.3, 130.2 (d, <i>J</i> = 9.0 Hz), 128.5, 122.7 (d, <i>J</i> = 3.0 Hz), 117.3, 114.9 (d, <i>J</i> = 21.0 Hz), 114.21 (d, <i>J</i> = 22.5 Hz), 112.1, 69.1 (d, <i>J</i> = 1.5 Hz), 44.9, 19.1. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>15</sub>H<sub>14</sub>FO ([M – Cl]<sup>+</sup>): 229.1023, found 229.0993.</div></div><div id="sec4_4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-(Chloromethyl)-2-fluoro-4-((3-fluorobenzyl)oxy)benzene (<b>c3</b>)</h4><div class="NLM_p last">Yellow oil, yield: 92%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.35 (m, 1H), 7.34–7.26 (m, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.04 (t, <i>J</i> = 8.0 Hz, 1H), 6.75 (d, <i>J</i> = 8.0 Hz, 1H), 6.70 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 5.05 (s, 2H), 4.61 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 244.5 Hz), 160.5, 160.1 (d, <i>J</i> = 10.5 Hz), 138.8 (d, <i>J</i> = 7.5 Hz), 131.6 (d, <i>J</i> = 4.5 Hz), 130.3 (d, <i>J</i> = 7.5 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 117.4 (d, <i>J</i> = 15.0 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 111.0 (d, <i>J</i> = 3.0 Hz), 102.8 (d, <i>J</i> = 25.5 Hz), 69.5 (d, <i>J</i> = 1.5 Hz), 39.5 (d, <i>J</i> = 4.5 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>F<sub>2</sub>O ([M – Cl]<sup>+</sup>): 233.0772, found 233.0776.</div></div><div id="sec4_4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-Chloro-1-(chloromethyl)-4-((3-fluorobenzyl)oxy)benzene (<b>c4</b>)</h4><div class="NLM_p last">Colorless oil, yield: 87%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.34 (m, 2H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 12.0 Hz, 1H), 7.06–7.02 (m, 2H), 6.87 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 5.05 (s, 2H), 4.67 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 163.0 (d, <i>J</i> = 246.0 Hz), 159.2, 138.7 (d, <i>J</i> = 7.5 Hz), 135.1, 131.9, 130.3 (d, <i>J</i> = 9.0 Hz), 127.8, 122.7 (d, <i>J</i> = 3.0 Hz), 116.2, 115.1 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 113.9, 69.5 (d, <i>J</i> = 1.5 Hz), 43.6. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>14</sub>H<sub>11</sub>FClO ([M – Cl]<sup>+</sup>): 249.0477, found 249.0487.</div></div><div id="sec4_4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for Preparation of Target Compounds <b>C1–C13</b></h4><div class="NLM_p last">The mixture of <b>c1</b>–<b>c4</b> (1.52 mmol, 1.00 equiv), (chiral) carboxamide derivatives (1.82 mmol, 1.20 equiv), NEt<sub>3</sub> (0.46 g, 4.56 mmol), and DMF (4 mL) was stirred at room temperature for 6–17 h. Water (30 mL) was added and the mixture was stirred for 0.5 h, followed by filtration to afford the crude product, which was purified by flash column chromatography on silica gel (EA) to give target compounds.</div></div><div id="sec4_4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(4-((3-Fluorobenzyl)oxy)benzyl)azetidine-3-carboxamide (<b>C1</b>)</h4><div class="NLM_p last">White solid, yield: 71%, mp 149–150 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.45–7.40 (m, 1H), 7.31–7.25 (m, 2H), 7.20–7.12 (m, 3H), 6.94 (d, <i>J</i> = 8.0 Hz, 2H), 5.10 (s, 2H), 3.48 (s, 4H), 3.33 (t, <i>J</i> = 8.0 Hz, 2H), 3.12–3.05 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.1, 162.7 (d, <i>J</i> = 242.0 Hz), 157.7, 140.6 (d, <i>J</i> = 7.0 Hz), 130.9 (d, <i>J</i> = 8.0 Hz), 130.6, 130.1, 123.9 (d, <i>J</i> = 3.0 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 115.0, 114.6 (d, <i>J</i> = 22.0 Hz), 68.8 (d, <i>J</i> = 1.0 Hz), 62.0, 56.6, 34.7. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 315.1503, found 315.1501. HPLC purity: 99.91%.</div></div><div id="sec4_4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(4-((3-Fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (<b>C2</b>)</h4><div class="NLM_p last">White solid, yield: 60%, mp 118–119 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (d, <i>J</i> = 4.0 Hz, 1H), 7.18–7.17 (m, 3H), 7.00–6.98 (m, 2H), 6.91–6.90 (m, 2H), 5.04 (s, 2H), 3.63 (d, <i>J</i> = 8.0 Hz, 2H), 3.51 (d, <i>J</i> = 12.0 Hz, 1H), 3.32 (s, 1H), 2.98 (d, <i>J</i> = 8.0 Hz, 1H), 2.39 (d, <i>J</i> = 8.0 Hz, 1H), 2.22–2.07 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 176.1, 162.9 (d, <i>J</i> = 244.5 Hz), 157.8, 139.5 (d, <i>J</i> = 7.5 Hz), 130.1 (d, <i>J</i> = 7.5 Hz), 129.8, 122.7 (d, <i>J</i> = 1.5 Hz), 114.9, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.5 Hz), 69.2 (d, <i>J</i> = 1.5 Hz), 65.9, 61.6, 50.5, 22.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 315.1503, found 315.1504. HPLC purity: 97.85%.</div></div><div id="sec4_4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>S</i>)-1-(4-((3-Fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (<b>C3</b>)</h4><div class="NLM_p last">White solid, yield: 50%, mp 94–95 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (d, <i>J</i> = 8.0 Hz, 1H), 7.19 (s, 1H), 7.16–7.13 (m, 2H), 7.01–6.98 (m, 2H), 6.92–6.90 (m, 2H), 5.04 (s, 2H), 3.63 (d, <i>J</i> = 8.0 Hz, 2H), 3.51 (d, <i>J</i> = 12.0 Hz, 1H), 3.32 (s, 1H), 2.99 (d, <i>J</i> = 4.0 Hz, 1H), 2.40 (d, <i>J</i> = 8.0 Hz, 1H), 2.24–2.03 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.0, 163.0 (d, <i>J</i> = 244.0 Hz), 157.9, 139.6 (d, <i>J</i> = 8.0 Hz), 130.1 (d, <i>J</i> = 8.0 Hz), 130.0, 129.9, 122.7 (d, <i>J</i> = 3.0 Hz), 114.9, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 69.2 (d, <i>J</i> = 2.0 Hz), 66.0, 61.6, 50.6, 22.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 315.1503, found 315.1504. HPLC purity: 97.99%.</div></div><div id="sec4_4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>S</i>)-1-(4-((3-Fluorobenzyl)oxy)-2-methylbenzyl)azetidine-2-carboxamide (<b>C4</b>)</h4><div class="NLM_p last">White solid, yield: 64%, mp 98–100 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, <i>J</i> = 4.0 Hz, 1H), 7.19–7.17 (m, 1H), 7.12–7.10 (m, 1H), 7.00 (s, 1H), 6.85 (s, 1H), 6.79 (s, 1H), 6.73 (s, 1H), 5.02 (s, 2H), 3.75–3.46 (m, 3H), 3.33 (s, 1H), 2.99 (d, <i>J</i> = 4.0 Hz, 1H), 2.40 (s, 1H), 2.33 (s, 3H), 2.16 (d, <i>J</i> = 8.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.1, 163.0 (d, <i>J</i> = 245.0 Hz), 157.9, 139.7 (d, <i>J</i> = 7.0 Hz), 138.0, 130.4, 130.1 (d, <i>J</i> = 8.0 Hz), 128.3, 122.7 (d, <i>J</i> = 3.0 Hz), 117.3, 114.7 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 111.7, 69.1 (d, <i>J</i> = 1.0 Hz), 66.4, 59.7, 50.8, 23.0, 19.3. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 329.1660, found 329.1660. HPLC purity: 97.93%.</div></div><div id="sec4_4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>S</i>)-1-(2-Fluoro-4-((3-fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (<b>C5</b>)</h4><div class="NLM_p last">White solid, yield: 56%, mp 104–105 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.47–7.42 (m, 1H), 7.34 (t, <i>J</i> = 12.0 Hz, 1H), 7.30–7.28 (m, 2H), 7.18–7.15 (m, 2H), 7.02 (s, 1H), 6.89 (dd, <i>J</i> = 12.0, 2.3 Hz, 1H), 6.82 (dd, <i>J</i> = 12.0, 2.4 Hz, 1H), 5.13 (s, 2H), 3.62 (d, <i>J</i> = 12.0 Hz, 1H), 3.51–3.47 (m, 2H), 3.15–3.12 (m, 1H), 2.91–2.87 (m, 1H), 2.19 (qd, <i>J</i> = 12.0, 2.2 Hz, 1H), 1.98–1.92 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.7, 162.7 (d, <i>J</i> = 242.0 Hz), 161.6 (d, <i>J</i> = 242.0 Hz), 159.2 (d, <i>J</i> = 11.0 Hz), 140.1 (d, <i>J</i> = 8.0Hz), 132.4 (d, <i>J</i> = 7.0 Hz), 131.0 (d, <i>J</i> = 8.0 Hz), 124.0 (d, <i>J</i> = 3.0 Hz), 116.9 (d, <i>J</i> = 15.0 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 114.7 (d, <i>J</i> = 22.0 Hz), 111.2 (d, <i>J</i> = 3.0 Hz), 102.7 (d, <i>J</i> = 25.5 Hz), 69.2, 65.7, 54.2, 50.2, 22.5. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>19</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 333.1409, found 333.1412. HPLC purity: 98.17%.</div></div><div id="sec4_4_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>S</i>)-1-(2-Chloro-4-((3-fluorobenzyl)oxy)benzyl)azetidine-2-carboxamide (<b>C6</b>)</h4><div class="NLM_p last">White solid, yield: 72%, mp 128–130 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 7.18–7.17 (m, 2H), 7.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 12.0 Hz, 1H), 6.99 (s, 1H), 6.85–6.77 (m, 1H), 5.01 (s, 2H), 3.74 (d, <i>J</i> = 12.0 Hz, 1H), 3.67 (t, <i>J</i> = 8.0 Hz, 1H), 3.57 (d, <i>J</i> = 12.0 Hz, 1H), 3.28 (t, <i>J</i> = 4.0 Hz, 1H), 3.00 (dd, <i>J</i> = 16.0, 8.0 Hz, 1H), 2.39 (dd, <i>J</i> = 20.0, 8.0 Hz, 1H), 2.21–2.07 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.1, 162.9 (d, <i>J</i> = 245.0 Hz), 158.4, 138.9 (d, <i>J</i> = 7.0 Hz), 134.8, 131.4, 130.1 (d, <i>J</i> = 8.0 Hz), 127.3, 122.6 (d, <i>J</i> = 3.0 Hz), 116.2, 114.9 (d, <i>J</i> = 21.0 Hz), 114.1 (d, <i>J</i> = 22.0 Hz), 113.4, 69.4 (d, <i>J</i> = 1.0 Hz), 65.7, 58.8, 50.6, 22.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>18</sub>H<sub>19</sub>ClFN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 349.1114, found 349.1113. HPLC purity: 99.09%.</div></div><div id="sec4_4_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>S</i>)-1-(4-((3-Fluorobenzyl)oxy)benzyl)pyrrolidine-2-carboxamide (<b>C7</b>)</h4><div class="NLM_p last">White solid, yield: 76%, mp 121–122 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36 (dd, <i>J</i> = 12.0, 8.0 Hz, 1H), 7.23–7.16 (m, 4H), 7.05–7.01 (m, 1H), 6.94 (s, 1H), 6.92 (s, 1H), 5.07 (s, 2H), 3.88 (d, <i>J</i> = 12.0 Hz, 1H), 3.45 (d, <i>J</i> = 12.0 Hz, 1H), 3.18 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 3.03 (t, <i>J</i> = 8.0 Hz, 1H), 2.93 (d, <i>J</i> = 28.0 Hz, 1H), 2.36 (dd, <i>J</i> = 16.0, 8.0 Hz, 1H), 2.31–2.14 (m, 1H), 1.99–1.93 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.0, 163.0 (d, <i>J</i> = 245.0 Hz), 157.8, 139.7 (d, <i>J</i> = 7.0 Hz), 131.2, 130.1 (d, <i>J</i> = 8.0 Hz), 129.9, 122.7 (d, <i>J</i> = 3.0 Hz), 114.8, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 69.3 (d, <i>J</i> = 2.0 Hz), 67.2, 59.1, 53.8, 30.7, 24.0. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 329.1660, found 329.1661. HPLC purity: 99.68%.</div></div><div id="sec4_4_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>S</i>)-1-(4-((3-Fluorobenzyl)oxy)benzyl)-4,4-dimethylpyrrolidine-2-carboxamide (<b>C8</b>)</h4><div class="NLM_p last">White solid, yield: 49%, mp 94–96 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.43 (s, 1H), 7.27 (s, 2H), 7.23 (s, 1H), 7.12 (s, 2H), 6.96 (s, 2H), 5.10 (s, 2H), 3.77 (d, <i>J</i> = 12.0 Hz, 1H), 3.23 (d, <i>J</i> = 12.0 Hz, 1H), 3.02 (s, 1H), 2.55 (d, <i>J</i> = 6.0 Hz, 1H), 2.03 (d, <i>J</i> = 6.0 Hz, 1H), 1.89 (d, <i>J</i> = 12.0 Hz, 1H), 1.55 (d, <i>J</i> = 6.0 Hz, 1H), 1.03 (s, 3H), 0.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.1, 162.7 (d, <i>J</i> = 242.0 Hz), 157.6, 140.6 (d, <i>J</i> = 8.0 Hz), 131.6, 130.9 (d, <i>J</i> = 8.0 Hz), 130.2, 123.9, 115.0, 115.0 (d, <i>J</i> = 21.0 Hz), 114.6 (d, <i>J</i> = 22.0 Hz), 68.8, 68.0, 66.7, 58.6, 45.0, 37.2, 29.4, 28.3. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>21</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 357.1973, found 357.1984. HPLC purity: 99.09%.</div></div><div id="sec4_4_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>S</i>)-1-(2-Fluoro-4-((3-fluorobenzyl)oxy)benzyl)-4,4-dimethylpyrrolidine-2-carboxamide (<b>C9</b>)</h4><div class="NLM_p last">White solid, yield: 46%, mp 104–106 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.43 (s, 1H), 7.34 (s, 1H), 7.28 (s, 2H), 7.18–7.15 (m, 3H), 6.89 (d, <i>J</i> = 12.0 Hz, 1H), 6.83 (s, 1H), 5.13 (s, 2H), 3.76 (d, <i>J</i> = 12.0 Hz, 1H), 3.40 (s, 1H), 3.04 (s, 1H), 2.54 (s, 1H), 2.14 (s, 1H), 1.90 (t, <i>J</i> = 12.0 Hz, 1H), 1.55–1.53 (m, 1H), 1.01 (s, 3H), 0.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.1, 162.7 (d, <i>J</i> = 242.0 Hz), 161.6 (d, <i>J</i> = 242.0 Hz), 159.1 (d, <i>J</i> = 11.0 Hz), 140.1 (d, <i>J</i> = 8.0Hz), 132.6 (d, <i>J</i> = 7.0 Hz), 130.9 (d, <i>J</i> = 8.0 Hz), 124.0 (d, <i>J</i> = 3.0 Hz), 117.7 (d, <i>J</i> = 15.0 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 114.7 (d, <i>J</i> = 22.0 Hz), 111.3 (d, <i>J</i> = 3.0 Hz), 102.7 (d, <i>J</i> = 26.0 Hz), 69.2, 67.4, 66.6, 51.9, 44.9, 37.2, 29.1, 28.0. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>21</sub>H<sub>25</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 375.1879, found 375.1878. HPLC purity: 99.25%.</div></div><div id="sec4_4_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>S</i>)-4,4-Difluoro-1-(4-((3-fluorobenzyl)oxy)benzyl)pyrrolidine-2-carboxamide (<b>C10</b>)</h4><div class="NLM_p last">White solid, yield: 58%, mp 80–82 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.37–7.33 (m, 1H), 7.20–7.17 (m, 2H), 7.15 (d, <i>J</i> = 12.0 Hz, 1H), 7.03–7.00 (m, 2H), 6.94 (s, 1H), 6.93 (s, 1H), 5.06 (s, 2H), 3.91 (d, <i>J</i> = 12.0 Hz, 1H), 3.47 −3.42 (m, 2H), 3.31–3.21 (m, 1H), 2.81–2.67 (m, 2H), 2.41–2.33 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 174.8, 163.0 (d, <i>J</i> = 241.5 Hz), 158.2, 139.5 (d, <i>J</i> = 7.5 Hz), 130.2 (d, <i>J</i> = 7.5 Hz), 130.0, 129.1, 127.3 (t, <i>J</i> = 247.5 Hz), 122.7 (d, <i>J</i> = 1.5 Hz), 115.1, 115.0 (d, <i>J</i> = 19.5 Hz), 114.3 (d, <i>J</i> = 21.0 Hz), 69.2 (d, <i>J</i> = 1.5 Hz), 65.1, 59.5 (t, <i>J</i> = 28.5 Hz), 58.5, 39.7 (t, <i>J</i> = 25.5 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 365.1471, found 365.1474. HPLC purity: 99.06%.</div></div><div id="sec4_4_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>S</i>)-4,4-Difluoro-1-(2-fluoro-4-((3-fluorobenzyl)oxy)benzyl)pyrrolidine-2-carboxamide (<b>C11</b>)</h4><div class="NLM_p last">White solid, yield: 49%, mp 117–118 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.48–7.42 (m, 1H), 7.37–7.29 (m, 5H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 6.95–6.89 (m, 1H), 6.89–6.81 (m, 1H), 5.14 (s, 2H), 3.78 (d, <i>J</i> = 12.0 Hz, 1H), 3.58 (d, <i>J</i> = 16.0 Hz, 1H), 3.32–3.31 (m, 1H), 3.23–3.15 (m, 1H), 2.84–2.73 (m, 1H), 2.69–2.56 (m, 1H), 2.30–2.17 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 174.5, 163.0 (d, <i>J</i> = 246 Hz), 162.0 (d, <i>J</i> = 245.5 Hz), 159.8 (d, <i>J</i> = 10.5 Hz), 138.8 (d, <i>J</i> = 7.5 Hz), 131.8 (d, <i>J</i> = 7.5 Hz), 130.3 (d, <i>J</i> = 7.5 Hz), 127.1 (t, <i>J</i> = 246.0 Hz), 122.7 (d, <i>J</i> = 3.0 Hz), 116.0 (d, <i>J</i> = 15.5 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 114.3 (d, <i>J</i> = 22.5 Hz), 110.7 (d, <i>J</i> = 3.0 Hz), 103.0 (d, <i>J</i> = 25.5 Hz), 69.5 (d, <i>J</i> = 1.5 Hz), 64.9, 59.5 (t, <i>J</i> = 28.5 Hz), 52.6, 39.9 (t, <i>J</i> = 25.5 Hz). HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>19</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub> ([M + H]<sup>+</sup>): 383.1377, found 383.1379. HPLC purity: 96.30%.</div></div><div id="sec4_4_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>S</i>)-4-(4-((3-Fluorobenzyl)oxy)benzyl)morpholine-3-carboxamide (<b>C12</b>)</h4><div class="NLM_p last">White solid, yield: 71%, mp 119–121 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (dd, <i>J</i> = 12.0, 8.0 Hz, 1H), 7.21 (s, 1H), 7.18 (d, <i>J</i> = 4.0 Hz, 2H), 7.15 (d, <i>J</i> = 12.0 Hz, 1H), 7.03–6.99 (m, 1H), 6.92 (d, <i>J</i> = 8.0 Hz, 2H), 5.04 (s, 2H), 4.03 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 3.89 (d, <i>J</i> = 12.0 Hz, 1H), 3.80 (d, <i>J</i> = 12.0 Hz, 1H), 3.54 (t, <i>J</i> = 12.0 Hz, 2H), 3.21 (d, <i>J</i> = 16.0 Hz, 1H), 3.07 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 2.73 (d, <i>J</i> = 12.0 Hz, 1H), 2.24 (td, <i>J</i> = 12.0, 4.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.6, 163.0 (d, <i>J</i> = 245.0 Hz), 158.0, 139.5 (d, <i>J</i> = 8.0 Hz), 130.1, 130.0, 129.2, 122.6 (d, <i>J</i> = 3.0 Hz), 114.9, 114.8 (d, <i>J</i> = 21.0 Hz), 114.2 (d, <i>J</i> = 22.0 Hz), 69.2 (d, <i>J</i> = 1.7 Hz), 69.1, 66.8, 66.6, 60.0, 49.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 345.1609, found 345.1610. HPLC purity: 99.56%.</div></div><div id="sec4_4_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>S</i>)-4-(2-Fluoro-4-((3-fluorobenzyl)oxy)benzyl)morpholine-3-carboxamide (<b>C13</b>)</h4><div class="NLM_p last">White solid, yield: 70%, mp 117–119 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37 (dd, <i>J</i> = 12.0, 8.0 Hz, 1H), 7.23– 7.12 (m, 3H), 7.06–7.02 (m, 1H), 6.77–6.66 (m, 2H), 5.05 (s, 2H), 4.06 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 3.99 (d, <i>J</i> = 12.0 Hz, 1H), 3.82 (d, <i>J</i> = 12.0 Hz, 1H), 3.58–3.45 (m, 2H), 3.19 (d, <i>J</i> = 12.0 Hz, 1H), 3.06 (dd, <i>J</i> = 12.0, 4.0 Hz, 1H), 2.70 (d, <i>J</i> = 12.0 Hz, 1H), 2.27 (td, <i>J</i> = 12.0, 4.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.4 (d, <i>J</i> = 3.0 Hz),162.9 (d, <i>J</i> = 245.0 Hz), 162.1 (d, <i>J</i> = 245.0 Hz), 159.4 (d, <i>J</i> = 12.0 Hz), 138.9 (d, <i>J</i> = 8.0 Hz), 132.3 (d, <i>J</i> = 7.0Hz), 130.2 (d, <i>J</i> = 8.0 Hz), 122.6 (d, <i>J</i> = 3.0 Hz), 115.8 (d, <i>J</i> = 15.0 Hz), 115.0 (d, <i>J</i> = 21.0 Hz), 114.1 (d, <i>J</i> = 22.0 Hz), 110.4 (d, <i>J</i> = 3.0 Hz), 102.8 (d, <i>J</i> = 25.0 Hz), 69.4 (d, <i>J</i> = 1.0 Hz), 69.3, 66.8, 66.7, 54.6, 49.9. HRMS <i>m</i>/<i>z</i> (ESI+): calcd for C<sub>19</sub>H<sub>21</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 363.1515, found 363.1517. HPLC purity: 99.55%.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> MAO Inhibitory <i>In Vitro</i> Assay</h3><div class="NLM_p">The inhibitory activity of the target compounds against MAOs was elevated by the Luminex assay. MAO inhibition was determined using commercially available recombinant human MAO-A and MAO-B enzymes expressed in Sf9 cells. The protocol of the MAO inhibition assay is as follows: in a 386-well black plate, the test compounds in DMSO and 10 μL of enzyme solution were incubated for 15 min at room temperature. A total of 10 μL of substrate solution (40 μM, benzylamine as the MAO-B substrate, <i>p</i>-tyramine as the MAO-A substrate) was added to each well to initiate the reaction, which was incubated at room temperature for 60 min. Then, the solution was mixed with 20 μL of Luciferin detection reagent and incubated for 20 min to generate the luminescent signal. The luminescent signal was measured and recorded using a plate-reading luminometer. Values are displayed as relative light units (RLU). The data were fitted in GraphPad Prism 5 to obtain IC<sub>50</sub> values using the following equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_m001.gif" alt="" id="_i67" /></img></span><i>Y</i> is %inhibition, and <i>X</i> is compound concentration.</div><div class="NLM_p last">The inhibition values were obtained using the following equation<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_m002.gif" alt="" id="_i68" /></img><span class="labelSpan">(1)</span></span></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> CoMFA Analysis</h3><div class="NLM_p last">The CoMFA analysis was performed using the Cloud 3D-QSAR web server (<a href="http://cloud3dqsar.cn/" class="extLink">http://cloud3dqsar.cn/</a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The studied compounds were divided into a training set (15 compounds) and a test set (6 compounds). The IC<sub>50</sub> value of each compound was converted into the pIC<sub>50</sub> value (−log IC<sub>50</sub>). All of the other studied compounds were aligned to the lowest-energy conformation of compound <b>C3</b>. The partial least square (PLS) regression approach was used to perform our CoMFA analysis. We employed the leave-one-out (LOO) method to calculate the cross-validation correlation coefficient (<i>q</i><sup>2</sup>) and the number of optimum components (NOC). The noncross-validated correlation coefficient (<i>r</i><sup>2</sup>), standard error of estimate (SEE), F-statistic values (F), and contributions of each field were also obtained. The predictive correlation coefficient (<i>r</i><sub>pred</sub><sup>2</sup>) value was a powerful tool to measure the predictive capability of our 3D-QSARmodels. A reliable CoMFA model should have high <i>q</i><sup>2</sup> and <i>r</i><sub>pred</sub><sup>2</sup> (>0.5). The contour maps could explain the structural requirements of studied compounds directly. For the steric field, green contours and yellow contours represented favorable and unfavorable regions for bulky groups. For the electrostatic field, blue contours indicated a favorable region for positively charged groups, while red contours indicated a favorable region for negatively charged groups.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Animal Statement</h3><div class="NLM_p last">Adult male Institute for Cancer Research (ICR) mice (weight, 22 g, 4-week-old, 120 in total) and adult C57BL/6 mice (weight, 25–30 g, 4-week-old, 104 in total) were obtained from the Hunan slake Jingda experimental animal Co., Ltd. For biochemical assays, the mice were housed in groups of six or eight in a controlled environment (20–23 °C), with free access to food and water, and maintained on a 12/12 h day/night cycle, with light on at 07:00 h. All efforts were taken to minimize animal suffering. The number of animals used was the minimum number consistent with obtaining significant data. The mice were randomly assigned to the treatment groups and were used only once. The pharmacological tests were evaluated by experimenters who were not aware of the treatments administered and were performed between 10:00 and 14:00 h. The housing, handling, and experimental procedures for mice complied with the recommendations set out by Guide for the Care and Use of Laboratory Animals (Eighth Edition), reversed 2011 the National Academics (Washington D.C.); General Guidelines for Biosafety in Microbiology laboratories, and the National Health and Family Planning Commission (China).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> MAO Inhibitory Assay <i>In Vivo</i></h3><div class="NLM_p last">ICR mice received the tested compounds intraperitoneally, and the whole brains were removed and frozen at −20 °C for 1 h. Tissue (700–1000 μg) was suspended in 5 volumes of 0.3 M sucrose solution using an Ultra-Turrax T8 (70 s, setting 60 Hz) and then centrifuged at 1500 rpm for 10 min at 4 °C. The supernatant (200 μL) was centrifuged at 15 000 rpm for 20 min at 4 °C. After the supernatant was discarded, the pellet was resuspended in 600 μL of KHPO<sub>4</sub> solution (pH 7.2) and centrifuged at 15 000 rpm for 20 min. A final resuspension after repeat centrifugation with the same conditions was performed in 600 μL of KHPO<sub>4</sub> solution (pH 7.2). Enzyme activities were measured using an Amplex Red Monoamine Oxidase Assay Kit (A12214, Invitrogen). MAO-B inhibition (%) was calculated against the vehicle-alone-treated group (100%) with an adjustment by protein quantification. For the time course of mice brain MAO-B inhibition, ICR mice received the tested compounds (<b>C3</b>, safinamide) intraperitoneally and were sacrificed 0.5–48 h later.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Suppression of MPTP-Induced Dopaminergic Toxicity by <b>C3</b></h3><div class="NLM_p last">The study examined the effect of <b>C3</b> pretreatment on MPTP-induced DA depletion in the striatum.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> After 30 min administration with <b>C3</b> (0.1, 1.0, 3.0 mg/kg) or safinamide (3.0 mg/kg) by i.p. injection, the mice received a single dose of MPTP (30 mg/kg) intraperitoneally. 5 days later, the mice were sacrificed. The brain tissues were carefully dissected in the brain matrix and the striatum region was isolated. Each sample was homogenized in a solution containing 0.1 M perchloric acid and 0.1 mM EDTA in an ultrasonicator. The homogenates were mixed with DA-d4 (50.0 ng/mL in 0.1% formic acid solution) and 150 μL of acetonitrile and centrifuged at 13000 rpm for 5 min at 4 °C. Then, 50 μL of boric acid buffer (pH 10.4) and 50 μL of 2% benzoyl chloroacetonitrile solution were added to the supernatant, mixed, and centrifuged under the same conditions. After centrifugation, a 10 μL of aliquot of the filtered solution was injected into an HPLC apparatus with electrochemical detection to measure the DA concentration.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Effects of <b>C3</b> on the Dopamine (DA) Concentration in the Striatum Administered with <span class="smallcaps smallerCapital">l</span>-dopa (LD)/Benserazide</h3><div class="NLM_p last">The aim of this study is to examine whether <b>C3</b> is effective in increasing the DA concentration in the striatum administered with LD/benserazide when administered after MPTP. Mice were injected with MPTP (30 mg/kg, i.p.). After 4 h, mice were treated with test compounds or vehicle five times at 24 h intervals. Controls were administered vehicle or MPTP alone. LD (50 mg/kg) and benserazide (12.5 mg/kg) were injected intraperitoneally 30 min before the last administration of test compounds. Mice were sacrificed 30 min after the last administration of test compounds, and the DA assay was performed as described above.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Statistical Analysis</h3><div class="NLM_p last">All experimental results are presented as the mean ± SEM. Data were statistically compared by Prism software (GraphPad Prism 6.0) using one-way analysis of variance (ANOVA). A <i>P</i> value < 0.05 was considered significant.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Molecular Dynamics (MD) Simulations and Binding Free Energy (Δ<i>G</i>) Calculation</h3><div class="NLM_p last">The MD simulations of MAO-A-<b>C3</b> and MAO-B-<b>C3</b> complexes were performed using the Amber 16 package. The receptor proteins were treated with the ff14SB force field, while the cofactor and <b>C3</b> were treated with the gaff force field. Energy minimization and 20 ns MD simulations of the two complexes were then performed. The Δ<i>G</i> values were calculated using the MM-PBSA method.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01663" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01663?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01663</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C NMR spectra of all new compounds; HPLC traces of final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf">jm0c01663_si_001.pdf (3.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_002.csv">jm0c01663_si_002.csv (1.86 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01663" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ge-Fei Hao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering,
Key Laboratory of Green Pesticide and Agricultural Bioengineering,
Ministry of Education, Research and Development Center for Fine Chemicals, Guizhou University, Guiyang 550025, P. R.
China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4090-8411" title="Orcid link">http://orcid.org/0000-0003-4090-8411</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#25424043404c7a4d444a65434a5d48444c490b464a48"><span class="__cf_email__" data-cfemail="bddad8dbd8d4e2d5dcd2fddbd2c5d0dcd4d193ded2d0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chuan-Fei Jin</span> - <span class="hlFld-Affiliation affiliation">Sunshine
Lake Pharma Co. Ltd.,
Shenzhen 518000; HEC Pharm Group, HEC Research
and Development Center, Dongguan 523871, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi-Zheng Wang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Pesticide & Chemical Biology, Ministry of Education,
College of Chemistry, Central China Normal
University, Wuhan 430079, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kang-Zhi Chen</span> - <span class="hlFld-Affiliation affiliation">Sunshine
Lake Pharma Co. Ltd.,
Shenzhen 518000; HEC Pharm Group, HEC Research
and Development Center, Dongguan 523871, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teng-Fei Xu</span> - <span class="hlFld-Affiliation affiliation">Sunshine
Lake Pharma Co. Ltd.,
Shenzhen 518000; HEC Pharm Group, HEC Research
and Development Center, Dongguan 523871, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.-F.J. and Z.-Z.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5336-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Key R&D Program (2018YFD0200100), the National Natural Science Foundation of China (21772059, 91853127, and 31960548), the Program of Introducing Talents of Discipline to Universities of China (111 Program, D20023), the Foundation and Applied Basic Research Fund of Guangdong Province (2019A1515110957), and the Key Research and Development Program of Guangdong Province (2019B02021002).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">FBDD</td><td class="NLM_def"><p class="first last">fragment-based drug design</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">PFVS</td><td class="NLM_def"><p class="first last">pharmacophore-linked fragment virtual screening</p></td></tr><tr><td class="NLM_term">ACFIS</td><td class="NLM_def"><p class="first last">Auto Core Fragment In silico Screening</p></td></tr><tr><td class="NLM_term">Δ<i>G</i></td><td class="NLM_def"><p class="first last">the binding free energy</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">NHAC</td><td class="NLM_def"><p class="first last">nonhydrogen atom count</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehagia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span> <span> </span><span class="NLM_article-title">Neuropsychological and Clinical Heterogeneity of Cognitive Impairment and Dementia in Patients with Parkinson’s Disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(10)70212-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1474-4422%2810%2970212-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=20880750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC3cbnsFWitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1200-1213&author=A.+A.+Kehagiaauthor=R.+A.+Barkerauthor=T.+W.+Robbins&title=Neuropsychological+and+Clinical+Heterogeneity+of+Cognitive+Impairment+and+Dementia+in+Patients+with+Parkinson%E2%80%99s+Disease&doi=10.1016%2FS1474-4422%2810%2970212-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease</span></div><div class="casAuthors">Kehagia Angie A; Barker Roger A; Robbins Trevor W</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1200-1213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cognitive impairment in patients with Parkinson's disease is gaining increased clinical significance owing to the relative success of therapeutic approaches to the motor symptoms of this disorder.  Early investigations contributed to the concept of subcortical dementia associated with bradyphrenia and cognitive rigidity.  For cognition in parkinsonian disorders, this notion developed into the concept of mild cognitive impairment and fronto-executive dysfunction in particular, driven mainly by dopaminergic dysmodulation and manifesting as deficits in flexibility, planning, working memory, and reinforcement learning.  However, patients with Parkinson's disease could also develop a syndrome of dementia that might depend on non-dopaminergic, cholinergic cortical dysfunction.  Recent findings, supplemented by advances in neuroimaging and genetic research, reveal substantial heterogeneity in the range of cognitive deficits in patients with Parkinson's disease.  Remediation and management prospects for these cognitive deficits are based on neuropharmacological and cognitive rehabilitation approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2jYKP9flaDS-bLEOO4dYpfW6udTcc2ebgMYtl_4pw3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbnsFWitg%253D%253D&md5=aa7c355574b4708f40ad200c0c176dd7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2810%2970212-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252810%252970212-X%26sid%3Dliteratum%253Aachs%26aulast%3DKehagia%26aufirst%3DA.%2BA.%26aulast%3DBarker%26aufirst%3DR.%2BA.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26atitle%3DNeuropsychological%2520and%2520Clinical%2520Heterogeneity%2520of%2520Cognitive%2520Impairment%2520and%2520Dementia%2520in%2520Patients%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D1200%26epage%3D1213%26doi%3D10.1016%2FS1474-4422%2810%2970212-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noyce, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bestwick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silveira-Moriyama, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, A.</span></span> <span> </span><span class="NLM_article-title">Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1002/ana.23687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fana.23687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=23071076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1yhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=893-901&author=A.+J.+Noyceauthor=J.+P.+Bestwickauthor=L.+Silveira-Moriyamaauthor=C.+H.+Hawkesauthor=G.+Giovannoniauthor=A.+J.+Leesauthor=A.+Schrag&title=Meta-Analysis+of+Early+Nonmotor+Features+and+Risk+Factors+for+Parkinson+Disease&doi=10.1002%2Fana.23687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of early nonmotor features and risk factors for Parkinson disease</span></div><div class="casAuthors">Noyce, Alastair J.; Bestwick, Jonathan P.; Silveira-Moriyama, Laura; Hawkes, Christopher H.; Giovannoni, Gavin; Lees, Andrew J.; Schrag, Anette</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">893-901</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the assocn. between diagnosis of Parkinson disease (PD) and risk factors or early symptoms amenable to population-based screening.  Methods: A systematic review and meta-anal. of risk factors for PD.  Results: The strongest assocns. with later diagnosis of PD were found for having a first-degree or any relative with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65-3.93 and OR, 4.45; 95% CI, 3.39-5.83) or any relative with tremor (OR, 2.74; 95% CI, 2.10-3.57), constipation (relative risk [RR], 2.34; 95% CI, 1.55-3.53), or lack of smoking history (current vs never: RR, 0.44; 95% CI, 0.39-0.50), each at least doubling the risk of PD.  Further pos. significant assocns. were found for history of anxiety or depression, pesticide exposure, head injury, rural living, beta-blockers, farming occupation, and well-water drinking, and neg. significant assocns. were found for coffee drinking, hypertension, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alc., but not for diabetes mellitus, cancer, oral contraceptive pill use, surgical menopause, hormone replacement therapy, statins, acetaminophen/paracetamol, aspirin, tea drinking, history of general anesthesia, or gastric ulcers.  In the systematic review, addnl. assocns. included neg. assocns. with raised serum urate, and single studies or studies with conflicting results.  Interpretation: The strongest risk factors assocd. with later PD diagnosis are having a family history of PD or tremor, a history of constipation, and lack of smoking history.  Further factors also but less strongly contribute to risk of PD diagnosis or, as some premotor symptoms, require further standardized studies to demonstrate the magnitude of risk assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNbbaMupRsoLVg90H21EOLACvtfcHk0ljzQC7xsEFdyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1yhtg%253D%253D&md5=ce1915cd74a2403039d08e3df404b16c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fana.23687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23687%26sid%3Dliteratum%253Aachs%26aulast%3DNoyce%26aufirst%3DA.%2BJ.%26aulast%3DBestwick%26aufirst%3DJ.%2BP.%26aulast%3DSilveira-Moriyama%26aufirst%3DL.%26aulast%3DHawkes%26aufirst%3DC.%2BH.%26aulast%3DGiovannoni%26aufirst%3DG.%26aulast%3DLees%26aufirst%3DA.%2BJ.%26aulast%3DSchrag%26aufirst%3DA.%26atitle%3DMeta-Analysis%2520of%2520Early%2520Nonmotor%2520Features%2520and%2520Risk%2520Factors%2520for%2520Parkinson%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D893%26epage%3D901%26doi%3D10.1002%2Fana.23687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascherio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">The Epidemiology of Parkinson’s Disease: Risk Factors and Prevention</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(16)30230-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1474-4422%2816%2930230-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27751556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC2srhsFSnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1257-1272&author=A.+Ascherioauthor=M.+A.+Schwarzschild&title=The+Epidemiology+of+Parkinson%E2%80%99s+Disease%3A+Risk+Factors+and+Prevention&doi=10.1016%2FS1474-4422%2816%2930230-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of Parkinson's disease: risk factors and prevention</span></div><div class="casAuthors">Ascherio Alberto; Schwarzschild Michael A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1257-1272</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since 2006, several longitudinal studies have assessed environmental or behavioural factors that seem to modify the risk of developing Parkinson's disease.  Increased risk of Parkinson's disease has been associated with exposure to pesticides, consumption of dairy products, history of melanoma, and traumatic brain injury, whereas a reduced risk has been reported in association with smoking, caffeine consumption, higher serum urate concentrations, physical activity, and use of ibuprofen and other common medications.  Randomised trials are investigating the possibility that some of the negative risk factors might be neuroprotective and thus beneficial in individuals with early Parkinson's disease, particularly with respect to smoking (nicotine), caffeine, and urate.  In the future, it might be possible to identify Parkinson's disease in its prodromal phase and to promote neuroprotective interventions before the onset of motor symptoms.  At this time, however, the only intervention that seems justifiable for the primary prevention of Parkinson's disease is the promotion of physical activity, which is likely to be beneficial for the prevention of several chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8H_Y4x8oN2m52AMpI4GK2fW6udTcc2eaEL30iJFaq_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhsFSnsQ%253D%253D&md5=728289c098321aa105b428ed1082dd6e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2816%2930230-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252816%252930230-7%26sid%3Dliteratum%253Aachs%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Epidemiology%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Risk%2520Factors%2520and%2520Prevention%26jtitle%3DLancet%2520Neurol.%26date%3D2016%26volume%3D15%26spage%3D1257%26epage%3D1272%26doi%3D10.1016%2FS1474-4422%2816%2930230-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">Enzymology of Monoamine Oxidase</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1002/cbf.290040202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fcbf.290040202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=3518979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaL28XhvVajur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1986&pages=79-87&author=K.+F.+Tipton&title=Enzymology+of+Monoamine+Oxidase&doi=10.1002%2Fcbf.290040202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology of monoamine oxidase</span></div><div class="casAuthors">Tipton, K. F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">0263-6484</span>.
    </div><div class="casAbstract">A review, with 144 refs., of the specificity occurrence, localization, mol. properties, catalytic and kinetic properties, multiplicity, and inhibitors of MAO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd0aEWs90XXrVg90H21EOLACvtfcHk0liB76DyB5ZerQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVajur4%253D&md5=8dcbed6596a4e2a4df37208f84464333</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fcbf.290040202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.290040202%26sid%3Dliteratum%253Aachs%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DEnzymology%2520of%2520Monoamine%2520Oxidase%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D1986%26volume%3D4%26spage%3D79%26epage%3D87%26doi%3D10.1002%2Fcbf.290040202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löhle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, H.</span></span> <span> </span><span class="NLM_article-title">Controversies in Neurology: Why Monoamine Oxidase B Inhibitors Could be a Good Choice for The Initial Treatment of Parkinson’s Disease</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">112</span> <span class="refDoi"> DOI: 10.1186/1471-2377-11-112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2F1471-2377-11-112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=21939547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC3MbgvFGltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&author=M.+L%C3%B6hleauthor=H.+Reichmann&title=Controversies+in+Neurology%3A+Why+Monoamine+Oxidase+B+Inhibitors+Could+be+a+Good+Choice+for+The+Initial+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1186%2F1471-2377-11-112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease</span></div><div class="casAuthors">Lohle Matthias; Reichmann Heinz</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Early initiation of pharmacotherapy in Parkinson's disease (PD) is nowadays widely advocated by experts since the delay of treatment has shown to be associated with a significant deterioration of health related quality of life in affected patients.  Due to marked advances in PD treatment during the last decades, physicians are nowadays fortunately equipped with a variety of substances that can effectively ameliorate emerging motor symptoms of the disease, among them levodopa, dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors.  Despite numerous drug intervention trials in early PD, there is however still ongoing controversy among neurologists which substance to use for the initial treatment of the disease.  DISCUSSION:  In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations.  Although their symptomatic efficacy is inferior compared to dopamine agonists and levodopa, MAO-B inhibitors undoubtedly have fewer side effects and are easy to administer.  In contrary to their competitors, MAO-B inhibitors may furthermore offer a chance for disease modification, which so far remains a major unmet need in the management of PD and eventually makes them ideal candidates for the early treatment of the disease.  SUMMARY:  MAO-B inhibitors may constitute a preferable therapeutic option for early PD, mainly due to their favourable safety profile and their putative neuroprotective capabilities.  Since the symptomatic effects of MAO-B inhibitors are comparatively mild, dopamine agonists and levodopa should however be considered for initial treatment in those PD patients, in whom robust and immediate symptomatic relief needs to be prioritized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQICir7hjn-6cScOqQTSkOffW6udTcc2eaEL30iJFaq_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbgvFGltw%253D%253D&md5=462eeda4fb9071015df6659e457efb3b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-11-112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-11-112%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6hle%26aufirst%3DM.%26aulast%3DReichmann%26aufirst%3DH.%26atitle%3DControversies%2520in%2520Neurology%253A%2520Why%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520Could%2520be%2520a%2520Good%2520Choice%2520for%2520The%2520Initial%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DBMC%2520Neurol.%26date%3D2011%26volume%3D11%26doi%3D10.1186%2F1471-2377-11-112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">New Frontiers in Selective Human MAO-B Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6717</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1021/jm501690r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501690r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6717-6732&author=S.+Carradoriauthor=R.+Silvestri&title=New+Frontiers+in+Selective+Human+MAO-B+Inhibitors&doi=10.1021%2Fjm501690r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New Frontiers in Selective Human MAO-B Inhibitors</span></div><div class="casAuthors">Carradori, Simone; Silvestri, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6717-6732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence shows a relationship between the human MAO-B (hMAO-B) enzyme and neuropsychiatric/degenerative disorder, personality traits, type II alcoholism, borderline personality disorders, aggressiveness and violence in crime, obsessive-compulsive disorder, depression, suicide, schizophrenia, anorexia nervosa, migraine, dementia, and PD.  Thus, MAO-B represents an attractive target for the treatment of a no. of human diseases.  The discovery, development, and therapeutic use of drugs that inhibit MAO-B are major challenges for future therapy.  Various compds. and drugs that selectively target this isoform have been discovered recently.  These agents are synthetic compds. or natural products and their analogs, including chalcones, pyrazoles, chromones, coumarins, xanthines, isatin derivs., thiazolidindiones, (thiazol-2-yl)hydrazones, and analogs of marketed drugs.  Despite considerable efforts in understanding the binding interaction with specific substrates or inhibitors, structural information available for the rational design of new hMAO-B inhibitors remains unsatisfactory.  Therefore, the quest for novel, potent, and selective hMAO-B inhibitors remains of high interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Xz4JhVXeRbVg90H21EOLACvtfcHk0ljkHn_0XLrYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGiurk%253D&md5=abe939ceae25d97e83243f9f0af6aef5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm501690r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501690r%26sid%3Dliteratum%253Aachs%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520Frontiers%2520in%2520Selective%2520Human%2520MAO-B%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6717%26epage%3D6732%26doi%3D10.1021%2Fjm501690r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=29335210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=445-497&author=A.+C.+Tripathiauthor=S.+Upadhyayauthor=S.+Paliwalauthor=S.+K.+Saraf&title=Privileged+Scaffolds+as+MAO+Inhibitors%3A+Retrospect+and+Prospects&doi=10.1016%2Fj.ejmech.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds as MAO inhibitors: Retrospect and prospects</span></div><div class="casAuthors">Tripathi, Avinash C.; Upadhyay, Savita; Paliwal, Sarvesh; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review aims to be a comprehensive, authoritative, crit., and readable review of general interest to the medicinal chem. community because it focuses on the pharmacol., chem., structural and computational aspects of diverse chem. categories as monoamine oxidase inhibitors (MAOIs).  Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiol. origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever.  Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).  The use of MAOIs declined due to some potential side effects, food and drug interactions, and introduction of other classes of drugs.  However, curiosity in MAOIs is reviving and the recent developments of new generation of highly selective and reversible MAOIs, have renewed the therapeutic prospective of these compds.  The initial section of the review emphasizes on the detailed classification, structural and binding characteristics, therapeutic potential, current status and future challenges of the privileged pharmacophores.  However, the chem. prospective of privileged scaffolds such as; aliph. and arom. amines, amides, hydrazines, azoles, diazoles, tetrazoles, indoles, azines, diazines, xanthenes, tricyclics, benzopyrones, and more interestingly natural products, along with their conclusive SARs have been discussed in the later segment of review.  The last segment of the article encompasses some patents granted in the field of MAOIs, in a simplistic way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqYob-n4zgsLVg90H21EOLACvtfcHk0ljkHn_0XLrYVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D&md5=4fa0cc226ee27522671188d0cfe62ab2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3DPrivileged%2520Scaffolds%2520as%2520MAO%2520Inhibitors%253A%2520Retrospect%2520and%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D445%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span> <span> </span><span class="NLM_article-title">Compulsivity and Impulsivity-Personal Reflections: Why Now and Why Here?</span>. <i>CNS Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1017/S1092852913000886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1017%2FS1092852913000886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=24284261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC2c3hsVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=6-7&author=E.+Hollander&title=Compulsivity+and+Impulsivity-Personal+Reflections%3A+Why+Now+and+Why+Here%3F&doi=10.1017%2FS1092852913000886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Compulsivity and impulsivity-personal reflections: why now and why here?</span></div><div class="casAuthors">Hollander Eric</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-7</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">This issue of CNS Spectrums contains a unique collection of manuscripts that examine compulsivity and impulsivity from a broad range of perspectives and helps to shape our evolving understanding of compulsivity and impulsivity as orthogonal symptom dimensions arising from parallel tightly regulated brain circuits giving rise to a spectrum of overlapping diagnostic categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0kmLwebtNR6x48Rj5GnGofW6udTcc2eb-24YKlcl-6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3hsVGquw%253D%253D&md5=8faf6c41965f77b45704bb5b042a0b5f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1017%2FS1092852913000886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852913000886%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26atitle%3DCompulsivity%2520and%2520Impulsivity-Personal%2520Reflections%253A%2520Why%2520Now%2520and%2520Why%2520Here%253F%26jtitle%3DCNS%2520Spectr.%26date%3D2014%26volume%3D19%26spage%3D6%26epage%3D7%26doi%3D10.1017%2FS1092852913000886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abodabos, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taban, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rfieda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anward, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizochenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H. I.</span></span> <span> </span><span class="NLM_article-title">Rutin as Promising Drug for the Treatment of Parkinson’s Disease: An Assessment of MAO-B Inhibitory Potential by Docking, Molecular Dynamics and DFT Studies</span>. <i>Mol. Simul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1571</span>, <span class="refDoi"> DOI: 10.1080/08927022.2019.1662003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1080%2F08927022.2019.1662003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleitr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2019&pages=1563-1571&author=F.+Azamauthor=H.+S.+Abodabosauthor=I.+M.+Tabanauthor=A.+R.+Rfiedaauthor=D.+Mahmoodauthor=J.+Anwardauthor=S.+Khanauthor=N.+Sizochenkoauthor=G.+Poliauthor=T.+Tuccinardiauthor=H.+I.+Ali&title=Rutin+as+Promising+Drug+for+the+Treatment+of+Parkinson%E2%80%99s+Disease%3A+An+Assessment+of+MAO-B+Inhibitory+Potential+by+Docking%2C+Molecular+Dynamics+and+DFT+Studies&doi=10.1080%2F08927022.2019.1662003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rutin as promising drug for the treatment of Parkinson's disease: an assessment of MAO-B inhibitory potential by docking, molecular dynamics and DFT studies</span></div><div class="casAuthors">Azam, Faizul; Abodabos, Honiwa Suliman; Taban, Ismail M.; Rfieda, Abdalla R.; Mahmood, Danish; Anwar, Md Jamir; Khan, Shamshir; Sizochenko, Natalia; Poli, Giulio; Tuccinardi, Tiziano; Ali, Hamed I.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Simulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1563-1571</span>CODEN:
                <span class="NLM_cas:coden">MOSIEA</span>;
        ISSN:<span class="NLM_cas:issn">0892-7022</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of monoamine oxidase (MAO)-B have been used for many years in the therapy of Parkinson's disease (PD).  Owing to the safety concerns of the currently used agents, the discovery of novel scaffolds is of considerable interest.  MAO-B inhibitory potential of rutin, a flavonoid derived from natural sources, has been established in exptl. findings.  Hence, the current study seeks to examine the interactions between rutin and crystal structure of human MAO-B enzyme.  Mol. docking calcns., as well as mol. dynamics simulations, were employed to investigate the binding mode and the stability of the rutin/MAO-B complex.  Energies of highest occupied/lowest unoccupied MOs were computed through DFT studies and used to calc. electron affinity, hardness, chem. potential, electronegativity, and electrophilicity index in order to investigate the capability of these parameters to influence the ligand-receptor interactions.  It was found that rutin traverses both the entrance cavity and the substrate cavity, forcing the Ile-199 'gate' to rotate into its open conformation.  It results in the fusion of the two cavities of the MAO-B binding site and directly leads to better binding interactions.  Results of the current study can be used for lead modification and development of novel drugs for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3FYd8WUJ9kLVg90H21EOLACvtfcHk0lhfKRII7od6NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleitr%252FM&md5=4d03af550292c4b40190b09d5496ac72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F08927022.2019.1662003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F08927022.2019.1662003%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DF.%26aulast%3DAbodabos%26aufirst%3DH.%2BS.%26aulast%3DTaban%26aufirst%3DI.%2BM.%26aulast%3DRfieda%26aufirst%3DA.%2BR.%26aulast%3DMahmood%26aufirst%3DD.%26aulast%3DAnward%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DSizochenko%26aufirst%3DN.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DAli%26aufirst%3DH.%2BI.%26atitle%3DRutin%2520as%2520Promising%2520Drug%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520An%2520Assessment%2520of%2520MAO-B%2520Inhibitory%2520Potential%2520by%2520Docking%252C%2520Molecular%2520Dynamics%2520and%2520DFT%2520Studies%26jtitle%3DMol.%2520Simul.%26date%3D2019%26volume%3D45%26spage%3D1563%26epage%3D1571%26doi%3D10.1080%2F08927022.2019.1662003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaurasiya, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerksen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera Diffusa (Damiana)</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">810</span>, <span class="refDoi"> DOI: 10.3390/molecules24040810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.3390%2Fmolecules24040810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=810&author=N.+D.+Chaurasiyaauthor=J.+Zhaoauthor=P.+Pandeyauthor=R.+J.+Doerksenauthor=I.+Muhammadauthor=B.+L.+Tekwani&title=Selective+Inhibition+of+Human+Monoamine+Oxidase+B+by+Acacetin+7-Methyl+Ether+Isolated+from+Turnera+Diffusa+%28Damiana%29&doi=10.3390%2Fmolecules24040810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of human monoamine oxidase B by acacetin 7-methyl ether isolated from Turnera diffusa (Damiana)</span></div><div class="casAuthors">Chaurasiya, Narayan D.; Zhao, Jianping; Pandey, Pankaj; Doerksen, Robert J.; Muhammad, Ilias; Tekwani, Babu L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">810/1-810/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The investigation of the constituents that were isolated from Turnera diffusa (damiana) for their inhibitory activities against recombinant human monoamine oxidases (MAO-A and MAO-B) in vitro identified acacetin 7-Me ether as a potent selective inhibitor of MAO-B (IC50 = 198 nM).  Acacetin 7-Me ether (also known as 5-hydroxy-4', 7-dimethoxyflavone) is a naturally occurring flavone that is present in many plants and vegetables.  Acacetin 7-Me ether was four-fold less potent as an inhibitor of MAO-B when compared to acacetin (IC50 = 50 nM).  However, acacetin 7-Me ether was >500-fold selective against MAO-B over MAO-A as compared to only two-fold selectivity shown by acacetin.  Even though the IC50 for inhibition of MAO-B by acacetin 7-Me ether was ∼four-fold higher than that of the std. drug deprenyl (i.e., Selegiline or Zelapar, a selective MAO-B inhibitor), acacetin 7-Me ether's selectivity for MAO-B over MAO-A inhibition was greater than that of deprenyl (>500- vs. 450-fold).  The binding of acacetin 7-Me ether to MAO-B was reversible and time-independent, as revealed by enzyme-inhibitor complex equil. dialysis assays.  The investigation on the enzyme inhibition-kinetics anal. with varying concns. of acacetin 7-Me ether and the substrate (kynuramine) suggested a competitive mechanism of inhibition of MAO-B by acacetin 7-Me ether with Ki value of 45 nM.  The docking scores and binding-free energies of acacetin 7-Me ether to the X-ray crystal structures of MAO-A and MAO-B confirmed the selectivity of binding of this mol. to MAO-B over MAO-A.  In addn., mol. dynamics results also revealed that acacetin 7-Me ether formed a stable and strong complex with MAO-B.  The selective inhibition of MAO-B suggests further investigations on acacetin 7-Me as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFW4SlfsYd7Vg90H21EOLACvtfcHk0lj0YcbFrxUOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7c%253D&md5=0b7c93f7f738147add1c630828c2636e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040810%26sid%3Dliteratum%253Aachs%26aulast%3DChaurasiya%26aufirst%3DN.%2BD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DP.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26aulast%3DMuhammad%26aufirst%3DI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26atitle%3DSelective%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidase%2520B%2520by%2520Acacetin%25207-Methyl%2520Ether%2520Isolated%2520from%2520Turnera%2520Diffusa%2520%2528Damiana%2529%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D810%26doi%3D10.3390%2Fmolecules24040810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel Human Monoamine Oxidase B Inhibitors Based on a Fragment in an X-Ray Crystal Structure</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bmcl.2019.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30792039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFSjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1012-1018&author=K.+Chengauthor=S.+Liauthor=X.+Lvauthor=Y.+Tianauthor=H.+Kongauthor=X.+Huangauthor=Y.+Duanauthor=J.+Hanauthor=Z.+Xieauthor=C.+Liao&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+Human+Monoamine+Oxidase+B+Inhibitors+Based+on+a+Fragment+in+an+X-Ray+Crystal+Structure&doi=10.1016%2Fj.bmcl.2019.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure</span></div><div class="casAuthors">Cheng, Kai; Li, Shiyu; Lv, Xiao; Tian, Yongbin; Kong, Haiyan; Huang, Xufeng; Duan, Yajun; Han, Jihong; Xie, Zhouling; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1012-1018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report our efforts of developing reversible selective hMAO-B inhibitors based on isatin, a fragment in an X-ray crystal structure.  Five different scaffolds were designed and many compds. were synthesized.  Among them, compd. A3(I) demonstrated very high potency and isoform selectivity against hMAO-B, 11 and 13 times more potent (IC50 = 3 nM) and 23.64 and 6.8 times more selective than the marked drugs, selegiline and safinamide.  However, the endeavors to modify the polar 3-one group of isatin, that is in a hydrophobic environment in the binding site of hMAO-B, to small nonpolar hydrophobic groups did not bring about improved hMAO-B inhibitors, which may challenge our understanding of mol. interactions and mol. recognition in biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwXtvwFRCBbVg90H21EOLACvtfcHk0lj0YcbFrxUOMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFSjt7o%253D&md5=404ba3ce4d058c2f6ccb1998a754825d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Human%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520Based%2520on%2520a%2520Fragment%2520in%2520an%2520X-Ray%2520Crystal%2520Structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1012%26epage%3D1018%26doi%3D10.1016%2Fj.bmcl.2019.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7212</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00918</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00918" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7206-7212&author=A.+Fonsecaauthor=J.+Reisauthor=T.+Silvaauthor=M.+J.+Matosauthor=D.+Bagettaauthor=F.+Ortusoauthor=S.+Alcaroauthor=E.+Uriarteauthor=F.+Borges&title=Coumarin+versus+Chromone+Monoamine+Oxidase+B+Inhibitors%3A+Quo+Vadis%3F&doi=10.1021%2Facs.jmedchem.7b00918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?</span></div><div class="casAuthors">Fonseca, Andre; Reis, Joana; Silva, Tiago; Matos, Maria Joao; Bagetta, Donatella; Ortuso, Francesco; Alcaro, Stefano; Uriarte, Eugenio; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7206-7212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chem. entities endowed with IMAO-B still exists.  Within this framework, and for the first time, a study was performed to compare coumarin- and chromone-3-phenylcarboxamide scaffolds.  Compds. I and II were the most potent, selective, and reversible noncompetitive IMAO-B.  The benzopyrone sp2 oxygen atom was found to be position independent and a productive contributor for the ligand-enzyme complex stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogLjC3cJIkZbVg90H21EOLACvtfcHk0lgFnL1e8qO3qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7K&md5=4af88b342ccfe910629ef704b6a65fc6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00918%26sid%3Dliteratum%253Aachs%26aulast%3DFonseca%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DMatos%26aufirst%3DM.%2BJ.%26aulast%3DBagetta%26aufirst%3DD.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DCoumarin%2520versus%2520Chromone%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%253A%2520Quo%2520Vadis%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7206%26epage%3D7212%26doi%3D10.1021%2Facs.jmedchem.7b00918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Multi-Functional Homoisoflavonoid Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterase for the Treatment of Alzheimer’s Disease</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1039/C7MD00199A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1039%2FC7MD00199A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30108857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlajsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1459-1467&author=Q.-H.+Liuauthor=J.-J.+Wuauthor=F.+Liauthor=P.+Caiauthor=X.-L.+Yangauthor=L.-Y.+Kongauthor=X.-B.+Wang&title=Synthesis+and+Pharmacological+Evaluation+of+Multi-Functional+Homoisoflavonoid+Derivatives+as+Potent+Inhibitors+of+Monoamine+Oxidase+B+and+Cholinesterase+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1039%2FC7MD00199A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Liu, Qiao-Hong; Wu, Jia-Jia; Li, Fan; Cai, Pei; Yang, Xue-Lian; Kong, Ling-Yi; Wang, Xiao-Bing</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1459-1467</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of homoisoflavonoid derivs. was designed, synthesized and evaluated as potential multi-functional anti-Alzheimer's agents for their inhibitory activity on cholinesterase and monoamine oxidase.  Among them, compd. 16 showed moderate acetylcholinesterase (AChE) inhibitory activity (eeAChE IC50 = 0.89 ± 0.02 μM; hAChE IC50 = 0.657 ± 0.002 μM) and significant monoamine oxidase B (MAO-B) inhibitory activity (hMAO-B IC50 = 0.0372 ± 0.0002 μM).  Kinetic anal. of AChE, MAO-B inhibition and mol. modeling studies revealed that compd. 16 is a dual binding site inhibitor of AChE and noncompetitive inhibitor of MAO-B.  Furthermore, 16 could penetrate through the blood-brain barrier (BBB) in vitro.  Most importantly, oral administration of 16 demonstrated no marked signs of acute toxicity and it could significantly reverse scopolamine-induced memory impairment in mice.  These results suggested that compd. 16 is a promising multifunctional drug candidate with potential effect for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsOsVTCqBiLVg90H21EOLACvtfcHk0lgFnL1e8qO3qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlajsL0%253D&md5=d79aec56970cb642e678f458900e8458</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC7MD00199A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00199A%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.-H.%26aulast%3DWu%26aufirst%3DJ.-J.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.-L.%26aulast%3DKong%26aufirst%3DL.-Y.%26aulast%3DWang%26aufirst%3DX.-B.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Multi-Functional%2520Homoisoflavonoid%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520of%2520Monoamine%2520Oxidase%2520B%2520and%2520Cholinesterase%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1459%26epage%3D1467%26doi%3D10.1039%2FC7MD00199A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathakam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, G. K.</span></span> <span> </span><span class="NLM_article-title">Refining the Structural Features of Chromones as Selective MAO-B Inhibitors: Exploration of Combined Pharmacophore-Based 3D-QSAR and Quantum Chemical Studies</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11645</span>– <span class="NLM_lpage">11652</span>, <span class="refDoi"> DOI: 10.1002/slct.201701213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fslct.201701213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ksLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=11645-11652&author=B.+Mathewauthor=S.+Devauthor=M.+Joyauthor=G.+E.+Mathewauthor=A.+Marathakamauthor=G.+K.+Krishnan&title=Refining+the+Structural+Features+of+Chromones+as+Selective+MAO-B+Inhibitors%3A+Exploration+of+Combined+Pharmacophore-Based+3D-QSAR+and+Quantum+Chemical+Studies&doi=10.1002%2Fslct.201701213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the Structural Features of Chromones as Selective MAO-B Inhibitors: Exploration of Combined Pharmacophore-Based 3D-QSAR and Quantum Chemical Studies</span></div><div class="casAuthors">Mathew, Bijo; Dev, Sanal; Joy, Monu; Mathew, Githa E.; Marathakam, Akash; Krishnan, Girish K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11645-11652</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthetic chromones are considered as a validated target of the inhibition of monoamine oxidase-B and its relationship to various neurodegenerative diseases is increasing.  Herein described is pharmacophore generation and atom-based 3D-QSAR anal. of previously reported chromone based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity.  The best four-point pharmacophore model with five features AAHRR-3, two hydrogen bond acceptor (A),one hydrophobic groups (H) and two arom. rings (R) as pharmacophore features was developed by PHASE module of Schrodinger suite.  The pharmacophore hypothesis yielded a statistically significant 3D-QSAR model, with a good correlation coeff. (R2=0. 8828), cross validation coeff. (Q2= 0. 7036), and F value 50.2.  In this series, the potent mol. 6-(3-bromobenzyl)-4H-chromen-4-one (5) is further exploited for electrostatic potential surface and analyze the natural bond orbital toward the binding characteristics by using d. functional theory calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv3E2B2ftPgbVg90H21EOLACvtfcHk0lhPpvK2j7ZJSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ksLfO&md5=b750135df682cfac8aa70f38bdfe79e7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fslct.201701213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201701213%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DDev%26aufirst%3DS.%26aulast%3DJoy%26aufirst%3DM.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DMarathakam%26aufirst%3DA.%26aulast%3DKrishnan%26aufirst%3DG.%2BK.%26atitle%3DRefining%2520the%2520Structural%2520Features%2520of%2520Chromones%2520as%2520Selective%2520MAO-B%2520Inhibitors%253A%2520Exploration%2520of%2520Combined%2520Pharmacophore-Based%25203D-QSAR%2520and%2520Quantum%2520Chemical%2520Studies%26jtitle%3DChemistrySelect%26date%3D2017%26volume%3D2%26spage%3D11645%26epage%3D11652%26doi%3D10.1002%2Fslct.201701213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, Y.</span></span> <span> </span><span class="NLM_article-title">2-Styrylchromone Derivatives as Potent and Selective Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>, <span class="NLM_elocation-id">103285</span> <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2019.103285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31561103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&author=K.+Takaoauthor=S.+Endoauthor=J.+Nagaiauthor=H.+Kamauchiauthor=Y.+Takemuraauthor=Y.+Uesawaauthor=Y.+Sugita&title=2-Styrylchromone+Derivatives+as+Potent+and+Selective+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">2-Styrylchromone derivatives as potent and selective monoamine oxidase B inhibitors</span></div><div class="casAuthors">Takao, Koichi; Endo, Saki; Nagai, Junko; Kamauchi, Hitoshi; Takemura, Yuri; Uesawa, Yoshihiro; Sugita, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103285pp.</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-styrylchromone derivs. I [R1 = H, MeO; R2 = H, MeO; R3 = H, MeO; R4 = H, MeO, F, Cl, Br] were synthesized and evaluated for their monoamine oxidase (MAO) A and B inhibitory activities.  Many of the compds. I inhibited MAO-B comparable to pargyline (a pos. control) and most of them inhibited MAO-B selectively.  Among the tested compds., compd. I [R1 = MeO, R2 = R3 = H, R4 = Cl] showed best MAO-B inhibitory activity (IC50 = 17 ± 2.4 nM) and best MAO-B selectivity (IC50 for MAO-A/IC50 for MAO-B = 1500).  The mode of inhibition of compd. I [R1 = MeO, R2 = H, R3 = H, R4 = Cl] against MAO-B was competitive and reversible.  Quant. structure-activity relationship (QSAR) anal. of the compds. I were conducted using their pIC50 values with use of Mol. Operating Environment (MOE) and Dragon, demonstrated that descriptors of MAO-B inhibitory activity and MAO-B selectivity were 1734 and 121, resp., that showed significant correlations (P < 0.05).  The compds. I were examd. through three-dimensional-QSAR studies using AutoGPA, which was based on mol. field anal. algorithm using MOE.  The model using pIC50 value indexes for MAO-B exhibited a detn. coeff. (R2) of 0.873 as well as a Leave-One-Out cross-validated detn. coeff. (Q2) of 0.675.  These data suggested that the 2-styrylchromone structure might be a useful scaffold for design and development of novel MAO-B inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZI-V2XX0HBLVg90H21EOLACvtfcHk0lhPpvK2j7ZJSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksrjL&md5=260276582092cf6034f22ae6c7de96ce</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103285%26sid%3Dliteratum%253Aachs%26aulast%3DTakao%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DNagai%26aufirst%3DJ.%26aulast%3DKamauchi%26aufirst%3DH.%26aulast%3DTakemura%26aufirst%3DY.%26aulast%3DUesawa%26aufirst%3DY.%26aulast%3DSugita%26aufirst%3DY.%26atitle%3D2-Styrylchromone%2520Derivatives%2520as%2520Potent%2520and%2520Selective%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26doi%3D10.1016%2Fj.bioorg.2019.103285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costas-Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Enriquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teran, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Study of Novel 3-Heteroarylcoumarins Based on Pyridazine Scaffold as Selective MAO-B Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=28797881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSmurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=1-11&author=M.+Costas-Lagoauthor=P.+Besadaauthor=F.+Rodriguez-Enriquezauthor=D.+Vinaauthor=S.+Vilarauthor=E.+Uriarteauthor=F.+Borgesauthor=C.+Teran&title=Synthesis+and+Structure-Activity+Relationship+Study+of+Novel+3-Heteroarylcoumarins+Based+on+Pyridazine+Scaffold+as+Selective+MAO-B+Inhibitors&doi=10.1016%2Fj.ejmech.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors</span></div><div class="casAuthors">Costas-Lago, Maria Carmen; Besada, Pedro; Rodriguez-Enriquez, Fernanda; Vina, Dolores; Vilar, Santiago; Uriarte, Eugenio; Borges, Fernanda; Teran, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Compds. of hybrid structure pyridazine-coumarin were discovered as potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B).  These compds. were synthesized in good yield following a multistep approach based on Knoevenagel reaction and using as key pyridazinone intermediate, which was obtained from maleic anhydride and furan.  Compds. I (R = 7-Me and 6-MeO) are the most active compds. of these series, with IC50 values in the sub-micromolar range, and lack of cytotoxic effects.  Theor. calcn. of ADME properties also suggested a good pharmacokinetic profile for both compds.  Docking simulations provided insights into enzyme inhibitor interactions and allowed us to rationalize the obsd. structure-activity relationships (SARs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3LHuEiebcE7Vg90H21EOLACvtfcHk0liSeqVEqIhOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSmurfL&md5=8e57033a18006ba5341e91421e18fa8d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DCostas-Lago%26aufirst%3DM.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DRodriguez-Enriquez%26aufirst%3DF.%26aulast%3DVina%26aufirst%3DD.%26aulast%3DVilar%26aufirst%3DS.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DTeran%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Study%2520of%2520Novel%25203-Heteroarylcoumarins%2520Based%2520on%2520Pyridazine%2520Scaffold%2520as%2520Selective%2520MAO-B%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.ejmech.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 6-methylcoumarin Derivatives as Potent and Selective Monoamine Oxidase B Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">592</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1039/C4MD00437J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1039%2FC4MD00437J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFehtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=592-600&author=J.-S.+Lanauthor=L.-F.+Panauthor=S.-S.+Xieauthor=X.-B.+Wangauthor=L.-Y.+Kong&title=Synthesis+and+Evaluation+of+6-methylcoumarin+Derivatives+as+Potent+and+Selective+Monoamine+Oxidase+B+Inhibitors&doi=10.1039%2FC4MD00437J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective Monoamine Oxidase B inhibitors</span></div><div class="casAuthors">Lan, Jin-Shuai; Pan, Long-Fei; Xie, Sai-Sai; Wang, Xiao-Bing; Kong, Ling-Yi</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">592-600</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new series of 6-methyl-3-phenylcoumarins, e.g., I, and 6-methyl-3-heteroarylcoumarins II (X = thiophen-2-yl, pyridin-3-yl, naphthalen-1-yl, indol-3-yl) had been designed, synthesized and evaluated as monoamine oxidases inhibitors.  The results demonstrated that a large proportion of the synthesized compds. selectively inhibited monoamine oxidase B with IC50 in the sub-micromolar range.  Among them, compd. I (IC50 = 0.0601 μM) exhibited the most potent inhibitory activity and the highest selectivity for monoamine oxidase B (SI > 1664-fold).  In addn., the active compd. I was measured the possible binding model by docking into the active site of hMAO-B complex structure.  The results showed that compd. I interacted with the well-known binding pocket of MAO-B, and a π-π interaction was found between the Ph ring at position 3 of coumarin and the Ph ring of Tyr 326.  Consequently, the useful information about the interaction between the enzyme and inhibitor, and developed the 6-methyl-3-phenylcoumarin scaffold as agents for multifaceted brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr77CJorX3gdLVg90H21EOLACvtfcHk0liSeqVEqIhOHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFehtL%252FE&md5=9c947b24063bdfc43d592f7a4b0caf7d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2FC4MD00437J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00437J%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DJ.-S.%26aulast%3DPan%26aufirst%3DL.-F.%26aulast%3DXie%26aufirst%3DS.-S.%26aulast%3DWang%26aufirst%3DX.-B.%26aulast%3DKong%26aufirst%3DL.-Y.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25206-methylcoumarin%2520Derivatives%2520as%2520Potent%2520and%2520Selective%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D592%26epage%3D600%26doi%3D10.1039%2FC4MD00437J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauhamäki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postila, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niinivehmas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manivannan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahinko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskimies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multamaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvonen, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raunio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentikainen, O. T.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.3389%2Ffchem.2018.00041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=29552556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=41&author=S.+Rauham%C3%A4kiauthor=P.+A.+Postilaauthor=S.+Niinivehmasauthor=S.+Kortetauthor=E.+Schildtauthor=M.+Pasanenauthor=E.+Manivannanauthor=M.+Ahinkoauthor=P.+Koskimiesauthor=N.+Nybergauthor=P.+Huuskonenauthor=E.+Multamakiauthor=M.+Pasanenauthor=R.+O.+Juvonenauthor=H.+Raunioauthor=J.+Huuskonenauthor=O.+T.+Pentikainen&title=Structure-Activity+Relationship+Analysis+of+3-Phenylcoumarin-Based+Monoamine+Oxidase+B+Inhibitors&doi=10.3389%2Ffchem.2018.00041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship analysis of 3-phenylcoumarin-based monoamine oxidase B inhibitors</span></div><div class="casAuthors">Rauhamaki, Sanna; Postila, Pekka A.; Niinivehmas, Sanna; Kortet, Sami; Schildt, Emmi; Pasanen, Mira; Manivannan, Elangovan; Ahinko, Mira; Koskimies, Pasi; Nyberg, Niina; Huuskonen, Pasi; Multamaki, Elina; Pasanen, Markku; Juvonen, Risto O.; Raunio, Hannu; Huuskonen, Juhani; Pentikainen, Olli T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41/1-41/18</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine.  Accordingly, small-mol. MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease.  Coumarin with a functionalized 3-Ph ring system is a promising scaffold for building potent MAO-B inhibitors.  Here, a vast set of 3-phenylcoumarin derivs. I (R = 4-F3CC6H4, 4-MeOC6H4, 3-MeOC6H4, etc.; R' = 6-OMe, 7-OMe, 7-AcO, etc.) was designed using virtual combinatorial chem. or rationally de novo and synthesized using microwave chem.  The derivs. inhibited the MAO-B at 100 nM-1 μM.  The IC50 value of the most potent deriv. I (R = 4-F3CC6H4; R' = 6-OMe) was 56 nM.  A docking-based structure-activity relationship anal. summarizes the atom-level determinants of the MAO-B inhibition by the derivs.  Finally, the cross-reactivity of the derivs. was tested against monoamine oxidase A and a specific subset of enzymes linked to estradiol metab., known to have coumarin-based inhibitors.  Overall, the results indicate that the 3-phenylcoumarins, esp. deriv. I (R = 4-F3CC6H4; R' = 6-OMe), present unique pharmacol. features worth considering in future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCjgSWub9FAbVg90H21EOLACvtfcHk0lhyPKDPNic1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egs7nK&md5=5f93818f66c330d30ba808c3a8923cf4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00041%26sid%3Dliteratum%253Aachs%26aulast%3DRauham%25C3%25A4ki%26aufirst%3DS.%26aulast%3DPostila%26aufirst%3DP.%2BA.%26aulast%3DNiinivehmas%26aufirst%3DS.%26aulast%3DKortet%26aufirst%3DS.%26aulast%3DSchildt%26aufirst%3DE.%26aulast%3DPasanen%26aufirst%3DM.%26aulast%3DManivannan%26aufirst%3DE.%26aulast%3DAhinko%26aufirst%3DM.%26aulast%3DKoskimies%26aufirst%3DP.%26aulast%3DNyberg%26aufirst%3DN.%26aulast%3DHuuskonen%26aufirst%3DP.%26aulast%3DMultamaki%26aufirst%3DE.%26aulast%3DPasanen%26aufirst%3DM.%26aulast%3DJuvonen%26aufirst%3DR.%2BO.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DHuuskonen%26aufirst%3DJ.%26aulast%3DPentikainen%26aufirst%3DO.%2BT.%26atitle%3DStructure-Activity%2520Relationship%2520Analysis%2520of%25203-Phenylcoumarin-Based%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D41%26doi%3D10.3389%2Ffchem.2018.00041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarmouh, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, K. F. A.</span></span> <span> </span><span class="NLM_article-title">The Benzopyrone Biochanin-A as a Reversible, Competitive, and Delective Monoamine Oxidase B inhibitor</span>. <i>BMC Complementary Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">34</span> <span class="refDoi"> DOI: 10.1186/s12906-016-1525-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2Fs12906-016-1525-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=28069007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12gurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&author=N.+O.+Zarmouhauthor=S.+K.+Eyunniauthor=K.+F.+A.+Soliman&title=The+Benzopyrone+Biochanin-A+as+a+Reversible%2C+Competitive%2C+and+Delective+Monoamine+Oxidase+B+inhibitor&doi=10.1186%2Fs12906-016-1525-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor</span></div><div class="casAuthors">Zarmouh, Najla O.; Eyunni, Suresh K.; Soliman, Karam F. A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Complementary and Alternative Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/13</span>CODEN:
                <span class="NLM_cas:coden">BCAMCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6882</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Monoamine oxidase-B (MAO-B) inhibitors are widely used in the treatment of Parkinson's disease.  They increase vital monoamine neurotransmitters in the brain.  However, there is a need for safer natural reversible MAO inhibitors with MAO-B selectivity.  Our previous studies showed that Psoralea corylifolia seeds (PCS) ext. contains compds. that inhibit monoamine oxidase-B.  Methods: In this study, six of PCS constituents sharing a benzopyrone structure were investigated.  The compds. Biochanin-A (BIO-A), isopsoralen, 6-prenylnaringenin, neobavaisoflavone, psoralen, and psoralidin, were tested for their ability to inhibit recombinant human MAO-A and B (hMAO-A and hMAO-B) isoenzymes.  The ability of these compds. to inhibit MAO-A and MAO-B were compared to that of PCS ethanolic ext. (PCSEE) using spectrophotometric assays and confirmed by luminescence assays.  The highly potent and selective MAO-B inhibitor, BIO-A, was further investigated for both isoenzymes reversibility and enzyme kinetics.  Mol. docking studies were used to predict the bioactive conformation and mol. interactions of BIO-A with both isoenzymes.  Results: The data obtained indicate that benzopyrones inhibited hMAO-A and hMAO-B with different degrees as confirmed with the luminescence assay.  BIO-A inhibited hMAO-B with high potency and selectivity in the present study (IC50 = 0.003 μg/mL) and showing 38-fold more selectivity than PCSEE (hMAO-B IC50 = 3.03 μg/mL, 17-fold selectivity) without affecting hydrogen peroxide.  Furthermore, BIO-A reversibly and competitively inhibited both hMAOs with significantly lower inhibitory const. (Ki) in hMAO-B (3.8 nM) than hMAO-A (99.3 nM).  Our docking studies indicated that the H-bonds and hydrophobic interactions at the human MAO-A and MAO-B active sites contributed to the reversibility and selectivity of BIO-A.  Conclusions: The data obtained indicate that BIO-A is a potent, reversible and selective MAO-B inhibitor and may be recommended for further investigation in its possible use in the therapeutic management of Parkinson's and Alzheimer's diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9S0IYf1Lw7Vg90H21EOLACvtfcHk0lhyPKDPNic1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12gurc%253D&md5=233bdfb95e7ddd2524648c1c1a768b26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs12906-016-1525-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12906-016-1525-y%26sid%3Dliteratum%253Aachs%26aulast%3DZarmouh%26aufirst%3DN.%2BO.%26aulast%3DEyunni%26aufirst%3DS.%2BK.%26aulast%3DSoliman%26aufirst%3DK.%2BF.%2BA.%26atitle%3DThe%2520Benzopyrone%2520Biochanin-A%2520as%2520a%2520Reversible%252C%2520Competitive%252C%2520and%2520Delective%2520Monoamine%2520Oxidase%2520B%2520inhibitor%26jtitle%3DBMC%2520Complementary%2520Altern.%2520Med.%26date%3D2017%26volume%3D17%26doi%3D10.1186%2Fs12906-016-1525-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orallo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span> <span> </span><span class="NLM_article-title">Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.1021/jm801590u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801590u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2818-2824&author=F.+Chimentiauthor=R.+Fioravantiauthor=A.+Bolascoauthor=P.+Chimentiauthor=D.+Secciauthor=F.+Rossiauthor=M.+Yanezauthor=F.+Oralloauthor=F.+Ortusoauthor=S.+Alcaro&title=Chalcones%3A+A+Valid+Scaffold+for+Monoamine+Oxidases+Inhibitors&doi=10.1021%2Fjm801590u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors</span></div><div class="casAuthors">Chimenti, Franco; Fioravanti, Rossella; Bolasco, Adriana; Chimenti, Paola; Secci, Daniela; Rossi, Francesca; Yanez, Matilde; Orallo, Francisco; Ortuso, Francesco; Alcaro, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2818-2824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A large series of substituted chalcones have been synthesized and tested in vitro for their ability to inhibit human monoamine oxidases A and B (hMAO-A and hMAO-B).  While all the compds. showed hMAO-B selective activity in the micro- and nanomolar ranges, the best results were obtained in the presence of chlorine and hydroxyl or methoxyl substituents.  To better understand the enzyme-inhibitor interaction and to explain the selectivity of the most active compds. toward hMAO-B, mol. modeling studies were carried out on new, high resoln., hMAO-B crystallog. structures.  For the only compd. that also showed activity against hMAO-A as well as low selectivity, the mol. modeling study was also performed on the hMAO-A crystallog. structure.  The docking technique provided new insight on the inhibition mechanism and the rational drug design of more potent/selective hMAO inhibitors based on the chalcone scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs56ytduJPsrVg90H21EOLACvtfcHk0lg4tFj-ppWvwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSltrs%253D&md5=19de38043049fc0249b2f9912bb32729</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm801590u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801590u%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26atitle%3DChalcones%253A%2520A%2520Valid%2520Scaffold%2520for%2520Monoamine%2520Oxidases%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2818%26epage%3D2824%26doi%3D10.1021%2Fjm801590u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Chalcones as Potent Selective Monoamine Oxidase-B Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2016.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26974383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=162-169&author=A.+Hammudaauthor=R.+Shalabyauthor=S.+Rovidaauthor=D.+E.+Edmondsonauthor=C.+Bindaauthor=A.+Khalil&title=Design+and+Synthesis+of+Novel+Chalcones+as+Potent+Selective+Monoamine+Oxidase-B+Inhibitors&doi=10.1016%2Fj.ejmech.2016.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors</span></div><div class="casAuthors">Hammuda, Arwa; Shalaby, Raed; Rovida, Stefano; Edmondson, Dale E.; Binda, Claudia; Khalil, Ashraf</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of substituted chalcones I (R1 = H, CF3; R2 = H, CF3, OCF3; R3 = H, SO2CH3, SCH3; R4 = R5 = OCH3, OCH2O) were designed and synthesized to be evaluated as selective human MAO-B inhibitors.  A combination of either methylsulfonyl or trifluoromethyl substituents on the arom. ketone moiety with a benzodioxol ring on the other end of the chalcone scaffold was investigated.  The compds. were tested for their inhibitory activities on both human MAO-A and B.  All compds. appeared to be selective MAO-B inhibitors with Ki values in the micromolar to submicromolar range.  Mol. modeling studies have been performed to get insight into the binding mode of the synthesized compds. to human MAO-B active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVIEGMTEF617Vg90H21EOLACvtfcHk0lg4tFj-ppWvwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gurg%253D&md5=cf213d3c91a3c52175ea29270ec8d8f2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DHammuda%26aufirst%3DA.%26aulast%3DShalaby%26aufirst%3DR.%26aulast%3DRovida%26aufirst%3DS.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DKhalil%26aufirst%3DA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Chalcones%2520as%2520Potent%2520Selective%2520Monoamine%2520Oxidase-B%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D114%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.ejmech.2016.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baysal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilapurathu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakasan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Development of Fluorinated Methoxylated Chalcones as Selective Monoamine Oxidase-B Inhibitors: Synthesis, Biochemistry and Molecular Docking Studies</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26189013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=22-29&author=B.+Mathewauthor=G.+E.+Mathewauthor=G.+Ucarauthor=I.+Baysalauthor=J.+Sureshauthor=J.+K.+Vilapurathuauthor=A.+Prakasanauthor=J.+K.+Sureshauthor=A.+Thomas&title=Development+of+Fluorinated+Methoxylated+Chalcones+as+Selective+Monoamine+Oxidase-B+Inhibitors%3A+Synthesis%2C+Biochemistry+and+Molecular+Docking+Studies&doi=10.1016%2Fj.bioorg.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies</span></div><div class="casAuthors">Mathew, Bijo; Mathew, Githa Elizabeth; Ucar, Gulberk; Baysal, Ipek; Suresh, Jerad; Vilapurathu, Jobin Kunjumon; Prakasan, Aneesh; Suresh, Jeethu Kuruppath; Thomas, Anjana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of methoxylated chalcones with fluoro and trifluoromethyl derivs. were synthesized and investigated for their ability to inhibit human monoamine oxidase A and B.  The chem. structures of the compds. have been characterized by means of their 1H NMR, 13C NMR, Mass spectroscopic datas and elemental anal.  The results demonstrate that these compds. are reversible and selective MAO-B inhibitors with a competitive mode of inhibition.  The most potent compd. (2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl] prop-2-en-1-one showed the best activity and higher selectivity towards hMAO-B with Ki and SI values of 0.22 ± 0.01 μM and 0.05 comparable to that std. drug, Selegiline Ki and SI values were found as 0.33 ± 0.03 μM and 0.04, resp.  Mol. docking studies were carried out to further explain the in vitro results of the new compds., and to identify the hypothetical binding mode for the compds. inside the inhibitor binding cavity of hMAO-B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt6ZptTGtMXbVg90H21EOLACvtfcHk0lgFGTLd4xBhrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktLjE&md5=03ebfa985474e683cbc2e89c956d981d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DUcar%26aufirst%3DG.%26aulast%3DBaysal%26aufirst%3DI.%26aulast%3DSuresh%26aufirst%3DJ.%26aulast%3DVilapurathu%26aufirst%3DJ.%2BK.%26aulast%3DPrakasan%26aufirst%3DA.%26aulast%3DSuresh%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Fluorinated%2520Methoxylated%2520Chalcones%2520as%2520Selective%2520Monoamine%2520Oxidase-B%2520Inhibitors%253A%2520Synthesis%252C%2520Biochemistry%2520and%2520Molecular%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Chem.%26date%3D2015%26volume%3D62%26spage%3D22%26epage%3D29%26doi%3D10.1016%2Fj.bioorg.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purapurath, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moolayil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2655</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fcmdc.201600497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27902880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2649-2655&author=B.+Mathewauthor=G.+Ucarauthor=G.+E.+Mathewauthor=S.+Mathewauthor=P.+K.+Purapurathauthor=F.+Moolayilauthor=S.+Mohanauthor=S.+V.+Gupta&title=Monoamine+Oxidase+Inhibitory+Activity%3A+Methyl-+versus+Chlorochalcone+Derivatives&doi=10.1002%2Fcmdc.201600497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives</span></div><div class="casAuthors">Mathew, Bijo; Ucar, Guelberk; Mathew, Githa Elizabeth; Mathew, Sincy; Kalatharakkal Purapurath, Praseedha; Moolayil, Fasil; Mohan, Smrithy; Varghese Gupta, Sheeba</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2649-2655</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Numerous studies have shown that chalcones are promising scaffolds for the development of new monoamine oxidase-B (MAO-B) inhibitors.  As a continuation of our ongoing research into the development of reversible human MAO-B (hMAO-B) inhibitors, two series of twenty chalcones contg. electron-donating and electron-withdrawing substituents were synthesized.  All compds. were found to be competitive, selective, and reversible inhibitors of hMAO-B except (2E)-1-(4-methylphenyl)-3-(4-nitrophenyl)prop-2-en-1-one (P7) and (2E)-1-(4-chlorophenyl)-3-(4-nitrophenyl)prop-2-en-1-one (P17), which were found to be selective inhibitors of hMAO-A.  The most potent hMAO-B inhibitor, (2E)-1-(4-chlorophenyl)-3-(4-ethylphenyl)prop-2-en-1-one (P16), showed a Ki value of 0.11±0.01 μM.  Mol. docking simulations were carried out to identify the hypothetical binding mode for the most potent compds. in the active sites of hMAO-A and B.  The ability of the compds. to cross the blood-brain barrier was assessed by parallel artificial membrane permeability assay (PAMPA).  Addnl., the most potent hMAO-B inhibitor P16 showed no toxicity in cultured hepatic cells at concns. of 5 and 25 μm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1gWxj-ViSlLVg90H21EOLACvtfcHk0lgFGTLd4xBhrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnu77N&md5=43c76cc1c40c6925590995ae03309fcb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600497%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DUcar%26aufirst%3DG.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DPurapurath%26aufirst%3DP.%2BK.%26aulast%3DMoolayil%26aufirst%3DF.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DS.%2BV.%26atitle%3DMonoamine%2520Oxidase%2520Inhibitory%2520Activity%253A%2520Methyl-%2520versus%2520Chlorochalcone%2520Derivatives%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2649%26epage%3D2655%26doi%3D10.1002%2Fcmdc.201600497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parambi, D. G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tondo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Oxygenated Chalcones as Potent and Selective MAO-B Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">103335</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2019.103335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31606547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKrs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=103335&author=D.+G.+T.+Parambiauthor=J.+M.+Ohauthor=S.+C.+Baekauthor=J.+P.+Leeauthor=A.+R.+Tondoauthor=O.+Nicolottiauthor=H.+Kimauthor=B.+Mathew&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Oxygenated+Chalcones+as+Potent+and+Selective+MAO-B+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors</span></div><div class="casAuthors">Parambi, Della Grace Thomas; Oh, Jong Min; Baek, Seung Cheol; Lee, Jae Pil; Tondo, Anna Rita; Nicolotti, Orazio; Kim, Hoon; Mathew, Bijo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103335pp.</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study documented the synthesis of oxygenated chalcone derivs. I [R = H, 4-OH, 4-Ph, etc.; n = 1, 2] and their abilities to inhibit monoamine oxidases.  Compd. I [R = 4-F, n = 2] showed the greatest inhibitory activity against MAO-B with an IC50 value of 0.0021 μM, followed by compds. I [R = 4-F, n = 1; R = 4-Me, n = 2] (IC50 = 0.0030 and 0.0034 μM, resp.).  In addn., most of the derivs. potently inhibited MAO-A and I [R = 4-Ph, n = 1] was the most potent inhibitor with an IC50 value of 0.029 μM, followed by I [R = 4-OMe, n = 1; R = 4-Me, n = 1; 4-Br, n = 1; 4-OH, n = 1] (IC50 = 0.035, 0.053, 0.072, and 0.082 μM, resp.).  Compd. I [R = 4-F, n = 2] had a high selectivity index (SI) value for MAO-B of 138.1, and Compd. I [R = 4-NO2, n = 2] (IC50 value for MAO-B = 0.010 μM) had an extremely high SI of >4000.  Kinetic studies revealed that I [R = 4-Ph, 2=1; R = 4-F, n = 2] competitively inhibited MAO-A and MAO-B, resp., with resp. Ki values of 0.016 ± 0.0007 and 0.00050 ± 0.00003 μM.  Lead compd. were also non-toxic at 200 μg/mL in normal rat spleen cells.  Mol. docking simulations and subsequent Mol. Mechanics/Generalized Born Surface Area calcns. provided a rationale that explained exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPZEFZVfdKhLVg90H21EOLACvtfcHk0lgHYb0hpeZUZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKrs77O&md5=e0f76ef7520947ec16d94b1b430f92b6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103335%26sid%3Dliteratum%253Aachs%26aulast%3DParambi%26aufirst%3DD.%2BG.%2BT.%26aulast%3DOh%26aufirst%3DJ.%2BM.%26aulast%3DBaek%26aufirst%3DS.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BP.%26aulast%3DTondo%26aufirst%3DA.%2BR.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMathew%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Oxygenated%2520Chalcones%2520as%2520Potent%2520and%2520Selective%2520MAO-B%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D93%26spage%3D103335%26doi%3D10.1016%2Fj.bioorg.2019.103335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Hydroxypyridinone-Coumarin Hybrids as Multimodal Monoamine Oxidase B Inhibitors and Iron Chelates Against Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2019.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31325784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWltLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2019&pages=367-382&author=C.+Zhangauthor=K.+Yangauthor=S.+Yuauthor=J.+Suauthor=S.+Yuanauthor=J.+Hanauthor=Y.+Chenauthor=J.+Guauthor=T.+Zhouauthor=R.+Baiauthor=Y.+Xie&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Hydroxypyridinone-Coumarin+Hybrids+as+Multimodal+Monoamine+Oxidase+B+Inhibitors+and+Iron+Chelates+Against+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2019.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease</span></div><div class="casAuthors">Zhang, Changjun; Yang, Ke; Yu, Sihang; Su, Jing; Yuan, Shengli; Han, Jiaxin; Chen, Yan; Gu, Jinping; Zhou, Tao; Bai, Renren; Xie, Yuanyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-382</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hydroxypyridinone-substituted coumarins I (R1 = H, Me; R2 = H, Me, Et; R3 = H, R4O; R4 = Me, PhCH2, HC≡CCH2, 3-ClC6H4CH2, 3-FC6H4CH2, 4-FC6H4CH2, 3,5-F2C6H3CH2) were prepd. as dual iron chelators and monoamine oxidase B (MAO-B) inhibitors for potential use in the treatment of Alzheimer's disease.  I (R1 = H; R2 = Me; R3 = 3-FC6H4CH2O) (II) exhibited the most potent activity against MAO-B, with an IC50 value of 14.7 nM.  II protected U251 cells against oxidative stress and ameliorated murine scopolamine-induced cognitive dysfunction in a model for Alzheimer's disease.  Mol. docking calcns. for the binding of II to MAO-B were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVzvO3fV-0LVg90H21EOLACvtfcHk0lgHYb0hpeZUZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWltLvK&md5=422cebd0966ebb383e0e5384e276ea21</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Hydroxypyridinone-Coumarin%2520Hybrids%2520as%2520Multimodal%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520and%2520Iron%2520Chelates%2520Against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D180%26spage%3D367%26epage%3D382%26doi%3D10.1016%2Fj.ejmech.2019.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span> <span> </span><span class="NLM_article-title">Novel Isoxazole Derivatives as Potential Antiparkinson Agents: Synthesis, Evaluation of Monoamine Oxidase Inhibitory Activity and Docking Studies</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1501</span>, <span class="refDoi"> DOI: 10.1007/s00044-019-02388-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1007%2Fs00044-019-02388-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yktLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=1488-1501&author=N.+Agrawalauthor=P.+Mishra&title=Novel+Isoxazole+Derivatives+as+Potential+Antiparkinson+Agents%3A+Synthesis%2C+Evaluation+of+Monoamine+Oxidase+Inhibitory+Activity+and+Docking+Studies&doi=10.1007%2Fs00044-019-02388-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies</span></div><div class="casAuthors">Agrawal, Neetu; Mishra, Pradeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1488-1501</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Selective monoamine oxidase B inhibitors are potential drug candidates for the treatment of Parkinson's disease.  A series of Ph substituted isoxazole carbohydrazides was designed by structural modification of isocarboxazid, a nonselective MAO inhibitor and evaluated as inhibitors of MAO-A and MAO-B.  The compds. were not able to inhibit MAO-A significantly, but most of the compds. exhibited potent inhibitory activity against MAO-B.  The enzyme kinetic study of the most active compds. 5d, 5-phenyl-N'-(1-(p-tolyl)ethylidene)isoxazole-3-carbohydrazide and 5g, N'-(1-(3,4-dimethoxyphenyl)ethylidene)-5-phenylisoxazole-3-carbohydrazide displayed reversible and competitive MAO-B inhibition.  In mol. modeling studies, compds. 5d and 5g exhibited strong binding affinity on MAO-B active site.  The administration of compds. 5d and 5g exhibited prevention of MPTP-induced Parkinsonism as indicated by footprint anal. and horizontal wire tests.  Further optimization studies are essential to exploit their potential for MAO-B assocd. neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDF_zYt8YmLVg90H21EOLACvtfcHk0lgHYb0hpeZUZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yktLvM&md5=a063f977546634efea11a18b94f9e7e9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00044-019-02388-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-019-02388-4%26sid%3Dliteratum%253Aachs%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%26atitle%3DNovel%2520Isoxazole%2520Derivatives%2520as%2520Potential%2520Antiparkinson%2520Agents%253A%2520Synthesis%252C%2520Evaluation%2520of%2520Monoamine%2520Oxidase%2520Inhibitory%2520Activity%2520and%2520Docking%2520Studies%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2019%26volume%3D28%26spage%3D1488%26epage%3D1501%26doi%3D10.1007%2Fs00044-019-02388-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Çevik, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmaniye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglik, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavusoglu, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozkay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplancikli, Z. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of New Pyrazoline-Thiazole Derivatives as Monoamine Oxidase Inhibitors</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3000</span>– <span class="NLM_lpage">3007</span>, <span class="refDoi"> DOI: 10.1002/jhet.3694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fjhet.3694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=3000-3007&author=U.+A.+%C3%87evikauthor=D.+Osmaniyeauthor=B.+N.+Saglikauthor=S.+Leventauthor=B.+K.+Cavusogluauthor=Y.+Ozkayauthor=Z.+A.+Kaplancikli&title=Synthesis+and+Evaluation+of+New+Pyrazoline-Thiazole+Derivatives+as+Monoamine+Oxidase+Inhibitors&doi=10.1002%2Fjhet.3694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjhet.3694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.3694%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2587evik%26aufirst%3DU.%2BA.%26aulast%3DOsmaniye%26aufirst%3DD.%26aulast%3DSaglik%26aufirst%3DB.%2BN.%26aulast%3DLevent%26aufirst%3DS.%26aulast%3DCavusoglu%26aufirst%3DB.%2BK.%26aulast%3DOzkay%26aufirst%3DY.%26aulast%3DKaplancikli%26aufirst%3DZ.%2BA.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520New%2520Pyrazoline-Thiazole%2520Derivatives%2520as%2520Monoamine%2520Oxidase%2520Inhibitors%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2019%26volume%3D56%26spage%3D3000%26epage%3D3007%26doi%3D10.1002%2Fjhet.3694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maccioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirilli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distinto, S.</span></span> <span> </span><span class="NLM_article-title">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: A New Scaffold for the Selective Inhibition of Monoamine Oxidase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6394</span>– <span class="NLM_lpage">6398</span>, <span class="refDoi"> DOI: 10.1021/jm2002876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2002876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6394-6398&author=E.+Maccioniauthor=S.+Alcaroauthor=R.+Cirilliauthor=S.+Vigoauthor=M.+C.+Cardiaauthor=M.+L.+Sannaauthor=R.+Meledduauthor=M.+Yanezauthor=G.+Costaauthor=L.+Casuauthor=P.+Matyusauthor=S.+Distinto&title=3-Acetyl-2%2C5-diaryl-2%2C3-dihydro-1%2C3%2C4-oxadiazoles%3A+A+New+Scaffold+for+the+Selective+Inhibition+of+Monoamine+Oxidase+B&doi=10.1021%2Fjm2002876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: A new scaffold for the selective inhibition of monoamine oxidase B</span></div><div class="casAuthors">Maccioni, Elias; Alcaro, Stefano; Cirilli, Roberto; Vigo, Sara; Cardia, Maria Cristina; Sanna, Maria Luisa; Meleddu, Rita; Yanez, Matilde; Costa, Giosue; Casu, Laura; Matyus, Peter; Distinto, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6394-6398</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles e. g., I were designed, synthesized, and tested as inhibitors against human monoamine oxidase (MAO) A and B isoforms.  Several compds., obtained as racemates, were identified as selective MAO-B inhibitors.  The enantiomers of some derivs. were sepd. by enantioselective HPLC and tested.  The R-enantiomers always showed the highest activity.  Docking study and mol. dynamic simulations demonstrated the putative binding mode.  We conclude that these 1,3,4-oxadiazoles derivs. are promising reversible and selective MAO-B inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9WwTBeNWDFrVg90H21EOLACvtfcHk0lifL1RRjZU1bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7zP&md5=0ebf27c64e591293045768508dd61ef8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm2002876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002876%26sid%3Dliteratum%253Aachs%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DVigo%26aufirst%3DS.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DMeleddu%26aufirst%3DR.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DCasu%26aufirst%3DL.%26aulast%3DMatyus%26aufirst%3DP.%26aulast%3DDistinto%26aufirst%3DS.%26atitle%3D3-Acetyl-2%252C5-diaryl-2%252C3-dihydro-1%252C3%252C4-oxadiazoles%253A%2520A%2520New%2520Scaffold%2520for%2520the%2520Selective%2520Inhibition%2520of%2520Monoamine%2520Oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6394%26epage%3D6398%26doi%3D10.1021%2Fjm2002876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chooaii, H.</span></span> <span> </span><span class="NLM_article-title">Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1519-1529&author=M.-H.+Namauthor=M.+Parkauthor=H.+Parkauthor=Y.+Kimauthor=S.+Yoonauthor=V.+S.+Sawantauthor=J.+W.+Choauthor=J.-H.+Parkauthor=K.+D.+Parkauthor=S.-J.+Minauthor=C.+J.+Leeauthor=H.+Chooaii&title=Indole-Substituted+Benzothiazoles+and+Benzoxazoles+as+Selective+and+Reversible+MAO-B+Inhibitors+for+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.7b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease</span></div><div class="casAuthors">Nam, Min-Ho; Park, Moosung; Park, Hyeri; Kim, Youngjae; Yoon, Seulki; Sawant, Vikram Shahaji; Choi, Ji Won; Park, Jong-Hyun; Park, Ki Duk; Min, Sun-Joon; Lee, C. Justin; Choo, Hyunah</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1529</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivs. with indole moiety were designed and synthesized.  Most of the synthesized compds. showed inhibitory activities against MAO-B and selectivity over MAO-A.  The most active compd. was Compd. 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 29 nM with no apparent effect on MAO-A activity at 10 nM.  Based on the reversibility assay, Compd. 5b turned out to be a fully reversible with over 95% of recovery of enzyme activity after washout of the compd.  Compd. 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isoenzymes, suggesting an absence of high-risk drug-drug interaction.  In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of Compd. 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test.  In summary, the novel, reversible and selective MAO-B inhibitor compd. 5b was synthesized and characterized.  We propose compd. 5b as an effective therapeutic compd. for relieving parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLH2gmh-wolLVg90H21EOLACvtfcHk0lifL1RRjZU1bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlsrk%253D&md5=e1b9a40a1fd21d03c467463d3c5c773e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00050%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DM.-H.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSawant%26aufirst%3DV.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DK.%2BD.%26aulast%3DMin%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DChooaii%26aufirst%3DH.%26atitle%3DIndole-Substituted%2520Benzothiazoles%2520and%2520Benzoxazoles%2520as%2520Selective%2520and%2520Reversible%2520MAO-B%2520Inhibitors%2520for%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1519%26epage%3D1529%26doi%3D10.1021%2Facschemneuro.7b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ascenzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span> <span> </span><span class="NLM_article-title">4-(3-Nitrophenyl)thiazol-2-ylhydrazone Derivatives as Antioxidants and Selective Hmao-B Inhibitors: Synthesis, Biological Activity and Computational Analysis</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1571272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1080%2F14756366.2019.1571272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30727777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFyls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=597-612&author=D.+Secciauthor=S.+Carradoriauthor=A.+Petzerauthor=P.+Guglielmiauthor=M.+D%E2%80%99Ascenzioauthor=P.+Chimentiauthor=D.+Bagettaauthor=S.+Alcaroauthor=G.+Zenginauthor=J.+P.+Petzerauthor=F.+Ortuso&title=4-%283-Nitrophenyl%29thiazol-2-ylhydrazone+Derivatives+as+Antioxidants+and+Selective+Hmao-B+Inhibitors%3A+Synthesis%2C+Biological+Activity+and+Computational+Analysis&doi=10.1080%2F14756366.2019.1571272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis</span></div><div class="casAuthors">Secci, Daniela; Carradori, Simone; Petzer, Anel; Guglielmi, Paolo; D'Ascenzio, Melissa; Chimenti, Paola; Bagetta, Donatella; Alcaro, Stefano; Zengin, Gokhan; Petzer, Jacobus P.; Ortuso, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">597-612</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivs. were designed, synthesized, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms.  Different (un)substituted (hetero)arom. substituents were linked to N1 of the hydrazone in order to establish robust structure-activity relationships.  The results of the biol. testing demonstrated that the presence of the hydrazothiazole nucleus bearing at C4 a Ph ring functionalised at the meta position with a nitro group represents an important pharmacophoric feature to obtain selective and reversible human MAO-B inhibition for the treatment of neurodegenerative disorders.  In addn., the most potent and selective MAO-B inhibitors were evaluated in silico as potential cholinesterase (AChE/BuChE) inhibitors and in vitro for antioxidant activities.  The results obtained from mol. modeling studies provided insight into the multiple interactions and structural requirements for the reported MAO inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVVXzLN6Ry-bVg90H21EOLACvtfcHk0lgEtb_i1cLRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFyls7o%253D&md5=17a294132656b24304b7d597c720ab29</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1571272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1571272%26sid%3Dliteratum%253Aachs%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DPetzer%26aufirst%3DA.%26aulast%3DGuglielmi%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Ascenzio%26aufirst%3DM.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DBagetta%26aufirst%3DD.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DZengin%26aufirst%3DG.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DOrtuso%26aufirst%3DF.%26atitle%3D4-%25283-Nitrophenyl%2529thiazol-2-ylhydrazone%2520Derivatives%2520as%2520Antioxidants%2520and%2520Selective%2520Hmao-B%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Activity%2520and%2520Computational%2520Analysis%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D597%26epage%3D612%26doi%3D10.1080%2F14756366.2019.1571272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer’s Disease Agents</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWhurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=482-496&author=Y.+Xuauthor=J.+Zhangauthor=H.+Wangauthor=F.+Maoauthor=K.+Baoauthor=W.+Liuauthor=J.+Zhuauthor=X.+Liauthor=H.+Zhangauthor=J.+Li&title=Rational+Design+of+Novel+Selective+Dual-Target+Inhibitors+of+Acetylcholinesterase+and+Monoamine+Oxidase+B+as+Potential+Anti-Alzheimer%E2%80%99s+Disease+Agents&doi=10.1021%2Facschemneuro.8b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents</span></div><div class="casAuthors">Xu, Yixiang; Zhang, Jian; Wang, Huan; Mao, Fei; Bao, Keting; Liu, Wenwen; Zhu, Jin; Li, Xiaokang; Zhang, Haiyan; Li, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-496</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multifunctional agents aiming at cholinesterases (ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer's disease (AD).  Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivs. (1-4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD.  Most of these derivs. inhibited ChEs and MAOs with IC50 values in the micro- or nanomolar ranges.  Compd. 1c displayed the dual functional profile of targeting the AChE (IC50 = 0.032 ± 0.007 μM) and MAO-B (IC50 = 2.117 ± 0.061 μM), along with the improved blood-brain barrier (BBB) permeability, antioxidant ability, and good copper chelating property in vitro.  Animal studies showed that compd. 1c·HCl could inhibit the cerebral AChE/MAO-B activities and alleviate scopolamine-induced cognitive impairment in mice.  Combined with good oral bioavailability (F = 45.55%), these findings demonstrated that compd. 1c may be a potent brain permeable multifunctional candidate for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCWPsXuTCo7Vg90H21EOLACvtfcHk0lgEtb_i1cLRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWhurjL&md5=c72dcad03095270b30de8a72ffe19ea1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00357%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DBao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRational%2520Design%2520of%2520Novel%2520Selective%2520Dual-Target%2520Inhibitors%2520of%2520Acetylcholinesterase%2520and%2520Monoamine%2520Oxidase%2520B%2520as%2520Potential%2520Anti-Alzheimer%25E2%2580%2599s%2520Disease%2520Agents%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D482%26epage%3D496%26doi%3D10.1021%2Facschemneuro.8b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagide, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavarria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5879</span>– <span class="NLM_lpage">5893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5879-5893&author=J.+Reisauthor=F.+Cagideauthor=D.+Chavarriaauthor=T.+Silvaauthor=C.+Fernandesauthor=A.+Gasparauthor=E.+Uriarteauthor=F.+Remiaoauthor=S.+Alcaroauthor=F.+Ortusoauthor=F.+Borges&title=Discovery+of+New+Chemical+Entities+for+Old+Targets%3A+Insights+on+the+Lead+Optimization+of+Chromone-Based+Monoamine+Oxidase+B+%28MAO-B%29+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors</span></div><div class="casAuthors">Reis, Joana; Cagide, Fernando; Chavarria, Daniel; Silva, Tiago; Fernandes, Carlos; Gaspar, Alexandra; Uriarte, Eugenio; Remiao, Fernando; Alcaro, Stefano; Ortuso, Francesco; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5879-5893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new chem. entities endowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clin. relevant subject.  Therefore, a small library of chromone derivs. was synthesized and screened toward human monoamine oxidase isoforms (hMAO-A and hMAO-B).  The structure-activity relationships studies strengthen the importance of the amide spacer and the direct linkage of carbonyl group to the γ-pyrone ring, along with the presence of meta and para substituents in the exocyclic ring.  The most potent MAO-B inhibitors were N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide (20) (IC50 = 403 pM) and N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide (27) (IC50 = 669 pM), acting as competitive and noncompetitive reversible inhibitors, resp.  Computational docking studies provided insights into enzyme-inhibitor interactions and a rationale for the obsd. selectivity and potency.  Compd. 27 stands out due to its favorable toxicol. profile and physicochem. properties, which pointed toward blood-brain barrier permeability, thus being a valid candidate for subsequent animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWONk5yTkyN7Vg90H21EOLACvtfcHk0lgEtb_i1cLRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVWksb8%253D&md5=361d3dde07c197e2bdc41d08746a35f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00527%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DCagide%26aufirst%3DF.%26aulast%3DChavarria%26aufirst%3DD.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DFernandes%26aufirst%3DC.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DRemiao%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520New%2520Chemical%2520Entities%2520for%2520Old%2520Targets%253A%2520Insights%2520on%2520the%2520Lead%2520Optimization%2520of%2520Chromone-Based%2520Monoamine%2520Oxidase%2520B%2520%2528MAO-B%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5879%26epage%3D5893%26doi%3D10.1021%2Facs.jmedchem.6b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colettis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovino, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pislar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamecki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangialavori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolsak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakelj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trontelj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01886</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01886" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVCqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1361-1387&author=D.+Knezauthor=N.+Colettisauthor=L.+G.+Iacovinoauthor=M.+Sovaauthor=A.+Pislarauthor=J.+Koncauthor=S.+Lesnikauthor=J.+Higgsauthor=F.+Kameckiauthor=I.+Mangialavoriauthor=A.+Dolsakauthor=S.+Zakeljauthor=J.+Tronteljauthor=J.+Kosauthor=C.+Bindaauthor=M.+Marderauthor=S.+Gobec&title=Stereoselective+Activity+of+1-Propargyl-4-styrylpiperidine-like+Analogues+That+Can+Discriminate+between+Monoamine+Oxidase+Isoforms+A+and+B&doi=10.1021%2Facs.jmedchem.9b01886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B</span></div><div class="casAuthors">Knez, Damijan; Colettis, Natalia; Iacovino, Luca G.; Sova, Matej; Pislar, Anja; Konc, Janez; Lesnik, Samo; Higgs, Josefina; Kamecki, Fabiola; Mangialavori, Irene; Dolsak, Ana; Zakelj, Simon; Trontelj, Jurij; Kos, Janko; Binda, Claudia; Marder, Mariel; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1361-1387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymic activity with cardiovascular, neurol., and oncol. disorders.  This has promoted increased research into selective MAO-A and MAO-B inhibitors.  Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis- and trans-1-propargyl-4-styrylpiperidines.  While the cis isomers are potent human MAO-A inhibitors, the trans analogs selectively target only the MAO-B isoform.  The inhibition was studied by kinetic anal., UV-vis spectrum measurements, and X-ray crystallog.  The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and addnl. in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders.  This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYa4wKcyp0JrVg90H21EOLACvtfcHk0liSRHxphiYSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVCqtg%253D%253D&md5=0a5e378381f1f72bf7624c5670d5a47c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01886%26sid%3Dliteratum%253Aachs%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DColettis%26aufirst%3DN.%26aulast%3DIacovino%26aufirst%3DL.%2BG.%26aulast%3DSova%26aufirst%3DM.%26aulast%3DPislar%26aufirst%3DA.%26aulast%3DKonc%26aufirst%3DJ.%26aulast%3DLesnik%26aufirst%3DS.%26aulast%3DHiggs%26aufirst%3DJ.%26aulast%3DKamecki%26aufirst%3DF.%26aulast%3DMangialavori%26aufirst%3DI.%26aulast%3DDolsak%26aufirst%3DA.%26aulast%3DZakelj%26aufirst%3DS.%26aulast%3DTrontelj%26aufirst%3DJ.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DMarder%26aufirst%3DM.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DStereoselective%2520Activity%2520of%25201-Propargyl-4-styrylpiperidine-like%2520Analogues%2520That%2520Can%2520Discriminate%2520between%2520Monoamine%2520Oxidase%2520Isoforms%2520A%2520and%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1361%26epage%3D1387%26doi%3D10.1021%2Facs.jmedchem.9b01886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidaro, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Human Monoamine Oxidase: Biological and Molecular Modeling Studies on Selected Natural Flavonoids</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">9004</span>– <span class="NLM_lpage">9011</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.6b03529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.6b03529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=9004-9011&author=S.+Carradoriauthor=M.+C.+Gidaroauthor=A.+Petzerauthor=G.+Costaauthor=P.+Guglielmiauthor=P.+Chimentiauthor=S.+Alcaroauthor=J.+P.+Petzer&title=Inhibition+of+Human+Monoamine+Oxidase%3A+Biological+and+Molecular+Modeling+Studies+on+Selected+Natural+Flavonoids&doi=10.1021%2Facs.jafc.6b03529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Human Monoamine Oxidase: Biological and Molecular Modeling Studies on Selected Natural Flavonoids</span></div><div class="casAuthors">Carradori, Simone; Gidaro, Maria Concetta; Petzer, Anel; Costa, Giosue; Guglielmi, Paolo; Chimenti, Paola; Alcaro, Stefano; Petzer, Jacobus P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">9004-9011</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Naturally occurring flavonoids display a plethora of different biol. activities, but emerging evidence suggests that this class of compds. may also act as antidepressant agents endowed with multiple mechanisms of action in the central nervous system, increasing central neurotransmission, limiting the reabsorption of bioamines by synaptosomes, and modulating the neuroendocrine and GABAA systems.  Due to their presence in foods, food-derived products, and nutraceuticals, we established their role and structure-activity relationships as reversible and competitive human monoamine oxidase (MAO) inhibitors.  In addn., mol. modeling studies, which evaluated their modes of MAO inhibition, are presented.  These findings could provide pivotal implications in the quest of novel drug-like compds. and for the establishment of harmful drug-dietary supplement interactions commonly reported in the therapy with antidepressant agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Xs8oOeyyqrVg90H21EOLACvtfcHk0liSRHxphiYSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmsrzK&md5=67ed28b3e4c59474c165d5c0a9cd2706</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.6b03529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.6b03529%26sid%3Dliteratum%253Aachs%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DGidaro%26aufirst%3DM.%2BC.%26aulast%3DPetzer%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DGuglielmi%26aufirst%3DP.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26atitle%3DInhibition%2520of%2520Human%2520Monoamine%2520Oxidase%253A%2520Biological%2520and%2520Molecular%2520Modeling%2520Studies%2520on%2520Selected%2520Natural%2520Flavonoids%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2016%26volume%3D64%26spage%3D9004%26epage%3D9011%26doi%3D10.1021%2Facs.jafc.6b03529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Applications of Selective and Non-Selective Inhibitors of Monoamine Oxidase A and B That Do Not Cause Significant Tyramine Potentiation</span>. <i>Neurotoxicology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/S0161-813X(03)00103-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS0161-813X%2803%2900103-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=14697899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=243-250&author=M.+B.+H.+Youdimauthor=M.+Weinstock&title=Therapeutic+Applications+of+Selective+and+Non-Selective+Inhibitors+of+Monoamine+Oxidase+A+and+B+That+Do+Not+Cause+Significant+Tyramine+Potentiation&doi=10.1016%2FS0161-813X%2803%2900103-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation</span></div><div class="casAuthors">Youdim, Moussa B. H.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">243-250</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The major side effect with the use of first generation of non selective monoamine oxidase (MAO) inhibitors as neuropsychiatric drugs was what became known as the "cheese reaction".  Namely, potentiation of sympathomimetic activity of ingested tyramine present in cheese and other food stuff, resulting from its ability to release noradrenaline, when prevented from metab. by MAO.  The identification of two forms of MAO, termed types A and B and their selective irreversible inhibitors resolved some of this problems.  However irreversible MAO-A inhibitors continue to induce a cheese reaction, whereas MAO-B inhibitors at their selective dosage did not and led to introduction of L-deprenyl (selegiline) as an anti-Parkinson drug, since dopamine is equally well metabolized by both enzyme forms.  The cheese reaction is a consequence of inhibition of MAO-A, the enzyme responsible for metab. of noradreanline and serotonin, located in peripheral adrenergic neurons.  The consequence of these findings were the development of reversible MAO-A inhibitors (RIMA), moclobemide and brofaromin, as antidepressants and possible anti-Parkinson activity, with limited tyramine potentiation, since the amine can displace the inhibitor from its binding site on the enzyme.  It has always been deemed a greater pharmacol. advantage to inhibit both forms of the enzymes to get the full functional activities of the amine neurotransmitters, and without inducing a "cheese reaction".  This was not possible until recently, with the development of the novel cholinesterase-brain selective MAO-AB inhibitor, TV3326 (N-propargyl-(3R)-aminoindan-5-yl-Et methylcarbamte hemitartate), a carbamte deriv. of the irreversible MAO-B inhibitor anti-Parkinson drug, rasagiline.  This drug is a brain selective MAO-A and B inhibitor, with little inhibition of liver and small intestine enzymes.  Pharmacol. it has limited tyramine potentiation, very similar to moclobemide and being a MAO-AB inhibitor it has the antidepressant, anti-Parkinson and anti-Alzheimer activities in the resp. models used to develop such drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa20KLpFvMErVg90H21EOLACvtfcHk0liSRHxphiYSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLjM&md5=d360334303dbe2d40879c68a3b4098c5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0161-813X%2803%2900103-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-813X%252803%252900103-7%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DTherapeutic%2520Applications%2520of%2520Selective%2520and%2520Non-Selective%2520Inhibitors%2520of%2520Monoamine%2520Oxidase%2520A%2520and%2520B%2520That%2520Do%2520Not%2520Cause%2520Significant%2520Tyramine%2520Potentiation%26jtitle%3DNeurotoxicology%26date%3D2004%26volume%3D25%26spage%3D243%26epage%3D250%26doi%3D10.1016%2FS0161-813X%2803%2900103-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Twenty Years On: The Impact of Fragments on Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd.2016.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27417849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=605-619&author=D.+A.+Erlansonauthor=S.+W.+Fesikauthor=R.+E.+Hubbardauthor=W.+Jahnkeauthor=H.+Jhoti&title=Twenty+Years+On%3A+The+Impact+of+Fragments+on+Drug+Discovery&doi=10.1038%2Fnrd.2016.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years on: the impact of fragments on drug discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Fesik, Stephen W.; Hubbard, Roderick E.; Jahnke, Wolfgang; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">605-619</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream.  More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials.  FBDD has been widely applied in both academia and industry, as evidenced by the large no. of papers from universities, non-profit research institutions, biotechnol. companies and pharmaceutical companies.  Moreover, FBDD draws on a diverse range of disciplines, from biochem. and biophysics to computational and medicinal chem.  As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future.  This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them.  It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrXQhFttydkrVg90H21EOLACvtfcHk0lgu1m0l7NX55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE&md5=fc2bcf0da6b7b1083a5ff263057cfa80</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.109%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DTwenty%2520Years%2520On%253A%2520The%2520Impact%2520of%2520Fragments%2520on%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D605%26epage%3D619%26doi%3D10.1038%2Fnrd.2016.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4990</span>– <span class="NLM_lpage">5003</span>, <span class="refDoi"> DOI: 10.1021/bi3005126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3005126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4990-5003&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=S.+A.+Hudsonauthor=C.+Abell&title=Fragment-Based+Approaches+in+Drug+Discovery+and+Chemical+Biology&doi=10.1021%2Fbi3005126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Hudson, Sean A.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4990-5003</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fragment-based approaches to finding novel small mols. that bind to proteins are now firmly established in drug discovery and chem. biol.  Initially developed primarily in a few centers in the biotech and pharma industry, this methodol. has now been adopted widely in both the pharmaceutical industry and academia.  After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes.  Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, β-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase.  The role of fragment-based approaches in an academic research environment is also examd. with an emphasis on neglected diseases such as tuberculosis.  The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2ry6mWC83bVg90H21EOLACvtfcHk0lgu1m0l7NX55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D&md5=39a6f0f741e711fd572e24c95142f55d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi3005126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3005126%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DHudson%26aufirst%3DS.%2BA.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-Based%2520Approaches%2520in%2520Drug%2520Discovery%2520and%2520Chemical%2520Biology%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D4990%26epage%3D5003%26doi%3D10.1021%2Fbi3005126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span> <span> </span><span class="NLM_article-title">The ‘Rule of Three’ for Fragment-Based Drug Discovery: Where Are We Now?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd3926-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd3926-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=23845999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ks7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=644&author=H.+Jhotiauthor=G.+Williamsauthor=D.+C.+Reesauthor=C.+W.+Murray&title=The+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Drug+Discovery%3A+Where+Are+We+Now%3F&doi=10.1038%2Fnrd3926-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The 'rule of three' for fragment-based drug discovery: where are we now?</span></div><div class="casAuthors">Jhoti, Harren; Williams, Glyn; Rees, David C.; Murray, Christopher W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The value of using the RO3 in FBDD is being (correctly) challenged as many useful fragment hits do not adhere to its restrictions (see the Practical Fragments blog website).  We have always believed that the RO3 concept has limitations and, like other rules related to desirable physicochem. properties, such as the 'rule of five' guidelines, it is simply a guideline that should not be overemphasized.  Nevertheless, we believe that the RO3 has been useful in ensuring that fragment libraries really do consist of compds. with fragment-like properties, although reports of 'fragment' hits that actually resemble lead-like compds. - particularly considering their substantial mol. mass - do still appear.  The fundamental concept of fragment screening is to use simpler mols. so that the chem. space can be sampled much more efficiently than is possible when using mols. of greater complexity.  One consequence of screening smaller, simpler fragments is that their affinity is expected to be relatively low (>1 mM), given the limited nos. of potential interactions that they can make with the protein.  Although weak in potency, fragment hits make high-quality interactions with the protein as they must overcome a substantial entropic barrier to binding, relative to their size.  The detection of low-potency fragment hits presents substantial tech. challenges, but to avoid these challenges and succumb to the temptation to screen larger, more complex mols. runs counter to the whole raison d'être of fragment screening.  We now have experience of over 30 fragment screens against a broad range of protein classes, and our results support the view that less complex mols. give a higher hit rate.  Consequently, our fragment library now almost exclusively contains mols. with fewer than 17 non-hydrogen atoms (mol. mass <230 Da).  As such, we believe the RO3 concept has assisted in limiting the mol. complexity in our fragment libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Jd0pJhvtnbVg90H21EOLACvtfcHk0lgu1m0l7NX55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ks7zP&md5=36ee69ae9c183b59da9afb8cb07c2c48</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd3926-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3926-c1%26sid%3Dliteratum%253Aachs%26aulast%3DJhoti%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26atitle%3DThe%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Drug%2520Discovery%253A%2520Where%2520Are%2520We%2520Now%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D644%26doi%3D10.1038%2Fnrd3926-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Experiences in Fragment-Based Drug Discovery</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.tips.2012.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=22459076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslejsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=224-232&author=C.+W.+Murrayauthor=M.+L.+Verdonkauthor=D.+C.+Rees&title=Experiences+in+Fragment-Based+Drug+Discovery&doi=10.1016%2Fj.tips.2012.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Experiences in fragment-based drug discovery</span></div><div class="casAuthors">Murray, Christopher W.; Verdonk, Marcel L.; Rees, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">224-232</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chem. leads for drug targets.  In FBDD, specialised detection methods are used to identify small chem. compds. (fragments) that bind to the drug target, and structural biol. is usually employed to establish their binding mode and to facilitate their optimization.  In this article, we present three recent and successful case histories in FBDD.  We then re-examine the key concepts and challenges of FBDD with particular emphasis on recent literature and our own experience from a substantial no. of FBDD applications.  Our opinion is that careful application of FBDD is living up to its promise of delivering high quality leads with good phys. properties and that in future many drug mols. will be derived from fragment-based approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUzcsuUdmx4bVg90H21EOLACvtfcHk0lgjtksoCKK_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslejsLs%253D&md5=c97b6b84a4afeadb87ee7d46e6d2bb91</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DExperiences%2520in%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D224%26epage%3D232%26doi%3D10.1016%2Fj.tips.2012.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Computational Discovery of Picomolar Q(o) Site Inhibitors of Cytochrome bc(1) Complex</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">11168</span>– <span class="NLM_lpage">11176</span>, <span class="refDoi"> DOI: 10.1021/ja3001908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja3001908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlemtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=11168-11176&author=G.-F.+Haoauthor=F.+Wangauthor=H.+Liauthor=X.-L.+Zhuauthor=W.-C.+Yangauthor=L.-S.+Huangauthor=J.-W.+Wuauthor=E.+A.+Berryauthor=G.-F.+Yang&title=Computational+Discovery+of+Picomolar+Q%28o%29+Site+Inhibitors+of+Cytochrome+bc%281%29+Complex&doi=10.1021%2Fja3001908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Discovery of Picomolar Qo Site Inhibitors of Cytochrome bc1 Complex</span></div><div class="casAuthors">Hao, Ge-Fei; Wang, Fu; Li, Hui; Zhu, Xiao-Lei; Yang, Wen-Chao; Huang, Li-Shar; Wu, Jia-Wei; Berry, Edward A.; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11168-11176</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. challenge to the fragment-based drug discovery (FBDD) is its low-throughput nature due to the necessity of biophys. method-based fragment screening.  Herein, a method of pharmacophore-linked fragment virtual screening (PFVS) was successfully developed.  Its application yielded the first picomolar-range Qo site inhibitors of the cytochrome bc1 complex, an important membrane protein for drug and fungicide discovery.  Compared with the original hit compd. 4 (Ki = 881.80 nM, porcine bc1), the most potent compd. 4f displayed 20 507-fold improved binding affinity (Ki = 43.00 pM).  Compd. 4f was proved to be a noncompetitive inhibitor with respect to the substrate cytochrome c, but a competitive inhibitor with respect to the substrate ubiquinol.  Addnl., the crystal structure of compd. 4e (Ki = 83.00 pM) bound to the chicken bc1 was detd. at 2.70 Å resoln., providing a mol. basis for understanding its ultrapotency.  To the authors' knowledge, this study is the first application of the FBDD method in the discovery of picomolar inhibitors of a membrane protein.  This work demonstrates that the novel PFVS approach is a high-throughput drug discovery method, independent of biophys. screening techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFot0FjSNmbVg90H21EOLACvtfcHk0lgjtksoCKK_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlemtLo%253D&md5=23821de7aaecdbcb8aa513a05fd5bc87</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja3001908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja3001908%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DYang%26aufirst%3DW.-C.%26aulast%3DHuang%26aufirst%3DL.-S.%26aulast%3DWu%26aufirst%3DJ.-W.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DComputational%2520Discovery%2520of%2520Picomolar%2520Q%2528o%2529%2520Site%2520Inhibitors%2520of%2520Cytochrome%2520bc%25281%2529%2520Complex%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D11168%26epage%3D11176%26doi%3D10.1021%2Fja3001908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">ACFIS: A Web Server for Fragment-Based Drug Discovery</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">W550</span>– <span class="NLM_lpage">W556</span>, <span class="refDoi"> DOI: 10.1093/nar/gkw393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fnar%2Fgkw393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27150808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2itrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=W550-W556&author=G.-F.+Haoauthor=W.+Jiangauthor=Y.-N.+Yeauthor=F.-X.+Wuauthor=X.-L.+Zhuauthor=F.-B.+Guoauthor=G.-F.+Yang&title=ACFIS%3A+A+Web+Server+for+Fragment-Based+Drug+Discovery&doi=10.1093%2Fnar%2Fgkw393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">ACFIS: a web server for fragment-based drug discovery</span></div><div class="casAuthors">Hao, Ge-Fei; Jiang, Wen; Ye, Yuan-Nong; Wu, Feng-Xu; Zhu, Xiao-Lei; Guo, Feng-Biao; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W550-W556</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In order to foster innovation and improve the effectiveness of drug discovery, there is a considerable interest in exploring unknown 'chem. space' to identify new bioactive compds. with novel and diverse scaffolds.  Hence, fragment-based drug discovery (FBDD) was developed rapidly due to its advanced expansive search for 'chem. space', which can lead to a higher hit rate and ligand efficiency (LE).  However, computational screening of fragments is always hampered by the promiscuous binding model.  In this study, we developed a new web server Auto Core Fragment in silico Screening (ACFIS).  It includes three computational modules, PARA_GEN, CORE_GEN and CAND_GEN.  ACFIS can generate core fragment structure from the active mol. using fragment deconstruction anal. and perform in silico screening by growing fragments to the junction of core fragment structure.  An integrated energy calcn. rapidly identifies which fragments fit the binding site of a protein.  We constructed a simple interface to enable users to view top-ranking mols. in 2D and the binding mode in 3D for further exptl. exploration.  This makes the ACFIS a highly valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7MTRU-oeBvrVg90H21EOLACvtfcHk0lgjtksoCKK_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2itrjF&md5=3d0086f13fb247d6735fb29568d2ee04</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw393%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DY.-N.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DGuo%26aufirst%3DF.-B.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DACFIS%253A%2520A%2520Web%2520Server%2520for%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3DW550%26epage%3DW556%26doi%3D10.1093%2Fnar%2Fgkw393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Phylogenetic and Structural Analysis Reveals the Molecular Evolution of the ABA Receptor Gene Family</span>. <i>J. Exp. Bot.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1322</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1093/jxb/erz511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fjxb%2Ferz511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31740933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKmtr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=1322-1336&author=J.-F.+Yangauthor=M.-X.+Chenauthor=J.-H.+Zhangauthor=G.-F.+Haoauthor=G.-F.+Yang&title=Genome-Wide+Phylogenetic+and+Structural+Analysis+Reveals+the+Molecular+Evolution+of+the+ABA+Receptor+Gene+Family&doi=10.1093%2Fjxb%2Ferz511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide phylogenetic and structural analysis reveals the molecular evolution of the ABA receptor gene family</span></div><div class="casAuthors">Yang, Jing-Fang; Chen, Mo-Xian; Zhang, Jian-Hua; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Botany</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1322-1336</span>CODEN:
                <span class="NLM_cas:coden">JEBOA6</span>;
        ISSN:<span class="NLM_cas:issn">1460-2431</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The plant hormone abscisic acid (ABA) plays a crucial role during the plant life cycle as well as in adaptive responses to environmental stresses.  The core regulatory components of ABA signaling in plants are the pyrabactin resistance1/PYR1- like/regulatory component of ABA receptor family (PYLs), which comprise the largest plant hormone receptor family known.  They act as neg. regulators of members of the protein phosphatase type 2C family.  Due to the biol. importance of PYLs, many researchers have focused on their genetic redundancy and consequent functional divergence.  However, little is understood of their evolution and its impact on the generation of regulatory diversity.  In this study, we identify pos. selection and functional divergence in PYLs through phylogenetic reconstruction, gene structure and expression pattern anal., pos. selection anal., functional divergence anal., and structure comparison.  We found the correlation of desensitization of PYLs under specifi modifiations in the mol. recognition domain with functional diversifiation.  Hence, an interesting antagonistic co-evolutionary mechanism is proposed for the functional diversifiation of ABA receptor family proteins.  We believe a compensatory evolutionary pathway may have occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptlFHeUobbcbVg90H21EOLACvtfcHk0lin7ctJf6NXcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKmtr%252FE&md5=d76ab7d89d37634d46f934a9f57b996f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjxb%2Ferz511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjxb%252Ferz511%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DM.-X.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DGenome-Wide%2520Phylogenetic%2520and%2520Structural%2520Analysis%2520Reveals%2520the%2520Molecular%2520Evolution%2520of%2520the%2520ABA%2520Receptor%2520Gene%2520Family%26jtitle%3DJ.%2520Exp.%2520Bot.%26date%3D2020%26volume%3D71%26spage%3D1322%26epage%3D1336%26doi%3D10.1093%2Fjxb%2Ferz511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserue, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keserueauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lin7ctJf6NXcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeserue%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=1725-1730&author=J.-F.+Yangauthor=F.+Wangauthor=W.+Jiangauthor=G.-Y.+Zhouauthor=C.-Z.+Liauthor=X.-L.+Zhuauthor=G.-F.+Haoauthor=G.-F.+Yang&title=PADFrag%3A+A+Database+Built+for+the+Exploration+of+Bioactive+Fragment+Space+for+Drug+Discovery&doi=10.1021%2Facs.jcim.8b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery</span></div><div class="casAuthors">Yang, Jing-Fang; Wang, Fan; Jiang, Wen; Zhou, Guang-You; Li, Cheng-Zhang; Zhu, Xiao-Lei; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1725-1730</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural analyses of drugs and pesticides can enable the identification of new bioactive compds. with novel and diverse scaffolds as well as improve our understanding of the bioactive fragment space.  The Pesticide And Drug Fragments (PADFrag) database is a unique bioinformatic-cheminformatic cross-referencing resource that combines detailed bioactive fragment data and potential targets with a strong focus on quant., analytic, and mol.-scale information for the exploration of bioactive fragment space for drug discovery (http://chemyang.ccnu.edu.cn/ccb/database/PADFrag/).  The main applications of PADFrag are the anal. of the privileged structures within known bioactive mols., ab initio mol. library design, and core fragment discovery for fragment-based drug design.  Other potential applications include prediction of fragment interactions and general pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoF3PkNXTMkrVg90H21EOLACvtfcHk0lin7ctJf6NXcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGru7fE&md5=c434a56ca94611f6e004daa8e28518cd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00285%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.-Y.%26aulast%3DLi%26aufirst%3DC.-Z.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DPADFrag%253A%2520A%2520Database%2520Built%2520for%2520the%2520Exploration%2520of%2520Bioactive%2520Fragment%2520Space%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D1725%26epage%3D1730%26doi%3D10.1021%2Facs.jcim.8b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">AIMMS Suite: A Web Server Dedicated for Prediction of Drug Resistance on Protein Mutation</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1093/bib/bbz092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbz092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2nsbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=318-328&author=F.-X.+Wuauthor=F.+Wangauthor=J.-F.+Yangauthor=W.+Jiangauthor=M.-Y.+Wangauthor=C.-Y.+Jiaauthor=G.-F.+Haoauthor=G.-F.+Yang&title=AIMMS+Suite%3A+A+Web+Server+Dedicated+for+Prediction+of+Drug+Resistance+on+Protein+Mutation&doi=10.1093%2Fbib%2Fbbz092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">AIMMS suite: a web server dedicated for prediction of drug resistance on protein mutation</span></div><div class="casAuthors">Wu, Feng-Xu; Wang, Fan; Yang, Jing-Fang; Jiang, Wen; Wang, Meng-Yao; Jia, Chen-Yang; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Briefings in Bioinformatics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">318-328</span>CODEN:
                <span class="NLM_cas:coden">BBIMFX</span>;
        ISSN:<span class="NLM_cas:issn">1477-4054</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug resistance is one of the most intractable issues for successful treatment in current clin. practice.  Although many mutations contributing to drug resistance have been identified, the relationship between the mutations and the related pharmacol. profile of drug candidates has yet to be fully elucidated, which is valuable both for the mol. dissection of drug resistance mechanisms and for suggestion of promising treatment strategies to counter resistant.  Hence, effective prediction approach for estg. the sensitivity of mutations to agents is a new opportunity that counters drug resistance and creates a high interest in pharmaceutical research.  However, this task is always hampered by limited known resistance training samples and accurately estn. of binding affinity.  Upon this challenge, we successfully developed Auto In Silico Macromol. Mutation Scanning (AIMMS), a web server for computer-aided de novo drug resistance prediction for any ligand-protein systems.  AIMMS can qual. est. the free energy consequences of any mutations through a fast mutagenesis scanning calcn. based on a single mol. dynamics trajectory, which is differentiated with other web services by a statistical learning system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8wUPr9bt9LVg90H21EOLACvtfcHk0lin7ctJf6NXcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2nsbbL&md5=c70fc164b4a18985cd921e5496bcdd63</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbz092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbz092%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.-Y.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DAIMMS%2520Suite%253A%2520A%2520Web%2520Server%2520Dedicated%2520for%2520Prediction%2520of%2520Drug%2520Resistance%2520on%2520Protein%2520Mutation%26jtitle%3DBriefings%2520Bioinf.%26date%3D2020%26volume%3D21%26spage%3D318%26epage%3D328%26doi%3D10.1093%2Fbib%2Fbbz092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orallo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirilli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Semipreparative HPLC Separation, Biological Evaluation, and 3D-QSAR of Hydrazothiazole Derivatives as Human Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5063</span>– <span class="NLM_lpage">5070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bmc.2010.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=20579890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5063-5070&author=F.+Chimentiauthor=D.+Secciauthor=A.+Bolascoauthor=P.+Chimentiauthor=A.+Graneseauthor=S.+Carradoriauthor=E.+Maccioniauthor=M.+C.+Cardiaauthor=M.+Yanezauthor=F.+Oralloauthor=S.+Alcaroauthor=F.+Ortusoauthor=R.+Cirilliauthor=R.+Ferrettiauthor=S.+Distintoauthor=J.+Kirchmairauthor=T.+Langer&title=Synthesis%2C+Semipreparative+HPLC+Separation%2C+Biological+Evaluation%2C+and+3D-QSAR+of+Hydrazothiazole+Derivatives+as+Human+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bmc.2010.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors</span></div><div class="casAuthors">Chimenti, Franco; Secci, Daniela; Bolasco, Adriana; Chimenti, Paola; Granese, Arianna; Carradori, Simone; Maccioni, Elias; Cardia, M. Cristina; Yanez, Matilde; Orallo, Francisco; Alcaro, Stefano; Ortuso, Francesco; Cirilli, Roberto; Ferretti, Rosella; Distinto, Simona; Kirchmair, Johannes; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5063-5070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study reports on synthesis in high yields (70-99%), HPLC enantiosepn., inhibitory activity against human monoamino oxidases, and mol. modeling including 3D-QSAR studies, of a large series of (4-aryl-thiazol-2-yl)hydrazones (1-45).  Most of the synthesized compds. proved to be potent and selective inhibitors of hMAO-B isoform in the micromolar or nanomolar range, thus demonstrating that hydrazothiazole could be considered a good pharmacophore to design new hMAO-B inhibitors.  Due to the presence in some derivs. of a chiral center, we also performed a semipreparative chromatog. enantiosepn. of these compds. obtained by a stereoconservative pattern.  The sepd. enantiomers were submitted to in vitro biol. evaluation to point out the stereorecognition of the active site of the enzyme towards these structures.  Finally, a 3D-QSAR study was carried out using Comparative Mol. Field Anal. (CoMFA), aiming to deduce rational guidelines for the further structural modification of these lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1QZPBAeaYGLVg90H21EOLACvtfcHk0ljl_KnqtHkwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslagtbs%253D&md5=7f4a33195161dccff09e9f98321249b9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DGranese%26aufirst%3DA.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DFerretti%26aufirst%3DR.%26aulast%3DDistinto%26aufirst%3DS.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520Semipreparative%2520HPLC%2520Separation%252C%2520Biological%2520Evaluation%252C%2520and%25203D-QSAR%2520of%2520Hydrazothiazole%2520Derivatives%2520as%2520Human%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5063%26epage%3D5070%26doi%3D10.1016%2Fj.bmc.2010.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morissette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Sweidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcangi, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, T.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice</span>. <i>Neuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1159/000438789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1159%2F000438789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26227546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=300-314&author=M.+Bourqueauthor=M.+Morissetteauthor=S.+Al+Sweidiauthor=D.+Carusoauthor=R.+C.+Melcangiauthor=T.+Di+Paolo&title=Neuroprotective+Effect+of+Progesterone+in+MPTP-Treated+Male+Mice&doi=10.1159%2F000438789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice</span></div><div class="casAuthors">Bourque, Melanie; Morissette, Marc; Al Sweidi, Sara; Caruso, Donatella; Melcangi, Roberto C.; Di Paolo, Therese</div><div class="citationInfo"><span class="NLM_cas:title">Neuroendocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">300-314</span>CODEN:
                <span class="NLM_cas:coden">NUNDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0028-3835</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Numerous studies have reported on the neuroprotective activity of estradiol, whereas the effect of the other ovarian steroid, progesterone, is much less documented.  Methods: This study sought to investigate neuroprotection with a low dose of progesterone (1 μg) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated male mice to model Parkinson's disease and compare it to the effect of this steroid in intact mice (expt. 1).  We also investigated if high doses of progesterone could protect dopaminergic neurons already exposed to MPTP (expt. 2).  We measured progesterone effects on various dopaminergic markers [dopamine and its metabolites, dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2)] and on neuroactive steroids in both plasma and the brain.  Results: For expt. 1, our results showed that progesterone completely prevented the effect of MPTP toxicity on dopamine concns., on the increase in the 3-methoxytyramine/dopamine ratio, as well as on VMAT2-specific binding in the striatum and the substantia nigra.  Progesterone decreased MPTP effects on 3,4-dihydroxyphenylacetic acid concns. and DAT-specific binding in the lateral part of the anterior striatum and in the middle striatum (medial and lateral parts).  Progesterone treatment of intact mice had no effect on the markers investigated.  For expt. 2, measures of dopaminergic markers in the striatum showed that 8 mg/kg of progesterone was the most ED to reduce MPTP effects, and more limited effects were obsd. with 16 mg/kg.  We found that progesterone treatment increases the levels of brain progesterone itself as well as of its metabolites.  Conclusion: Our result showed that progesterone has neuroprotective effects on dopaminergic neurons in MPTP-treated male mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2qq343wfbEbVg90H21EOLACvtfcHk0ljl_KnqtHkwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFWisrc%253D&md5=6e61cc79a0865453cf1177be32591850</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1159%2F000438789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000438789%26sid%3Dliteratum%253Aachs%26aulast%3DBourque%26aufirst%3DM.%26aulast%3DMorissette%26aufirst%3DM.%26aulast%3DAl%2BSweidi%26aufirst%3DS.%26aulast%3DCaruso%26aufirst%3DD.%26aulast%3DMelcangi%26aufirst%3DR.%2BC.%26aulast%3DDi%2BPaolo%26aufirst%3DT.%26atitle%3DNeuroprotective%2520Effect%2520of%2520Progesterone%2520in%2520MPTP-Treated%2520Male%2520Mice%26jtitle%3DNeuroendocrinology%26date%3D2016%26volume%3D103%26spage%3D300%26epage%3D314%26doi%3D10.1159%2F000438789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faravelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fariello, R. G.</span></span> <span> </span><span class="NLM_article-title">Safinamide - From Molecular Targets To A New Anti-Parkinson Drug</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S18</span>– <span class="NLM_lpage">S23</span>, <span class="refDoi"> DOI: 10.1212/WNL.67.7_suppl_2.S18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1212%2FWNL.67.7_suppl_2.S18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=17030736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVeqsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=S18-S23&author=C.+Cacciaauthor=R.+Majauthor=M.+Calabresiauthor=S.+Maestroniauthor=L.+Faravelliauthor=L.+Curatoloauthor=P.+Salvatiauthor=R.+G.+Fariello&title=Safinamide+-+From+Molecular+Targets+To+A+New+Anti-Parkinson+Drug&doi=10.1212%2FWNL.67.7_suppl_2.S18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Safinamide: From molecular targets to a new anti-Parkinson drug</span></div><div class="casAuthors">Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7, Suppl. 2</span>),
    <span class="NLM_cas:pages">S18-S23</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Ideal treatment in Parkinson's disease (PD) aims at relieving symptoms and slowing disease progression.  Of all remedies, levodopa remains the most effective for symptomatic relief, but the medical need for neuroprotectant drugs is still unfulfilled.  Safinamide, currently in phase III clin. trials for the treatment of PD, is a unique mol. with multiple mechanisms of action and a very high therapeutic index.  It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na and Ca channels and inhibition of glutamate release.  Safinamide has neuroprotective and neuro rescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.  Safinamide potentiates levodopa-mediated increase of DA levels in DA-depleted mice and reverses the waning motor response after prolonged levodopa treatment in 6-OHDA-lesioned rats.  Safinamide has excellent bioavailability, linear kinetics, and is suitable for once-a-day administration.  Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyY9RqTsiL5LVg90H21EOLACvtfcHk0ljl_KnqtHkwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVeqsLfL&md5=51e4743fd40d5a177ebd2e7f14c7cd4d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1212%2FWNL.67.7_suppl_2.S18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.67.7_suppl_2.S18%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DMaj%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DM.%26aulast%3DMaestroni%26aufirst%3DS.%26aulast%3DFaravelli%26aufirst%3DL.%26aulast%3DCuratolo%26aufirst%3DL.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%2520-%2520From%2520Molecular%2520Targets%2520To%2520A%2520New%2520Anti-Parkinson%2520Drug%26jtitle%3DNeurology%26date%3D2006%26volume%3D67%26spage%3DS18%26epage%3DS23%26doi%3D10.1212%2FWNL.67.7_suppl_2.S18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Lewis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przedborski, S.</span></span> <span> </span><span class="NLM_article-title">Protocol for the MPTP Mouse Model of Parkinson’s Disease</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1038/nprot.2006.342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnprot.2006.342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=17401348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGntb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=141-151&author=V.+Jackson-Lewisauthor=S.+Przedborski&title=Protocol+for+the+MPTP+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1038%2Fnprot.2006.342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Protocol for the MPTP mouse model of Parkinson's disease</span></div><div class="casAuthors">Jackson-Lewis, Vernice; Przedborski, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol describes our method of producing a reliable mouse model of Parkinson's disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  We discuss the particulars of the model, provide key refs. and outline what investigators need to know to develop the MPTP mouse model of PD safely and successfully.  Completion of this protocol depends on the regimen of MPTP used and on the actual planned studies, which often range from 7 to 30 d.  This protocol calls for implementation of safety measures and for the acquisition of several pieces of equipment, which are a one-time investment worth making if one elects to use this model on a regular basis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq4GX2AMcV_LVg90H21EOLACvtfcHk0lh5PuW8jZOfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGntb3N&md5=19737029e8ea7ab7626172d29daf8678</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.342%26sid%3Dliteratum%253Aachs%26aulast%3DJackson-Lewis%26aufirst%3DV.%26aulast%3DPrzedborski%26aufirst%3DS.%26atitle%3DProtocol%2520for%2520the%2520MPTP%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D141%26epage%3D151%26doi%3D10.1038%2Fnprot.2006.342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouradian, M. M.</span></span> <span> </span><span class="NLM_article-title">Protection Against Acute MPTP-Induced Dopamine Depletion in Mice by Adenosine A1 Agonist</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">768</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1993.tb03215.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1111%2Fj.1471-4159.1993.tb03215.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=8419552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFymsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=768-771&author=Y.+S.+Lauauthor=M.+M.+Mouradian&title=Protection+Against+Acute+MPTP-Induced+Dopamine+Depletion+in+Mice+by+Adenosine+A1+Agonist&doi=10.1111%2Fj.1471-4159.1993.tb03215.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist</span></div><div class="casAuthors">Lau, Yuen Sum; Mouradian, M. Maral</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">768-71</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">The effects of the adenosine A1 agonist N6-cyclohexyladenosine (CHA) on MPTP-induced dopamine (DA) depletion in the striatum of C57BL/6 mice were studied.  Twenty hours after a single injection of MPTP (30 mg/kg, s.c.), the toxin caused 62% depletion of striatal DA.  CHA (0.2-3 mg/kg, s.c.), when given together with MPTP, prevented the toxin-induced DA depletion in a dose-dependent manner.  This protective action was apparently mediated by the A1 receptors, because this effect was selectively antagonized by pretreating the animals with the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (25 mg/kg, i.p.).  When CHA (3 mg/kg) was injected 5 h after MPTP administration, at which point striatal DA levels were already reduced significantly, a rapid and complete recovery of the striatal DA levels occurred.  These neurochem. data suggest that the A1 agonist CHA is potentially useful as a neuroprotective agent against MPTP-induced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObJxurREH4LVg90H21EOLACvtfcHk0lh5PuW8jZOfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFymsrg%253D&md5=1f61f347ea64790b75fbd36924f9ac6c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1993.tb03215.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1993.tb03215.x%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DY.%2BS.%26aulast%3DMouradian%26aufirst%3DM.%2BM.%26atitle%3DProtection%2520Against%2520Acute%2520MPTP-Induced%2520Dopamine%2520Depletion%2520in%2520Mice%2520by%2520Adenosine%2520A1%2520Agonist%26jtitle%3DJ.%2520Neurochem.%26date%3D1993%26volume%3D60%26spage%3D768%26epage%3D771%26doi%3D10.1111%2Fj.1471-4159.1993.tb03215.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span> <span> </span><span class="NLM_article-title">Resveratrol Synergizes with Low Doses of L-DOPA To Improve MPTP-Induced Parkinson Disease in Mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2019.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bbr.2019.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30922940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVWhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2019&pages=10-18&author=Q.+Liuauthor=D.+Zhuauthor=P.+Jiangauthor=X.+Tangauthor=Q.+Langauthor=Q.+Yuauthor=S.+Zhangauthor=Y.+Cheauthor=X.+Feng&title=Resveratrol+Synergizes+with+Low+Doses+of+L-DOPA+To+Improve+MPTP-Induced+Parkinson+Disease+in+Mice&doi=10.1016%2Fj.bbr.2019.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice</span></div><div class="casAuthors">Liu, Qianqian; Zhu, Dashuai; Jiang, Peien; Tang, Xinyu; Lang, Qiuhan; Yu, Qinyi; Zhang, Shaozhi; Che, Yongzhe; Feng, Xizeng</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-DOPA (L-3,4-dihydroxyphenylalanine) relieves symptoms of Parkinson disease (PD), but long-term use can cause serious side effects.  Resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV), a polyphenolic compd. derived from grapes and red wine that has antioxidant activity, has been shown to have neuroprotective effects.  RV was investigated to enhance the therapeutic effect of L-DOPA in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson disease.  Mice received a saline or RV injection (10 mg/kg/day), then 2 h later, saline or MPTP (15 mg/kg/day) was administered for 7 consecutive days.  Saline or L-DOPA (5 or 8 mg/kg/day) was injected post-administration of MPTP for the last 2 consecutive days.  Our results indicated that RV alleviated MPTP-induced loss of dopaminergic neurons and attenuated astroglial activation in the nigrostriatal pathway.  In parallel, RV reduced the expression of α-synuclein in the striatum.  In addn., RV also increased levels of the anti-apoptotic signalling mol. Bcl-2, reduced levels of the pro-apoptotic signalling mol. Bax, and reduced activation of caspase-3 in the striatum.  Specifically, RV significantly reduced motor dysfunction in MPTP-treated mice.  Furthermore, the RV-treated group showed less IL-1β and an enhanced pAkt/Akt ratio, which promoted dopamine neuron survival in the striatum.  We found that the effects of co-administration of RV with L-DOPA (5 mg/kg) were equiv. to those of administration of 8 mg/kg L-DOPA in MPTP-induced PD mice.  Therefore, with fewer side effects, L-DOPA can be effectively used in the treatment of PD over a long period of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyUVrCpxuWbVg90H21EOLACvtfcHk0lh5PuW8jZOfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVWhtLs%253D&md5=3558fd48197b6564863adac9b6223008</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2019.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2019.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DLang%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DX.%26atitle%3DResveratrol%2520Synergizes%2520with%2520Low%2520Doses%2520of%2520L-DOPA%2520To%2520Improve%2520MPTP-Induced%2520Parkinson%2520Disease%2520in%2520Mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2019%26volume%3D367%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.bbr.2019.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel-Gunkel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luebbert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenscroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Effects of Rotigotine in the Acute MPTP-Lesioned Mouse Model of Parkinson’s Disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2007.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.neulet.2007.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=18162314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2008&pages=30-34&author=D.+Schellerauthor=C.+Stichel-Gunkelauthor=H.+Luebbertauthor=G.+Porrasauthor=P.+Ravenscroftauthor=M.+Hillauthor=E.+Bezard&title=Neuroprotective+Effects+of+Rotigotine+in+the+Acute+MPTP-Lesioned+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.neulet.2007.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease</span></div><div class="casAuthors">Scheller, Dieter; Stichel-Gunkel, Christine; Luebbert, Hermann; Porras, Gregory; Ravenscroft, Paula; Hill, Michael; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-34</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dopamine agonists used to manage Parkinsonian motor symptoms have been suggested to be neuroprotective.  The study was designed to assess the neuroprotective potential of the D3/D2/D1 dopamine receptor agonist rotigotine in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned (MPTP) mouse model of Parkinson's disease by measuring mesencephalic degenerating neurons using FluoroJade staining and the remaining dopaminergic nerve endings in the striatum using dopamine transporter binding.  Continuous administration of rotigotine at a dose of 3 mg/kg significantly attenuated MPTP-induced acute cell degeneration in the FluoroJade-staining paradigm.  Rotigotine (0.3-3 mg/kg) partially protected dopamine nerve endings from MPTP-induced degeneration in a dose-dependent manner.  These data suggest that rotigotine, at the doses employed, significantly protected dopamine neurons from degeneration in an acute mouse model of MPTP intoxication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIBulvYTClObVg90H21EOLACvtfcHk0lh5PuW8jZOfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslaqtLs%253D&md5=04e756a9bed937879dc2cb5c515c1a83</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2007.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2007.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DScheller%26aufirst%3DD.%26aulast%3DStichel-Gunkel%26aufirst%3DC.%26aulast%3DLuebbert%26aufirst%3DH.%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DRavenscroft%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DNeuroprotective%2520Effects%2520of%2520Rotigotine%2520in%2520the%2520Acute%2520MPTP-Lesioned%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2008%26volume%3D432%26spage%3D30%26epage%3D34%26doi%3D10.1016%2Fj.neulet.2007.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heikkila, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvoisin, R. C.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1126/science.6610213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1126%2Fscience.6610213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=6610213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVertr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=1451-1453&author=R.+E.+Heikkilaauthor=A.+Hessauthor=R.+C.+Duvoisin&title=Dopaminergic+Neurotoxicity+of+1-Methyl-4-Phenyl-1%2C2%2C5%2C6-Tetrahydropyridine+in+Mice&doi=10.1126%2Fscience.6610213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice</span></div><div class="casAuthors">Heikkila, Richard E.; Hess, Arthur; Duvoisin, Roger C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4656</span>),
    <span class="NLM_cas:pages">1451-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)(I)  [28289-54-5] is known to cause an irreversible destruction of the dopaminergic nigrostriatal pathway and symptoms of parkinsonism in humans and in monkeys.  However, MPTP has been reported to act only minimally or not at all in several other animal species.  When MPTP (30 mg/kg) was administered parenterally to mice, a decrease in concns. of neostriatal dopamine and its metabolites, a decrease in the capacity of neostriatal synaptosomal prepns. to accumulate [3H]dopamine, and a disappearance of nerve cells in the zona compacta of the substantia nigra were obsd.  In contrast, MPTP administration had no effect on neostriatal concns. of serotonin and its metabolites.  MPTP administration thus results in biochem. and histol. changes in mice similar to those reported in humans and monkeys and similar to those seen in Parkinson's disease in humans.  The mouse should prove to be a useful small animal with which to study the mode of action of MPTP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwJkIdGXUurVg90H21EOLACvtfcHk0li2-H9P9CZtxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVertr0%253D&md5=cf0098a4c243c87e35af0380ad3b6145</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscience.6610213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6610213%26sid%3Dliteratum%253Aachs%26aulast%3DHeikkila%26aufirst%3DR.%2BE.%26aulast%3DHess%26aufirst%3DA.%26aulast%3DDuvoisin%26aufirst%3DR.%2BC.%26atitle%3DDopaminergic%2520Neurotoxicity%2520of%25201-Methyl-4-Phenyl-1%252C2%252C5%252C6-Tetrahydropyridine%2520in%2520Mice%26jtitle%3DScience%26date%3D1984%26volume%3D224%26spage%3D1451%26epage%3D1453%26doi%3D10.1126%2Fscience.6610213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michimata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span> <span> </span><span class="NLM_article-title">Role of Dopamine Transporter Against MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Neurotoxicity in Mice</span>. <i>Metab. Brain Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1023/A:1023863003093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1023%2FA%3A1023863003093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=12822832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=139-146&author=R.+Kurosakiauthor=Y.+Muramatsuauthor=H.+Watanabeauthor=M.+Michimataauthor=M.+Matsubaraauthor=Y.+Imaiauthor=T.+Araki&title=Role+of+Dopamine+Transporter+Against+MPTP+%281-Methyl-4-Phenyl-1%2C2%2C3%2C6-Tetrahydropyridine%29+Neurotoxicity+in+Mice&doi=10.1023%2FA%3A1023863003093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Dopamine Transporter Against MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Neurotoxicity in Mice</span></div><div class="casAuthors">Kurosaki, R.; Muramatsu, Y.; Watanabe, H.; Michimata, M.; Matsubara, M.; Imai, Y.; Araki, T.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-146</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">We investigated the alterations of dopamine transporter (DAT)-immunopos. cells against MPTP neurotoxicity, in comparison with tyrosine hydroxylase (TH)- immunopos. neurons and glial fibrillary acidic protein (GFAP)-immunopos. cells.  This study showed that DAT and TH immunoreactivity was decreased gradually in the striatum and substantia nigra of mice after MPTP treatment.  The patterns of the intense TH-immunoreactive fibers and cell bodies were similar to those of DAT-immunoreactive fibers and cell bodies in the striatum and substantia nigra of mice after MPTP treatment.  In contrast, GFAP immunoreactivity was increased gradually in the striatum and substantia nigra after MPTP treatment.  In our double-labeled immunostaining with anti-DAT and anti-GFAP antibodies, DAT immunoreactivity was obsd. only in the nigral dopaminergic neurons, but not in the reactive astrocytes.  The present results provide further evidence that the functional damage of DAT may precede dopaminergic neuronal death after MPTP treatment, although the decrease in the no. of TH-immunopos. neurons was more pronounced than that in the no. of DAT-immunopos. neurons.  Furthermore,these findings demonstrate that MPTP can selectively injure the dopaminergic neurons which DAT proteins are predominantly distributed on the striatum and substantia nigra.  The results provide beneficial information for MPTP-induced neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLdLa0x3LbvLVg90H21EOLACvtfcHk0li2-H9P9CZtxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVagsbs%253D&md5=80cb584593e77b029cb09d0efba35486</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023863003093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023863003093%26sid%3Dliteratum%253Aachs%26aulast%3DKurosaki%26aufirst%3DR.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMichimata%26aufirst%3DM.%26aulast%3DMatsubara%26aufirst%3DM.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26atitle%3DRole%2520of%2520Dopamine%2520Transporter%2520Against%2520MPTP%2520%25281-Methyl-4-Phenyl-1%252C2%252C3%252C6-Tetrahydropyridine%2529%2520Neurotoxicity%2520in%2520Mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2003%26volume%3D18%26spage%3D139%26epage%3D146%26doi%3D10.1023%2FA%3A1023863003093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span> <span> </span><span class="NLM_article-title">MAO-B Inhibitors: Multiple Roles in the Therapy of Neurodegenerative Disorders?</span>. <i>Parkinsonism Relat. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/S1353-8020(99)00043-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1353-8020%2899%2900043-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=18591148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BD1cvitFyrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=25-47&author=P.+Foleyauthor=M.+Gerlachauthor=M.+B.+Youdimauthor=P.+Riederer&title=MAO-B+Inhibitors%3A+Multiple+Roles+in+the+Therapy+of+Neurodegenerative+Disorders%3F&doi=10.1016%2FS1353-8020%2899%2900043-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?</span></div><div class="casAuthors">Foley P; Gerlach M; Youdim M B; Riederer P</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-47</span>
        ISSN:<span class="NLM_cas:issn">1353-8020</span>.
    </div><div class="casAbstract">Monoamine oxidases play a central role in catecholamine catabolism in the central nervous system.  The biochemical and pharmacological properties of inhibitors of the monoamine oxidase type B are reviewed.  The evidence for biochemical activities distinct from their ability to inhibit MAO-B is discussed, including possible antioxidative and antiapoptotic activities of these agents.  The significance of these properties for the pharmacological management of Parkinson's disease and the evidence for a neuroprotective effect of one such agent (selegiline) is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZCSetTAu6zNbHMBt0mMIXfW6udTcc2eavLnF4J22XArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvitFyrtQ%253D%253D&md5=aa64555d2fd4bbd0b9d748ce8ad1a1e1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1353-8020%2899%2900043-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1353-8020%252899%252900043-7%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGerlach%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DRiederer%26aufirst%3DP.%26atitle%3DMAO-B%2520Inhibitors%253A%2520Multiple%2520Roles%2520in%2520the%2520Therapy%2520of%2520Neurodegenerative%2520Disorders%253F%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2000%26volume%3D6%26spage%3D25%26epage%3D47%26doi%3D10.1016%2FS1353-8020%2899%2900043-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">LARMD: Integration of Bioinformatic Resources to Profile Ligand-Driven Protein Dynamics With a Case on the Activation of Estrogen Receptor</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1093/bib/bbz141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbz141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.-F.+Yangauthor=F.+Wangauthor=Y.-Z.+Chenauthor=G.-F.+Haoauthor=G.-F.+Yang&title=LARMD%3A+Integration+of+Bioinformatic+Resources+to+Profile+Ligand-Driven+Protein+Dynamics+With+a+Case+on+the+Activation+of+Estrogen+Receptor&doi=10.1093%2Fbib%2Fbbz141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbz141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbz141%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.-Z.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DLARMD%253A%2520Integration%2520of%2520Bioinformatic%2520Resources%2520to%2520Profile%2520Ligand-Driven%2520Protein%2520Dynamics%2520With%2520a%2520Case%2520on%2520the%2520Activation%2520of%2520Estrogen%2520Receptor%26jtitle%3DBriefings%2520Bioinf.%26date%3D2019%26doi%3D10.1093%2Fbib%2Fbbz141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0ljWGpGfM3wXYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">ACID: A Free Tool for Drug Repurposing Using Consensus Inverse Docking Strategy</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">73</span> <span class="refDoi"> DOI: 10.1186/s13321-019-0394-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2Fs13321-019-0394-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=F.+Wangauthor=F.-X.+Wuauthor=C.-Z.+Liauthor=C.-Y.+Jiaauthor=S.-W.+Suauthor=G.-F.+Haoauthor=G.-F.+Yang&title=ACID%3A+A+Free+Tool+for+Drug+Repurposing+Using+Consensus+Inverse+Docking+Strategy&doi=10.1186%2Fs13321-019-0394-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs13321-019-0394-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-019-0394-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DLi%26aufirst%3DC.-Z.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DSu%26aufirst%3DS.-W.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DACID%253A%2520A%2520Free%2520Tool%2520for%2520Drug%2520Repurposing%2520Using%2520Consensus%2520Inverse%2520Docking%2520Strategy%26jtitle%3DJ.%2520Cheminf.%26date%3D2019%26volume%3D11%26doi%3D10.1186%2Fs13321-019-0394-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, T. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swails, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitberg, A. E.</span></span> <span> </span><span class="NLM_article-title">MMPBSA.py: An Efficient Program for End-State Free Energy Calculations</span>. <i>J. Chem. Theory. Comput.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3321</span>, <span class="refDoi"> DOI: 10.1021/ct300418h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300418h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2gtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=3314-3321&author=B.+R.+Millerauthor=T.+D.+McGeeauthor=J.+M.+Swailsauthor=N.+Homeyerauthor=H.+Gohlkeauthor=A.+E.+Roitberg&title=MMPBSA.py%3A+An+Efficient+Program+for+End-State+Free+Energy+Calculations&doi=10.1021%2Fct300418h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">MMPBSA.py: An Efficient Program for End-State Free Energy Calculations</span></div><div class="casAuthors">Miller, Bill R., III; McGee, T. Dwight, Jr.; Swails, Jason M.; Homeyer, Nadine; Gohlke, Holger; Roitberg, Adrian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3314-3321</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MM-PBSA is a post-processing end-state method to calc. free energies of mols. in soln.  MMPBSA.py is a program written in Python for streamlining end-state free energy calcns. using ensembles derived from mol. dynamics (MD) or Monte Carlo (MC) simulations.  Several implicit solvation models are available with MMPBSA.py, including the Poisson-Boltzmann Model, the Generalized Born Model, and the Ref. Interaction Site Model.  Vibrational frequencies may be calcd. using normal mode or quasi-harmonic anal. to approx. the solute entropy.  Specific interactions can also be dissected using free energy decompn. or alanine scanning.  A parallel implementation significantly speeds up the calcn. by dividing frames evenly across available processors.  MMPBSA.py is an efficient, user-friendly program with the flexibility to accommodate the needs of users performing end-state free energy calcns.  The source code can be downloaded at http://ambermd.org/ with AmberTools, released under the GNU General Public License.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZK3C1jqiSULVg90H21EOLACvtfcHk0ljWGpGfM3wXYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2gtrzP&md5=cc4148bd8f70c7cad94fd3ec6f580e52</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fct300418h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300418h%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DMcGee%26aufirst%3DT.%2BD.%26aulast%3DSwails%26aufirst%3DJ.%2BM.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DRoitberg%26aufirst%3DA.%2BE.%26atitle%3DMMPBSA.py%253A%2520An%2520Efficient%2520Program%2520for%2520End-State%2520Free%2520Energy%2520Calculations%26jtitle%3DJ.%2520Chem.%2520Theory.%2520Comput.%26date%3D2012%26volume%3D8%26spage%3D3314%26epage%3D3321%26doi%3D10.1021%2Fct300418h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">FungiPAD: A Free Web Tool for Compound Property Evaluation and Fungicide-Likeness Analysis</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.8b06596</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.8b06596" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=1823-1830&author=M.-y.+Wangauthor=F.+Wangauthor=G.-F.+Haoauthor=G.-F.+Yang&title=FungiPAD%3A+A+Free+Web+Tool+for+Compound+Property+Evaluation+and+Fungicide-Likeness+Analysis&doi=10.1021%2Facs.jafc.8b06596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">FungiPAD: A Free Web Tool for Compound Property Evaluation and Fungicide-Likeness Analysis</span></div><div class="casAuthors">Wang, Meng-yao; Wang, Fan; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1823-1830</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing prevalence of fungal diseases, continual development of resistance, and stringent environmental regulation have revealed an urgent need to develop more selective, safer, resistance-breaking, and cost-effective fungicides.  However, most new fungicidal lead compds. fail in their late stages of development due to poor soly. or permeability, meaning they have suboptimal physicochem. properties.  Hence, the exploration of advanced technologies for compds. 'fungicide-likeness' assessment might overcome these obstacles and bring more chem. entities to market.  FungiPAD (http://chemyang.ccnu.edu.cn/ccb/database/FungiPAD/) is a free platform employed to predict physicochem. properties, bioavailability and fungicide-likeness swiftly and powerfully by using comprehensive approaches, such as physicochem. radars, qual. and quant. anal.  This platform contains data for over 16000 physicochem. descriptors, the results of 2200 qual. and 1100 quant. analyses of marketed fungicides, and provides comprehensive fungicide-likeness anal. for different compds.  The user-friendly interface facilitates interpretation and manipulation by non-computational scientist in support of fungicide discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRz5rSPirfu7Vg90H21EOLACvtfcHk0ljgAP8ugMGD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleqtL4%253D&md5=4b50ef4d1f1e38c520616c54977c5db2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.8b06596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.8b06596%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.-y.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DFungiPAD%253A%2520A%2520Free%2520Web%2520Tool%2520for%2520Compound%2520Property%2520Evaluation%2520and%2520Fungicide-Likeness%2520Analysis%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2019%26volume%3D67%26spage%3D1823%26epage%3D1830%26doi%3D10.1021%2Facs.jafc.8b06596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukrishnan, M.</span></span> <span> </span><span class="NLM_article-title">A New Enantioselective Synthesis of the Anti-Parkinson Agent Safinamide</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1756</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1341104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1055%2Fs-0033-1341104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1amtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1751-1756&author=A.+Reddiauthor=M.+Mujahidauthor=M.+Sasikumarauthor=M.+Muthukrishnan&title=A+New+Enantioselective+Synthesis+of+the+Anti-Parkinson+Agent+Safinamide&doi=10.1055%2Fs-0033-1341104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A new enantioselective synthesis of the anti-Parkinson agent safinamide</span></div><div class="casAuthors">Reddi, Anjaneyulu; Mujahid, Mohammad; Sasikumar, Murugesan; Muthukrishnan, Murugan</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1751-1756, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An alternative highly enantioselective synthesis of the anti-Parkinson agent safinamide from simple, com. available, starting materials is described.  The protocol might also be useful in the synthesis of structural variants of safinamide, such as ralfinamide or related analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf19y3UMaUILVg90H21EOLACvtfcHk0ljgAP8ugMGD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1amtbbJ&md5=31d4bde2667bcd4ec1d724bac8927a96</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1341104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1341104%26sid%3Dliteratum%253Aachs%26aulast%3DReddi%26aufirst%3DA.%26aulast%3DMujahid%26aufirst%3DM.%26aulast%3DSasikumar%26aufirst%3DM.%26aulast%3DMuthukrishnan%26aufirst%3DM.%26atitle%3DA%2520New%2520Enantioselective%2520Synthesis%2520of%2520the%2520Anti-Parkinson%2520Agent%2520Safinamide%26jtitle%3DSynthesis%26date%3D2014%26volume%3D46%26spage%3D1751%26epage%3D1756%26doi%3D10.1055%2Fs-0033-1341104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Cloud 3D-QSAR: A Web Tool for the Development of Quantitative Structure-Activity Relationship Models in Drug Discovery</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1093/bib/bbaa276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbaa276" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Y.-L.+Wangauthor=F.+Wangauthor=X.-X.+Shiauthor=C.-Y.+Jiaauthor=F.-X.+Wuauthor=G.-F.+Haoauthor=G.-F.+Yang&title=Cloud+3D-QSAR%3A+A+Web+Tool+for+the+Development+of+Quantitative+Structure-Activity+Relationship+Models+in+Drug+Discovery&doi=10.1093%2Fbib%2Fbbaa276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbaa276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbaa276%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.-X.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DCloud%25203D-QSAR%253A%2520A%2520Web%2520Tool%2520for%2520the%2520Development%2520of%2520Quantitative%2520Structure-Activity%2520Relationship%2520Models%2520in%2520Drug%2520Discovery%26jtitle%3DBriefings%2520Bioinf.%26date%3D2020%26doi%3D10.1093%2Fbib%2Fbbaa276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y.-K.</span></span> <span> </span><span class="NLM_article-title">Hederagenin and Alpha-Hederin Promote Degradation of Proteins in Neurodegenerative Diseases and Improve Motor Deficits in MPTP-Mice</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.phrs.2016.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27838509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2017&pages=25-44&author=A.-G.+Wuauthor=W.+Zengauthor=V.+K.-W.+Wongauthor=Y.-Z.+Zhuauthor=A.+C.+Y.+Loauthor=L.+Liuauthor=B.+Y.-K.+Law&title=Hederagenin+and+Alpha-Hederin+Promote+Degradation+of+Proteins+in+Neurodegenerative+Diseases+and+Improve+Motor+Deficits+in+MPTP-Mice&doi=10.1016%2Fj.phrs.2016.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice</span></div><div class="casAuthors">Wu, An-Guo; Zeng, Wu; Wong, Vincent Kam-Wai; Zhu, Yi-Zhun; Lo, Amy C. Y.; Liu, Liang; Law, Betty Yuen-Kwan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-44</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pathogenesis of neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's disease (HD) are closely related to the formation of protein aggregates and inclusion body.  For instance, active autophagic components from Chinese herbal medicines (CHMs) are highlighted to modulate neurodegeneration via degrdn. of disease proteins.  In this study, the neuroprotective effect of the purified Hedera helix (HH) fraction contg. both hederagenin and α-hederin, is confirmed by the improvement of motor deficits in PD mice model.  Furthermore, hederagenin and α-hederin derived from HH are confirmed as novel autophagic enhancers.  Both compds. reduce the protein level of mutant huntington with 74 CAG repeats and A53T α-synuclein, and inhibit the oligomerization of α-synuclein and inclusion formation of huntington, via AMPK-mTOR dependent autophagy induction.  Both hederagenin and α-hederin induce autophagy and promote the degrdn. of neurodegenerative mutant disease proteins in vitro, suggesting the therapeutic roles of HH in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH-LNj0NxMXrVg90H21EOLACvtfcHk0ljgAP8ugMGD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjtb7K&md5=09222a752ae8a3621374a239c9aed87c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.-G.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DWong%26aufirst%3DV.%2BK.-W.%26aulast%3DZhu%26aufirst%3DY.-Z.%26aulast%3DLo%26aufirst%3DA.%2BC.%2BY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLaw%26aufirst%3DB.%2BY.-K.%26atitle%3DHederagenin%2520and%2520Alpha-Hederin%2520Promote%2520Degradation%2520of%2520Proteins%2520in%2520Neurodegenerative%2520Diseases%2520and%2520Improve%2520Motor%2520Deficits%2520in%2520MPTP-Mice%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D115%26spage%3D25%26epage%3D44%26doi%3D10.1016%2Fj.phrs.2016.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pedro  Cruz-Vicente</span>, <span class="hlFld-ContribAuthor ">Luís A.  Passarinha</span>, <span class="hlFld-ContribAuthor ">Samuel  Silvestre</span>, <span class="hlFld-ContribAuthor ">Eugenia  Gallardo</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (8)
                                     , 2193. <a href="https://doi.org/10.3390/molecules26082193" title="DOI URL">https://doi.org/10.3390/molecules26082193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26082193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26082193%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BDevelopments%252Bin%252BNew%252BTherapeutic%252BAgents%252Bagainst%252BAlzheimer%252Band%252BParkinson%252BDiseases%25253A%252BIn-Silico%252BApproaches%26aulast%3DCruz-Vicente%26aufirst%3DPedro%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D8%26spage%3D2193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Known MAO-B inhibitors in clinical use and several research chemical scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding pocket of MAO-A and MAO-B. (A) Docking result of MAO-A with safinamide. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y">2Z5Y</a> was used as docking receptor. (B) Crystal structure of MAO-B with safinamide (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>). The subpocket size of S1 was narrowed for MAO-A (59 Å<sup>3</sup>) compared with MAO-B (76 Å<sup>3</sup>) because of Phe208 of MAO-A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Workflow of the SCIBA strategy. Based on the binding mode of safinamide with MAO-A and MAO-B, fragment deconstruction and protein fragment Δ<i>G</i> calculations were performed. Then, the fragment with the highest ΔLE in complex with MAO-A and MAO-B was used for fragment screening. The newly generated compound with the lowest ΔΔ<i>G</i> value might be a selective inhibitor of MAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>A1</b>–<b>A10</b> and <b>C1</b>–<b>C13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (I) K<sub>2</sub>CO<sub>3</sub>, KI, EtOH, 85 °C, 12–18 h; (II and V) (<i>S</i>)-2-(benzylamino)propanamide derivatives, Et<sub>3</sub>N, AcOH, NaBH<sub>3</sub>(CN), MeOH, 0 °C-rt, 19 h; or <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), LiCl, MeOH, rt, 15 h, then KBH<sub>4</sub>, 0 °C, 2 h; (III) 3-bromopropyne, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), rt, 12 h; (IIII) cyclopropylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene/H<sub>2</sub>O, 100 °C, 4 h; (VI) NaBH<sub>4</sub>, MeOH, 0 °C-rt, 2–22 h; (VII) SOCl<sub>2</sub>, DMF, 0 °C, 2–5 h; and (VIII) (chiral) cyclic carboxamides, Et<sub>3</sub>N, DMF, rt, 6–17 h.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Result of CoMFA analysis. (A) Correlation between the experimental versus predicted activities of training and test set of MAO-B. (B) Contour maps of the CoMFA model, <b>C3</b> was used as the template compound. For the steric field, green contours and yellow contours represent favorable and unfavorable regions for bulky groups. For the electrostatic field, blue contours indicate the favorable region for positively charged groups, while red contours indicate the favorable region for negatively charged groups. (C) Statistical result of the CoMFA model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of compounds in different configurations with MAO-B. The binding mode of (<i>S</i>)-safinamide with MAO-B (A) came from the crystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>), and (<i>S</i>)-safinamide is shown in the yellow stick. The binding mode of (<i>R</i>)-safinamide (B), (<i>S</i>)-<b>C3</b> (C), and (<i>R</i>)-<b>C3</b> (D) with MAO-B was predicted via molecular docking. <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a> was used as the docking receptor. (<i>R</i>)-safinamide, (<i>S</i>)-<b>C3</b>, and (<i>R</i>)-<b>C3</b> are shown in green, peach, and cyan stick, respectively. Hydrogen bonds are given in the black dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>C3</b> on MAO activity in the brains of mice. MAO-B (a) and MAO-A (b) inhibitory activities with Saf (400 μg/kg) as a positive control. Data are shown as the mean ± standard error of the mean (SEM): *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001 vs Ctrl, <i>N</i> = 6, Saf: Safinamide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of mice brain MAO-B inhibition <i>ex vivo</i> by a single dose of <b>C3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Effects of <b>C3</b> pretreatment on MPTP-induced DA depletion in the striatum. (b) Effects of <b>C3</b> on the DA concentration in the striatum administered with LD/benserazide (50.0/12.5 mg/kg) in MPTP mice. Saf (3.0 mg/kg) is the positive control. Data are shown as the mean ± SEM: <sup>###</sup><i>P</i> < 0.001 vs Ctrl; *<i>P</i> < 0.05, **<i>P</i> < 0.01 vs MPTP alone; <sup>$</sup><i>P</i> < 0.05, <sup>$$</sup><i>P</i> < 0.01, <sup>$$$</sup><i>P</i> < 0.001 vs LD/benserazide, <i>N</i> = 8, Saf: Safinamide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/medium/jm0c01663_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Proposed binding mode of compound <b>C3</b> with MAO-A (A) and MAO-B (B) via molecular docking. Crystal structures of MAO-A (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y">2Z5Y</a>) and MAO-B (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z">2V5Z</a>) were used in docking. Compound <b>C3</b> is shown as a peach stick model. The hydrogen bonds are shown as black dotted lines. (C) Δ<i>G</i> of <b>C3</b> with MAO-A and MAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01663/20201203/images/large/jm0c01663_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01663&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kehagia, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span> <span> </span><span class="NLM_article-title">Neuropsychological and Clinical Heterogeneity of Cognitive Impairment and Dementia in Patients with Parkinson’s Disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(10)70212-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1474-4422%2810%2970212-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=20880750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC3cbnsFWitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1200-1213&author=A.+A.+Kehagiaauthor=R.+A.+Barkerauthor=T.+W.+Robbins&title=Neuropsychological+and+Clinical+Heterogeneity+of+Cognitive+Impairment+and+Dementia+in+Patients+with+Parkinson%E2%80%99s+Disease&doi=10.1016%2FS1474-4422%2810%2970212-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease</span></div><div class="casAuthors">Kehagia Angie A; Barker Roger A; Robbins Trevor W</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1200-1213</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cognitive impairment in patients with Parkinson's disease is gaining increased clinical significance owing to the relative success of therapeutic approaches to the motor symptoms of this disorder.  Early investigations contributed to the concept of subcortical dementia associated with bradyphrenia and cognitive rigidity.  For cognition in parkinsonian disorders, this notion developed into the concept of mild cognitive impairment and fronto-executive dysfunction in particular, driven mainly by dopaminergic dysmodulation and manifesting as deficits in flexibility, planning, working memory, and reinforcement learning.  However, patients with Parkinson's disease could also develop a syndrome of dementia that might depend on non-dopaminergic, cholinergic cortical dysfunction.  Recent findings, supplemented by advances in neuroimaging and genetic research, reveal substantial heterogeneity in the range of cognitive deficits in patients with Parkinson's disease.  Remediation and management prospects for these cognitive deficits are based on neuropharmacological and cognitive rehabilitation approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2jYKP9flaDS-bLEOO4dYpfW6udTcc2eZ3Y7m4ttdrCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbnsFWitg%253D%253D&md5=aa7c355574b4708f40ad200c0c176dd7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2810%2970212-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252810%252970212-X%26sid%3Dliteratum%253Aachs%26aulast%3DKehagia%26aufirst%3DA.%2BA.%26aulast%3DBarker%26aufirst%3DR.%2BA.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26atitle%3DNeuropsychological%2520and%2520Clinical%2520Heterogeneity%2520of%2520Cognitive%2520Impairment%2520and%2520Dementia%2520in%2520Patients%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D1200%26epage%3D1213%26doi%3D10.1016%2FS1474-4422%2810%2970212-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noyce, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bestwick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silveira-Moriyama, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrag, A.</span></span> <span> </span><span class="NLM_article-title">Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1002/ana.23687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fana.23687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=23071076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1yhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=893-901&author=A.+J.+Noyceauthor=J.+P.+Bestwickauthor=L.+Silveira-Moriyamaauthor=C.+H.+Hawkesauthor=G.+Giovannoniauthor=A.+J.+Leesauthor=A.+Schrag&title=Meta-Analysis+of+Early+Nonmotor+Features+and+Risk+Factors+for+Parkinson+Disease&doi=10.1002%2Fana.23687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of early nonmotor features and risk factors for Parkinson disease</span></div><div class="casAuthors">Noyce, Alastair J.; Bestwick, Jonathan P.; Silveira-Moriyama, Laura; Hawkes, Christopher H.; Giovannoni, Gavin; Lees, Andrew J.; Schrag, Anette</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">893-901</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the assocn. between diagnosis of Parkinson disease (PD) and risk factors or early symptoms amenable to population-based screening.  Methods: A systematic review and meta-anal. of risk factors for PD.  Results: The strongest assocns. with later diagnosis of PD were found for having a first-degree or any relative with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65-3.93 and OR, 4.45; 95% CI, 3.39-5.83) or any relative with tremor (OR, 2.74; 95% CI, 2.10-3.57), constipation (relative risk [RR], 2.34; 95% CI, 1.55-3.53), or lack of smoking history (current vs never: RR, 0.44; 95% CI, 0.39-0.50), each at least doubling the risk of PD.  Further pos. significant assocns. were found for history of anxiety or depression, pesticide exposure, head injury, rural living, beta-blockers, farming occupation, and well-water drinking, and neg. significant assocns. were found for coffee drinking, hypertension, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alc., but not for diabetes mellitus, cancer, oral contraceptive pill use, surgical menopause, hormone replacement therapy, statins, acetaminophen/paracetamol, aspirin, tea drinking, history of general anesthesia, or gastric ulcers.  In the systematic review, addnl. assocns. included neg. assocns. with raised serum urate, and single studies or studies with conflicting results.  Interpretation: The strongest risk factors assocd. with later PD diagnosis are having a family history of PD or tremor, a history of constipation, and lack of smoking history.  Further factors also but less strongly contribute to risk of PD diagnosis or, as some premotor symptoms, require further standardized studies to demonstrate the magnitude of risk assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNbbaMupRsoLVg90H21EOLACvtfcHk0lh9eUk0Hl-Cbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1yhtg%253D%253D&md5=ce1915cd74a2403039d08e3df404b16c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fana.23687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23687%26sid%3Dliteratum%253Aachs%26aulast%3DNoyce%26aufirst%3DA.%2BJ.%26aulast%3DBestwick%26aufirst%3DJ.%2BP.%26aulast%3DSilveira-Moriyama%26aufirst%3DL.%26aulast%3DHawkes%26aufirst%3DC.%2BH.%26aulast%3DGiovannoni%26aufirst%3DG.%26aulast%3DLees%26aufirst%3DA.%2BJ.%26aulast%3DSchrag%26aufirst%3DA.%26atitle%3DMeta-Analysis%2520of%2520Early%2520Nonmotor%2520Features%2520and%2520Risk%2520Factors%2520for%2520Parkinson%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D893%26epage%3D901%26doi%3D10.1002%2Fana.23687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascherio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">The Epidemiology of Parkinson’s Disease: Risk Factors and Prevention</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(16)30230-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1474-4422%2816%2930230-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27751556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC2srhsFSnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1257-1272&author=A.+Ascherioauthor=M.+A.+Schwarzschild&title=The+Epidemiology+of+Parkinson%E2%80%99s+Disease%3A+Risk+Factors+and+Prevention&doi=10.1016%2FS1474-4422%2816%2930230-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of Parkinson's disease: risk factors and prevention</span></div><div class="casAuthors">Ascherio Alberto; Schwarzschild Michael A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1257-1272</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since 2006, several longitudinal studies have assessed environmental or behavioural factors that seem to modify the risk of developing Parkinson's disease.  Increased risk of Parkinson's disease has been associated with exposure to pesticides, consumption of dairy products, history of melanoma, and traumatic brain injury, whereas a reduced risk has been reported in association with smoking, caffeine consumption, higher serum urate concentrations, physical activity, and use of ibuprofen and other common medications.  Randomised trials are investigating the possibility that some of the negative risk factors might be neuroprotective and thus beneficial in individuals with early Parkinson's disease, particularly with respect to smoking (nicotine), caffeine, and urate.  In the future, it might be possible to identify Parkinson's disease in its prodromal phase and to promote neuroprotective interventions before the onset of motor symptoms.  At this time, however, the only intervention that seems justifiable for the primary prevention of Parkinson's disease is the promotion of physical activity, which is likely to be beneficial for the prevention of several chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8H_Y4x8oN2m52AMpI4GK2fW6udTcc2ebcWrhO_UqV1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srhsFSnsQ%253D%253D&md5=728289c098321aa105b428ed1082dd6e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2816%2930230-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252816%252930230-7%26sid%3Dliteratum%253Aachs%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Epidemiology%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Risk%2520Factors%2520and%2520Prevention%26jtitle%3DLancet%2520Neurol.%26date%3D2016%26volume%3D15%26spage%3D1257%26epage%3D1272%26doi%3D10.1016%2FS1474-4422%2816%2930230-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">Enzymology of Monoamine Oxidase</span>. <i>Cell Biochem. Funct.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1002/cbf.290040202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fcbf.290040202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=3518979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaL28XhvVajur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1986&pages=79-87&author=K.+F.+Tipton&title=Enzymology+of+Monoamine+Oxidase&doi=10.1002%2Fcbf.290040202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology of monoamine oxidase</span></div><div class="casAuthors">Tipton, K. F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">0263-6484</span>.
    </div><div class="casAbstract">A review, with 144 refs., of the specificity occurrence, localization, mol. properties, catalytic and kinetic properties, multiplicity, and inhibitors of MAO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd0aEWs90XXrVg90H21EOLACvtfcHk0lij0vTPfZfwhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVajur4%253D&md5=8dcbed6596a4e2a4df37208f84464333</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fcbf.290040202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.290040202%26sid%3Dliteratum%253Aachs%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DEnzymology%2520of%2520Monoamine%2520Oxidase%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D1986%26volume%3D4%26spage%3D79%26epage%3D87%26doi%3D10.1002%2Fcbf.290040202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löhle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, H.</span></span> <span> </span><span class="NLM_article-title">Controversies in Neurology: Why Monoamine Oxidase B Inhibitors Could be a Good Choice for The Initial Treatment of Parkinson’s Disease</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">112</span> <span class="refDoi"> DOI: 10.1186/1471-2377-11-112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2F1471-2377-11-112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=21939547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC3MbgvFGltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&author=M.+L%C3%B6hleauthor=H.+Reichmann&title=Controversies+in+Neurology%3A+Why+Monoamine+Oxidase+B+Inhibitors+Could+be+a+Good+Choice+for+The+Initial+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1186%2F1471-2377-11-112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease</span></div><div class="casAuthors">Lohle Matthias; Reichmann Heinz</div><div class="citationInfo"><span class="NLM_cas:title">BMC neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Early initiation of pharmacotherapy in Parkinson's disease (PD) is nowadays widely advocated by experts since the delay of treatment has shown to be associated with a significant deterioration of health related quality of life in affected patients.  Due to marked advances in PD treatment during the last decades, physicians are nowadays fortunately equipped with a variety of substances that can effectively ameliorate emerging motor symptoms of the disease, among them levodopa, dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors.  Despite numerous drug intervention trials in early PD, there is however still ongoing controversy among neurologists which substance to use for the initial treatment of the disease.  DISCUSSION:  In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations.  Although their symptomatic efficacy is inferior compared to dopamine agonists and levodopa, MAO-B inhibitors undoubtedly have fewer side effects and are easy to administer.  In contrary to their competitors, MAO-B inhibitors may furthermore offer a chance for disease modification, which so far remains a major unmet need in the management of PD and eventually makes them ideal candidates for the early treatment of the disease.  SUMMARY:  MAO-B inhibitors may constitute a preferable therapeutic option for early PD, mainly due to their favourable safety profile and their putative neuroprotective capabilities.  Since the symptomatic effects of MAO-B inhibitors are comparatively mild, dopamine agonists and levodopa should however be considered for initial treatment in those PD patients, in whom robust and immediate symptomatic relief needs to be prioritized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQICir7hjn-6cScOqQTSkOffW6udTcc2ebcWrhO_UqV1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbgvFGltw%253D%253D&md5=462eeda4fb9071015df6659e457efb3b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1471-2377-11-112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2377-11-112%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6hle%26aufirst%3DM.%26aulast%3DReichmann%26aufirst%3DH.%26atitle%3DControversies%2520in%2520Neurology%253A%2520Why%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520Could%2520be%2520a%2520Good%2520Choice%2520for%2520The%2520Initial%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DBMC%2520Neurol.%26date%3D2011%26volume%3D11%26doi%3D10.1186%2F1471-2377-11-112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">New Frontiers in Selective Human MAO-B Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6717</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1021/jm501690r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501690r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6717-6732&author=S.+Carradoriauthor=R.+Silvestri&title=New+Frontiers+in+Selective+Human+MAO-B+Inhibitors&doi=10.1021%2Fjm501690r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New Frontiers in Selective Human MAO-B Inhibitors</span></div><div class="casAuthors">Carradori, Simone; Silvestri, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6717-6732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence shows a relationship between the human MAO-B (hMAO-B) enzyme and neuropsychiatric/degenerative disorder, personality traits, type II alcoholism, borderline personality disorders, aggressiveness and violence in crime, obsessive-compulsive disorder, depression, suicide, schizophrenia, anorexia nervosa, migraine, dementia, and PD.  Thus, MAO-B represents an attractive target for the treatment of a no. of human diseases.  The discovery, development, and therapeutic use of drugs that inhibit MAO-B are major challenges for future therapy.  Various compds. and drugs that selectively target this isoform have been discovered recently.  These agents are synthetic compds. or natural products and their analogs, including chalcones, pyrazoles, chromones, coumarins, xanthines, isatin derivs., thiazolidindiones, (thiazol-2-yl)hydrazones, and analogs of marketed drugs.  Despite considerable efforts in understanding the binding interaction with specific substrates or inhibitors, structural information available for the rational design of new hMAO-B inhibitors remains unsatisfactory.  Therefore, the quest for novel, potent, and selective hMAO-B inhibitors remains of high interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Xz4JhVXeRbVg90H21EOLACvtfcHk0lg-Doy5gowq0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGiurk%253D&md5=abe939ceae25d97e83243f9f0af6aef5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm501690r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501690r%26sid%3Dliteratum%253Aachs%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520Frontiers%2520in%2520Selective%2520Human%2520MAO-B%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6717%26epage%3D6732%26doi%3D10.1021%2Fjm501690r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=29335210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=445-497&author=A.+C.+Tripathiauthor=S.+Upadhyayauthor=S.+Paliwalauthor=S.+K.+Saraf&title=Privileged+Scaffolds+as+MAO+Inhibitors%3A+Retrospect+and+Prospects&doi=10.1016%2Fj.ejmech.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds as MAO inhibitors: Retrospect and prospects</span></div><div class="casAuthors">Tripathi, Avinash C.; Upadhyay, Savita; Paliwal, Sarvesh; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review aims to be a comprehensive, authoritative, crit., and readable review of general interest to the medicinal chem. community because it focuses on the pharmacol., chem., structural and computational aspects of diverse chem. categories as monoamine oxidase inhibitors (MAOIs).  Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiol. origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever.  Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).  The use of MAOIs declined due to some potential side effects, food and drug interactions, and introduction of other classes of drugs.  However, curiosity in MAOIs is reviving and the recent developments of new generation of highly selective and reversible MAOIs, have renewed the therapeutic prospective of these compds.  The initial section of the review emphasizes on the detailed classification, structural and binding characteristics, therapeutic potential, current status and future challenges of the privileged pharmacophores.  However, the chem. prospective of privileged scaffolds such as; aliph. and arom. amines, amides, hydrazines, azoles, diazoles, tetrazoles, indoles, azines, diazines, xanthenes, tricyclics, benzopyrones, and more interestingly natural products, along with their conclusive SARs have been discussed in the later segment of review.  The last segment of the article encompasses some patents granted in the field of MAOIs, in a simplistic way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqYob-n4zgsLVg90H21EOLACvtfcHk0lg-Doy5gowq0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D&md5=4fa0cc226ee27522671188d0cfe62ab2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3DPrivileged%2520Scaffolds%2520as%2520MAO%2520Inhibitors%253A%2520Retrospect%2520and%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D445%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span> <span> </span><span class="NLM_article-title">Compulsivity and Impulsivity-Personal Reflections: Why Now and Why Here?</span>. <i>CNS Spectr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1017/S1092852913000886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1017%2FS1092852913000886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=24284261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BC2c3hsVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=6-7&author=E.+Hollander&title=Compulsivity+and+Impulsivity-Personal+Reflections%3A+Why+Now+and+Why+Here%3F&doi=10.1017%2FS1092852913000886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Compulsivity and impulsivity-personal reflections: why now and why here?</span></div><div class="casAuthors">Hollander Eric</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-7</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">This issue of CNS Spectrums contains a unique collection of manuscripts that examine compulsivity and impulsivity from a broad range of perspectives and helps to shape our evolving understanding of compulsivity and impulsivity as orthogonal symptom dimensions arising from parallel tightly regulated brain circuits giving rise to a spectrum of overlapping diagnostic categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0kmLwebtNR6x48Rj5GnGofW6udTcc2eYrRpIXAskRWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3hsVGquw%253D%253D&md5=8faf6c41965f77b45704bb5b042a0b5f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1017%2FS1092852913000886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852913000886%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26atitle%3DCompulsivity%2520and%2520Impulsivity-Personal%2520Reflections%253A%2520Why%2520Now%2520and%2520Why%2520Here%253F%26jtitle%3DCNS%2520Spectr.%26date%3D2014%26volume%3D19%26spage%3D6%26epage%3D7%26doi%3D10.1017%2FS1092852913000886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abodabos, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taban, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rfieda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anward, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sizochenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H. I.</span></span> <span> </span><span class="NLM_article-title">Rutin as Promising Drug for the Treatment of Parkinson’s Disease: An Assessment of MAO-B Inhibitory Potential by Docking, Molecular Dynamics and DFT Studies</span>. <i>Mol. Simul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1563</span>– <span class="NLM_lpage">1571</span>, <span class="refDoi"> DOI: 10.1080/08927022.2019.1662003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1080%2F08927022.2019.1662003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleitr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2019&pages=1563-1571&author=F.+Azamauthor=H.+S.+Abodabosauthor=I.+M.+Tabanauthor=A.+R.+Rfiedaauthor=D.+Mahmoodauthor=J.+Anwardauthor=S.+Khanauthor=N.+Sizochenkoauthor=G.+Poliauthor=T.+Tuccinardiauthor=H.+I.+Ali&title=Rutin+as+Promising+Drug+for+the+Treatment+of+Parkinson%E2%80%99s+Disease%3A+An+Assessment+of+MAO-B+Inhibitory+Potential+by+Docking%2C+Molecular+Dynamics+and+DFT+Studies&doi=10.1080%2F08927022.2019.1662003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rutin as promising drug for the treatment of Parkinson's disease: an assessment of MAO-B inhibitory potential by docking, molecular dynamics and DFT studies</span></div><div class="casAuthors">Azam, Faizul; Abodabos, Honiwa Suliman; Taban, Ismail M.; Rfieda, Abdalla R.; Mahmood, Danish; Anwar, Md Jamir; Khan, Shamshir; Sizochenko, Natalia; Poli, Giulio; Tuccinardi, Tiziano; Ali, Hamed I.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Simulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1563-1571</span>CODEN:
                <span class="NLM_cas:coden">MOSIEA</span>;
        ISSN:<span class="NLM_cas:issn">0892-7022</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of monoamine oxidase (MAO)-B have been used for many years in the therapy of Parkinson's disease (PD).  Owing to the safety concerns of the currently used agents, the discovery of novel scaffolds is of considerable interest.  MAO-B inhibitory potential of rutin, a flavonoid derived from natural sources, has been established in exptl. findings.  Hence, the current study seeks to examine the interactions between rutin and crystal structure of human MAO-B enzyme.  Mol. docking calcns., as well as mol. dynamics simulations, were employed to investigate the binding mode and the stability of the rutin/MAO-B complex.  Energies of highest occupied/lowest unoccupied MOs were computed through DFT studies and used to calc. electron affinity, hardness, chem. potential, electronegativity, and electrophilicity index in order to investigate the capability of these parameters to influence the ligand-receptor interactions.  It was found that rutin traverses both the entrance cavity and the substrate cavity, forcing the Ile-199 'gate' to rotate into its open conformation.  It results in the fusion of the two cavities of the MAO-B binding site and directly leads to better binding interactions.  Results of the current study can be used for lead modification and development of novel drugs for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3FYd8WUJ9kLVg90H21EOLACvtfcHk0liBLc4j01E7ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleitr%252FM&md5=4d03af550292c4b40190b09d5496ac72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F08927022.2019.1662003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F08927022.2019.1662003%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DF.%26aulast%3DAbodabos%26aufirst%3DH.%2BS.%26aulast%3DTaban%26aufirst%3DI.%2BM.%26aulast%3DRfieda%26aufirst%3DA.%2BR.%26aulast%3DMahmood%26aufirst%3DD.%26aulast%3DAnward%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DSizochenko%26aufirst%3DN.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DAli%26aufirst%3DH.%2BI.%26atitle%3DRutin%2520as%2520Promising%2520Drug%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520An%2520Assessment%2520of%2520MAO-B%2520Inhibitory%2520Potential%2520by%2520Docking%252C%2520Molecular%2520Dynamics%2520and%2520DFT%2520Studies%26jtitle%3DMol.%2520Simul.%26date%3D2019%26volume%3D45%26spage%3D1563%26epage%3D1571%26doi%3D10.1080%2F08927022.2019.1662003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaurasiya, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerksen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera Diffusa (Damiana)</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">810</span>, <span class="refDoi"> DOI: 10.3390/molecules24040810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.3390%2Fmolecules24040810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=810&author=N.+D.+Chaurasiyaauthor=J.+Zhaoauthor=P.+Pandeyauthor=R.+J.+Doerksenauthor=I.+Muhammadauthor=B.+L.+Tekwani&title=Selective+Inhibition+of+Human+Monoamine+Oxidase+B+by+Acacetin+7-Methyl+Ether+Isolated+from+Turnera+Diffusa+%28Damiana%29&doi=10.3390%2Fmolecules24040810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of human monoamine oxidase B by acacetin 7-methyl ether isolated from Turnera diffusa (Damiana)</span></div><div class="casAuthors">Chaurasiya, Narayan D.; Zhao, Jianping; Pandey, Pankaj; Doerksen, Robert J.; Muhammad, Ilias; Tekwani, Babu L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">810/1-810/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The investigation of the constituents that were isolated from Turnera diffusa (damiana) for their inhibitory activities against recombinant human monoamine oxidases (MAO-A and MAO-B) in vitro identified acacetin 7-Me ether as a potent selective inhibitor of MAO-B (IC50 = 198 nM).  Acacetin 7-Me ether (also known as 5-hydroxy-4', 7-dimethoxyflavone) is a naturally occurring flavone that is present in many plants and vegetables.  Acacetin 7-Me ether was four-fold less potent as an inhibitor of MAO-B when compared to acacetin (IC50 = 50 nM).  However, acacetin 7-Me ether was >500-fold selective against MAO-B over MAO-A as compared to only two-fold selectivity shown by acacetin.  Even though the IC50 for inhibition of MAO-B by acacetin 7-Me ether was ∼four-fold higher than that of the std. drug deprenyl (i.e., Selegiline or Zelapar, a selective MAO-B inhibitor), acacetin 7-Me ether's selectivity for MAO-B over MAO-A inhibition was greater than that of deprenyl (>500- vs. 450-fold).  The binding of acacetin 7-Me ether to MAO-B was reversible and time-independent, as revealed by enzyme-inhibitor complex equil. dialysis assays.  The investigation on the enzyme inhibition-kinetics anal. with varying concns. of acacetin 7-Me ether and the substrate (kynuramine) suggested a competitive mechanism of inhibition of MAO-B by acacetin 7-Me ether with Ki value of 45 nM.  The docking scores and binding-free energies of acacetin 7-Me ether to the X-ray crystal structures of MAO-A and MAO-B confirmed the selectivity of binding of this mol. to MAO-B over MAO-A.  In addn., mol. dynamics results also revealed that acacetin 7-Me ether formed a stable and strong complex with MAO-B.  The selective inhibition of MAO-B suggests further investigations on acacetin 7-Me as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFW4SlfsYd7Vg90H21EOLACvtfcHk0ljQVu1A6-HDLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7c%253D&md5=0b7c93f7f738147add1c630828c2636e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040810%26sid%3Dliteratum%253Aachs%26aulast%3DChaurasiya%26aufirst%3DN.%2BD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DP.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26aulast%3DMuhammad%26aufirst%3DI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26atitle%3DSelective%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidase%2520B%2520by%2520Acacetin%25207-Methyl%2520Ether%2520Isolated%2520from%2520Turnera%2520Diffusa%2520%2528Damiana%2529%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D810%26doi%3D10.3390%2Fmolecules24040810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel Human Monoamine Oxidase B Inhibitors Based on a Fragment in an X-Ray Crystal Structure</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bmcl.2019.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30792039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFSjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1012-1018&author=K.+Chengauthor=S.+Liauthor=X.+Lvauthor=Y.+Tianauthor=H.+Kongauthor=X.+Huangauthor=Y.+Duanauthor=J.+Hanauthor=Z.+Xieauthor=C.+Liao&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+Human+Monoamine+Oxidase+B+Inhibitors+Based+on+a+Fragment+in+an+X-Ray+Crystal+Structure&doi=10.1016%2Fj.bmcl.2019.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure</span></div><div class="casAuthors">Cheng, Kai; Li, Shiyu; Lv, Xiao; Tian, Yongbin; Kong, Haiyan; Huang, Xufeng; Duan, Yajun; Han, Jihong; Xie, Zhouling; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1012-1018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report our efforts of developing reversible selective hMAO-B inhibitors based on isatin, a fragment in an X-ray crystal structure.  Five different scaffolds were designed and many compds. were synthesized.  Among them, compd. A3(I) demonstrated very high potency and isoform selectivity against hMAO-B, 11 and 13 times more potent (IC50 = 3 nM) and 23.64 and 6.8 times more selective than the marked drugs, selegiline and safinamide.  However, the endeavors to modify the polar 3-one group of isatin, that is in a hydrophobic environment in the binding site of hMAO-B, to small nonpolar hydrophobic groups did not bring about improved hMAO-B inhibitors, which may challenge our understanding of mol. interactions and mol. recognition in biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwXtvwFRCBbVg90H21EOLACvtfcHk0ljQVu1A6-HDLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFSjt7o%253D&md5=404ba3ce4d058c2f6ccb1998a754825d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Human%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520Based%2520on%2520a%2520Fragment%2520in%2520an%2520X-Ray%2520Crystal%2520Structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1012%26epage%3D1018%26doi%3D10.1016%2Fj.bmcl.2019.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7212</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00918</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00918" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7206-7212&author=A.+Fonsecaauthor=J.+Reisauthor=T.+Silvaauthor=M.+J.+Matosauthor=D.+Bagettaauthor=F.+Ortusoauthor=S.+Alcaroauthor=E.+Uriarteauthor=F.+Borges&title=Coumarin+versus+Chromone+Monoamine+Oxidase+B+Inhibitors%3A+Quo+Vadis%3F&doi=10.1021%2Facs.jmedchem.7b00918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?</span></div><div class="casAuthors">Fonseca, Andre; Reis, Joana; Silva, Tiago; Matos, Maria Joao; Bagetta, Donatella; Ortuso, Francesco; Alcaro, Stefano; Uriarte, Eugenio; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7206-7212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chem. entities endowed with IMAO-B still exists.  Within this framework, and for the first time, a study was performed to compare coumarin- and chromone-3-phenylcarboxamide scaffolds.  Compds. I and II were the most potent, selective, and reversible noncompetitive IMAO-B.  The benzopyrone sp2 oxygen atom was found to be position independent and a productive contributor for the ligand-enzyme complex stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogLjC3cJIkZbVg90H21EOLACvtfcHk0ljQVu1A6-HDLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Cntb7K&md5=4af88b342ccfe910629ef704b6a65fc6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00918%26sid%3Dliteratum%253Aachs%26aulast%3DFonseca%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DMatos%26aufirst%3DM.%2BJ.%26aulast%3DBagetta%26aufirst%3DD.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DCoumarin%2520versus%2520Chromone%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%253A%2520Quo%2520Vadis%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7206%26epage%3D7212%26doi%3D10.1021%2Facs.jmedchem.7b00918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Multi-Functional Homoisoflavonoid Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterase for the Treatment of Alzheimer’s Disease</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1467</span>, <span class="refDoi"> DOI: 10.1039/C7MD00199A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1039%2FC7MD00199A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30108857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlajsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1459-1467&author=Q.-H.+Liuauthor=J.-J.+Wuauthor=F.+Liauthor=P.+Caiauthor=X.-L.+Yangauthor=L.-Y.+Kongauthor=X.-B.+Wang&title=Synthesis+and+Pharmacological+Evaluation+of+Multi-Functional+Homoisoflavonoid+Derivatives+as+Potent+Inhibitors+of+Monoamine+Oxidase+B+and+Cholinesterase+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1039%2FC7MD00199A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Liu, Qiao-Hong; Wu, Jia-Jia; Li, Fan; Cai, Pei; Yang, Xue-Lian; Kong, Ling-Yi; Wang, Xiao-Bing</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1459-1467</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of homoisoflavonoid derivs. was designed, synthesized and evaluated as potential multi-functional anti-Alzheimer's agents for their inhibitory activity on cholinesterase and monoamine oxidase.  Among them, compd. 16 showed moderate acetylcholinesterase (AChE) inhibitory activity (eeAChE IC50 = 0.89 ± 0.02 μM; hAChE IC50 = 0.657 ± 0.002 μM) and significant monoamine oxidase B (MAO-B) inhibitory activity (hMAO-B IC50 = 0.0372 ± 0.0002 μM).  Kinetic anal. of AChE, MAO-B inhibition and mol. modeling studies revealed that compd. 16 is a dual binding site inhibitor of AChE and noncompetitive inhibitor of MAO-B.  Furthermore, 16 could penetrate through the blood-brain barrier (BBB) in vitro.  Most importantly, oral administration of 16 demonstrated no marked signs of acute toxicity and it could significantly reverse scopolamine-induced memory impairment in mice.  These results suggested that compd. 16 is a promising multifunctional drug candidate with potential effect for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsOsVTCqBiLVg90H21EOLACvtfcHk0liKTuOIgn2lgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlajsL0%253D&md5=d79aec56970cb642e678f458900e8458</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC7MD00199A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00199A%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.-H.%26aulast%3DWu%26aufirst%3DJ.-J.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DX.-L.%26aulast%3DKong%26aufirst%3DL.-Y.%26aulast%3DWang%26aufirst%3DX.-B.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Multi-Functional%2520Homoisoflavonoid%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520of%2520Monoamine%2520Oxidase%2520B%2520and%2520Cholinesterase%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1459%26epage%3D1467%26doi%3D10.1039%2FC7MD00199A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathakam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, G. K.</span></span> <span> </span><span class="NLM_article-title">Refining the Structural Features of Chromones as Selective MAO-B Inhibitors: Exploration of Combined Pharmacophore-Based 3D-QSAR and Quantum Chemical Studies</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11645</span>– <span class="NLM_lpage">11652</span>, <span class="refDoi"> DOI: 10.1002/slct.201701213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fslct.201701213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ksLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=11645-11652&author=B.+Mathewauthor=S.+Devauthor=M.+Joyauthor=G.+E.+Mathewauthor=A.+Marathakamauthor=G.+K.+Krishnan&title=Refining+the+Structural+Features+of+Chromones+as+Selective+MAO-B+Inhibitors%3A+Exploration+of+Combined+Pharmacophore-Based+3D-QSAR+and+Quantum+Chemical+Studies&doi=10.1002%2Fslct.201701213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the Structural Features of Chromones as Selective MAO-B Inhibitors: Exploration of Combined Pharmacophore-Based 3D-QSAR and Quantum Chemical Studies</span></div><div class="casAuthors">Mathew, Bijo; Dev, Sanal; Joy, Monu; Mathew, Githa E.; Marathakam, Akash; Krishnan, Girish K.</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11645-11652</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthetic chromones are considered as a validated target of the inhibition of monoamine oxidase-B and its relationship to various neurodegenerative diseases is increasing.  Herein described is pharmacophore generation and atom-based 3D-QSAR anal. of previously reported chromone based MAO-B inhibitors in order to get insight into their structural requirements responsible for high affinity.  The best four-point pharmacophore model with five features AAHRR-3, two hydrogen bond acceptor (A),one hydrophobic groups (H) and two arom. rings (R) as pharmacophore features was developed by PHASE module of Schrodinger suite.  The pharmacophore hypothesis yielded a statistically significant 3D-QSAR model, with a good correlation coeff. (R2=0. 8828), cross validation coeff. (Q2= 0. 7036), and F value 50.2.  In this series, the potent mol. 6-(3-bromobenzyl)-4H-chromen-4-one (5) is further exploited for electrostatic potential surface and analyze the natural bond orbital toward the binding characteristics by using d. functional theory calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv3E2B2ftPgbVg90H21EOLACvtfcHk0liKTuOIgn2lgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ksLfO&md5=b750135df682cfac8aa70f38bdfe79e7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fslct.201701213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201701213%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DDev%26aufirst%3DS.%26aulast%3DJoy%26aufirst%3DM.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DMarathakam%26aufirst%3DA.%26aulast%3DKrishnan%26aufirst%3DG.%2BK.%26atitle%3DRefining%2520the%2520Structural%2520Features%2520of%2520Chromones%2520as%2520Selective%2520MAO-B%2520Inhibitors%253A%2520Exploration%2520of%2520Combined%2520Pharmacophore-Based%25203D-QSAR%2520and%2520Quantum%2520Chemical%2520Studies%26jtitle%3DChemistrySelect%26date%3D2017%26volume%3D2%26spage%3D11645%26epage%3D11652%26doi%3D10.1002%2Fslct.201701213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamauchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uesawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, Y.</span></span> <span> </span><span class="NLM_article-title">2-Styrylchromone Derivatives as Potent and Selective Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>, <span class="NLM_elocation-id">103285</span> <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2019.103285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31561103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&author=K.+Takaoauthor=S.+Endoauthor=J.+Nagaiauthor=H.+Kamauchiauthor=Y.+Takemuraauthor=Y.+Uesawaauthor=Y.+Sugita&title=2-Styrylchromone+Derivatives+as+Potent+and+Selective+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">2-Styrylchromone derivatives as potent and selective monoamine oxidase B inhibitors</span></div><div class="casAuthors">Takao, Koichi; Endo, Saki; Nagai, Junko; Kamauchi, Hitoshi; Takemura, Yuri; Uesawa, Yoshihiro; Sugita, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103285pp.</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-styrylchromone derivs. I [R1 = H, MeO; R2 = H, MeO; R3 = H, MeO; R4 = H, MeO, F, Cl, Br] were synthesized and evaluated for their monoamine oxidase (MAO) A and B inhibitory activities.  Many of the compds. I inhibited MAO-B comparable to pargyline (a pos. control) and most of them inhibited MAO-B selectively.  Among the tested compds., compd. I [R1 = MeO, R2 = R3 = H, R4 = Cl] showed best MAO-B inhibitory activity (IC50 = 17 ± 2.4 nM) and best MAO-B selectivity (IC50 for MAO-A/IC50 for MAO-B = 1500).  The mode of inhibition of compd. I [R1 = MeO, R2 = H, R3 = H, R4 = Cl] against MAO-B was competitive and reversible.  Quant. structure-activity relationship (QSAR) anal. of the compds. I were conducted using their pIC50 values with use of Mol. Operating Environment (MOE) and Dragon, demonstrated that descriptors of MAO-B inhibitory activity and MAO-B selectivity were 1734 and 121, resp., that showed significant correlations (P < 0.05).  The compds. I were examd. through three-dimensional-QSAR studies using AutoGPA, which was based on mol. field anal. algorithm using MOE.  The model using pIC50 value indexes for MAO-B exhibited a detn. coeff. (R2) of 0.873 as well as a Leave-One-Out cross-validated detn. coeff. (Q2) of 0.675.  These data suggested that the 2-styrylchromone structure might be a useful scaffold for design and development of novel MAO-B inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZI-V2XX0HBLVg90H21EOLACvtfcHk0li_Gjje20lc6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksrjL&md5=260276582092cf6034f22ae6c7de96ce</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103285%26sid%3Dliteratum%253Aachs%26aulast%3DTakao%26aufirst%3DK.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DNagai%26aufirst%3DJ.%26aulast%3DKamauchi%26aufirst%3DH.%26aulast%3DTakemura%26aufirst%3DY.%26aulast%3DUesawa%26aufirst%3DY.%26aulast%3DSugita%26aufirst%3DY.%26atitle%3D2-Styrylchromone%2520Derivatives%2520as%2520Potent%2520and%2520Selective%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26doi%3D10.1016%2Fj.bioorg.2019.103285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costas-Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Enriquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teran, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Study of Novel 3-Heteroarylcoumarins Based on Pyridazine Scaffold as Selective MAO-B Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=28797881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSmurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=1-11&author=M.+Costas-Lagoauthor=P.+Besadaauthor=F.+Rodriguez-Enriquezauthor=D.+Vinaauthor=S.+Vilarauthor=E.+Uriarteauthor=F.+Borgesauthor=C.+Teran&title=Synthesis+and+Structure-Activity+Relationship+Study+of+Novel+3-Heteroarylcoumarins+Based+on+Pyridazine+Scaffold+as+Selective+MAO-B+Inhibitors&doi=10.1016%2Fj.ejmech.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors</span></div><div class="casAuthors">Costas-Lago, Maria Carmen; Besada, Pedro; Rodriguez-Enriquez, Fernanda; Vina, Dolores; Vilar, Santiago; Uriarte, Eugenio; Borges, Fernanda; Teran, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Compds. of hybrid structure pyridazine-coumarin were discovered as potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B).  These compds. were synthesized in good yield following a multistep approach based on Knoevenagel reaction and using as key pyridazinone intermediate, which was obtained from maleic anhydride and furan.  Compds. I (R = 7-Me and 6-MeO) are the most active compds. of these series, with IC50 values in the sub-micromolar range, and lack of cytotoxic effects.  Theor. calcn. of ADME properties also suggested a good pharmacokinetic profile for both compds.  Docking simulations provided insights into enzyme inhibitor interactions and allowed us to rationalize the obsd. structure-activity relationships (SARs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3LHuEiebcE7Vg90H21EOLACvtfcHk0li_Gjje20lc6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSmurfL&md5=8e57033a18006ba5341e91421e18fa8d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DCostas-Lago%26aufirst%3DM.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DRodriguez-Enriquez%26aufirst%3DF.%26aulast%3DVina%26aufirst%3DD.%26aulast%3DVilar%26aufirst%3DS.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DTeran%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Study%2520of%2520Novel%25203-Heteroarylcoumarins%2520Based%2520on%2520Pyridazine%2520Scaffold%2520as%2520Selective%2520MAO-B%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.ejmech.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 6-methylcoumarin Derivatives as Potent and Selective Monoamine Oxidase B Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">592</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1039/C4MD00437J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1039%2FC4MD00437J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFehtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=592-600&author=J.-S.+Lanauthor=L.-F.+Panauthor=S.-S.+Xieauthor=X.-B.+Wangauthor=L.-Y.+Kong&title=Synthesis+and+Evaluation+of+6-methylcoumarin+Derivatives+as+Potent+and+Selective+Monoamine+Oxidase+B+Inhibitors&doi=10.1039%2FC4MD00437J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective Monoamine Oxidase B inhibitors</span></div><div class="casAuthors">Lan, Jin-Shuai; Pan, Long-Fei; Xie, Sai-Sai; Wang, Xiao-Bing; Kong, Ling-Yi</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">592-600</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new series of 6-methyl-3-phenylcoumarins, e.g., I, and 6-methyl-3-heteroarylcoumarins II (X = thiophen-2-yl, pyridin-3-yl, naphthalen-1-yl, indol-3-yl) had been designed, synthesized and evaluated as monoamine oxidases inhibitors.  The results demonstrated that a large proportion of the synthesized compds. selectively inhibited monoamine oxidase B with IC50 in the sub-micromolar range.  Among them, compd. I (IC50 = 0.0601 μM) exhibited the most potent inhibitory activity and the highest selectivity for monoamine oxidase B (SI > 1664-fold).  In addn., the active compd. I was measured the possible binding model by docking into the active site of hMAO-B complex structure.  The results showed that compd. I interacted with the well-known binding pocket of MAO-B, and a π-π interaction was found between the Ph ring at position 3 of coumarin and the Ph ring of Tyr 326.  Consequently, the useful information about the interaction between the enzyme and inhibitor, and developed the 6-methyl-3-phenylcoumarin scaffold as agents for multifaceted brain disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr77CJorX3gdLVg90H21EOLACvtfcHk0li_Gjje20lc6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFehtL%252FE&md5=9c947b24063bdfc43d592f7a4b0caf7d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2FC4MD00437J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00437J%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DJ.-S.%26aulast%3DPan%26aufirst%3DL.-F.%26aulast%3DXie%26aufirst%3DS.-S.%26aulast%3DWang%26aufirst%3DX.-B.%26aulast%3DKong%26aufirst%3DL.-Y.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25206-methylcoumarin%2520Derivatives%2520as%2520Potent%2520and%2520Selective%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D592%26epage%3D600%26doi%3D10.1039%2FC4MD00437J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauhamäki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postila, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niinivehmas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manivannan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahinko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskimies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multamaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvonen, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raunio, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentikainen, O. T.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.3389%2Ffchem.2018.00041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=29552556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=41&author=S.+Rauham%C3%A4kiauthor=P.+A.+Postilaauthor=S.+Niinivehmasauthor=S.+Kortetauthor=E.+Schildtauthor=M.+Pasanenauthor=E.+Manivannanauthor=M.+Ahinkoauthor=P.+Koskimiesauthor=N.+Nybergauthor=P.+Huuskonenauthor=E.+Multamakiauthor=M.+Pasanenauthor=R.+O.+Juvonenauthor=H.+Raunioauthor=J.+Huuskonenauthor=O.+T.+Pentikainen&title=Structure-Activity+Relationship+Analysis+of+3-Phenylcoumarin-Based+Monoamine+Oxidase+B+Inhibitors&doi=10.3389%2Ffchem.2018.00041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship analysis of 3-phenylcoumarin-based monoamine oxidase B inhibitors</span></div><div class="casAuthors">Rauhamaki, Sanna; Postila, Pekka A.; Niinivehmas, Sanna; Kortet, Sami; Schildt, Emmi; Pasanen, Mira; Manivannan, Elangovan; Ahinko, Mira; Koskimies, Pasi; Nyberg, Niina; Huuskonen, Pasi; Multamaki, Elina; Pasanen, Markku; Juvonen, Risto O.; Raunio, Hannu; Huuskonen, Juhani; Pentikainen, Olli T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41/1-41/18</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine.  Accordingly, small-mol. MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease.  Coumarin with a functionalized 3-Ph ring system is a promising scaffold for building potent MAO-B inhibitors.  Here, a vast set of 3-phenylcoumarin derivs. I (R = 4-F3CC6H4, 4-MeOC6H4, 3-MeOC6H4, etc.; R' = 6-OMe, 7-OMe, 7-AcO, etc.) was designed using virtual combinatorial chem. or rationally de novo and synthesized using microwave chem.  The derivs. inhibited the MAO-B at 100 nM-1 μM.  The IC50 value of the most potent deriv. I (R = 4-F3CC6H4; R' = 6-OMe) was 56 nM.  A docking-based structure-activity relationship anal. summarizes the atom-level determinants of the MAO-B inhibition by the derivs.  Finally, the cross-reactivity of the derivs. was tested against monoamine oxidase A and a specific subset of enzymes linked to estradiol metab., known to have coumarin-based inhibitors.  Overall, the results indicate that the 3-phenylcoumarins, esp. deriv. I (R = 4-F3CC6H4; R' = 6-OMe), present unique pharmacol. features worth considering in future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCjgSWub9FAbVg90H21EOLACvtfcHk0ljrXKEMw6Gbdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egs7nK&md5=5f93818f66c330d30ba808c3a8923cf4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00041%26sid%3Dliteratum%253Aachs%26aulast%3DRauham%25C3%25A4ki%26aufirst%3DS.%26aulast%3DPostila%26aufirst%3DP.%2BA.%26aulast%3DNiinivehmas%26aufirst%3DS.%26aulast%3DKortet%26aufirst%3DS.%26aulast%3DSchildt%26aufirst%3DE.%26aulast%3DPasanen%26aufirst%3DM.%26aulast%3DManivannan%26aufirst%3DE.%26aulast%3DAhinko%26aufirst%3DM.%26aulast%3DKoskimies%26aufirst%3DP.%26aulast%3DNyberg%26aufirst%3DN.%26aulast%3DHuuskonen%26aufirst%3DP.%26aulast%3DMultamaki%26aufirst%3DE.%26aulast%3DPasanen%26aufirst%3DM.%26aulast%3DJuvonen%26aufirst%3DR.%2BO.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DHuuskonen%26aufirst%3DJ.%26aulast%3DPentikainen%26aufirst%3DO.%2BT.%26atitle%3DStructure-Activity%2520Relationship%2520Analysis%2520of%25203-Phenylcoumarin-Based%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D41%26doi%3D10.3389%2Ffchem.2018.00041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarmouh, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, K. F. A.</span></span> <span> </span><span class="NLM_article-title">The Benzopyrone Biochanin-A as a Reversible, Competitive, and Delective Monoamine Oxidase B inhibitor</span>. <i>BMC Complementary Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">34</span> <span class="refDoi"> DOI: 10.1186/s12906-016-1525-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2Fs12906-016-1525-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=28069007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12gurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&author=N.+O.+Zarmouhauthor=S.+K.+Eyunniauthor=K.+F.+A.+Soliman&title=The+Benzopyrone+Biochanin-A+as+a+Reversible%2C+Competitive%2C+and+Delective+Monoamine+Oxidase+B+inhibitor&doi=10.1186%2Fs12906-016-1525-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor</span></div><div class="casAuthors">Zarmouh, Najla O.; Eyunni, Suresh K.; Soliman, Karam F. A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Complementary and Alternative Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/13</span>CODEN:
                <span class="NLM_cas:coden">BCAMCV</span>;
        ISSN:<span class="NLM_cas:issn">1472-6882</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Monoamine oxidase-B (MAO-B) inhibitors are widely used in the treatment of Parkinson's disease.  They increase vital monoamine neurotransmitters in the brain.  However, there is a need for safer natural reversible MAO inhibitors with MAO-B selectivity.  Our previous studies showed that Psoralea corylifolia seeds (PCS) ext. contains compds. that inhibit monoamine oxidase-B.  Methods: In this study, six of PCS constituents sharing a benzopyrone structure were investigated.  The compds. Biochanin-A (BIO-A), isopsoralen, 6-prenylnaringenin, neobavaisoflavone, psoralen, and psoralidin, were tested for their ability to inhibit recombinant human MAO-A and B (hMAO-A and hMAO-B) isoenzymes.  The ability of these compds. to inhibit MAO-A and MAO-B were compared to that of PCS ethanolic ext. (PCSEE) using spectrophotometric assays and confirmed by luminescence assays.  The highly potent and selective MAO-B inhibitor, BIO-A, was further investigated for both isoenzymes reversibility and enzyme kinetics.  Mol. docking studies were used to predict the bioactive conformation and mol. interactions of BIO-A with both isoenzymes.  Results: The data obtained indicate that benzopyrones inhibited hMAO-A and hMAO-B with different degrees as confirmed with the luminescence assay.  BIO-A inhibited hMAO-B with high potency and selectivity in the present study (IC50 = 0.003 μg/mL) and showing 38-fold more selectivity than PCSEE (hMAO-B IC50 = 3.03 μg/mL, 17-fold selectivity) without affecting hydrogen peroxide.  Furthermore, BIO-A reversibly and competitively inhibited both hMAOs with significantly lower inhibitory const. (Ki) in hMAO-B (3.8 nM) than hMAO-A (99.3 nM).  Our docking studies indicated that the H-bonds and hydrophobic interactions at the human MAO-A and MAO-B active sites contributed to the reversibility and selectivity of BIO-A.  Conclusions: The data obtained indicate that BIO-A is a potent, reversible and selective MAO-B inhibitor and may be recommended for further investigation in its possible use in the therapeutic management of Parkinson's and Alzheimer's diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9S0IYf1Lw7Vg90H21EOLACvtfcHk0ljrXKEMw6Gbdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12gurc%253D&md5=233bdfb95e7ddd2524648c1c1a768b26</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs12906-016-1525-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12906-016-1525-y%26sid%3Dliteratum%253Aachs%26aulast%3DZarmouh%26aufirst%3DN.%2BO.%26aulast%3DEyunni%26aufirst%3DS.%2BK.%26aulast%3DSoliman%26aufirst%3DK.%2BF.%2BA.%26atitle%3DThe%2520Benzopyrone%2520Biochanin-A%2520as%2520a%2520Reversible%252C%2520Competitive%252C%2520and%2520Delective%2520Monoamine%2520Oxidase%2520B%2520inhibitor%26jtitle%3DBMC%2520Complementary%2520Altern.%2520Med.%26date%3D2017%26volume%3D17%26doi%3D10.1186%2Fs12906-016-1525-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orallo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span> <span> </span><span class="NLM_article-title">Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.1021/jm801590u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801590u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2818-2824&author=F.+Chimentiauthor=R.+Fioravantiauthor=A.+Bolascoauthor=P.+Chimentiauthor=D.+Secciauthor=F.+Rossiauthor=M.+Yanezauthor=F.+Oralloauthor=F.+Ortusoauthor=S.+Alcaro&title=Chalcones%3A+A+Valid+Scaffold+for+Monoamine+Oxidases+Inhibitors&doi=10.1021%2Fjm801590u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors</span></div><div class="casAuthors">Chimenti, Franco; Fioravanti, Rossella; Bolasco, Adriana; Chimenti, Paola; Secci, Daniela; Rossi, Francesca; Yanez, Matilde; Orallo, Francisco; Ortuso, Francesco; Alcaro, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2818-2824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A large series of substituted chalcones have been synthesized and tested in vitro for their ability to inhibit human monoamine oxidases A and B (hMAO-A and hMAO-B).  While all the compds. showed hMAO-B selective activity in the micro- and nanomolar ranges, the best results were obtained in the presence of chlorine and hydroxyl or methoxyl substituents.  To better understand the enzyme-inhibitor interaction and to explain the selectivity of the most active compds. toward hMAO-B, mol. modeling studies were carried out on new, high resoln., hMAO-B crystallog. structures.  For the only compd. that also showed activity against hMAO-A as well as low selectivity, the mol. modeling study was also performed on the hMAO-A crystallog. structure.  The docking technique provided new insight on the inhibition mechanism and the rational drug design of more potent/selective hMAO inhibitors based on the chalcone scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs56ytduJPsrVg90H21EOLACvtfcHk0ljrXKEMw6Gbdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSltrs%253D&md5=19de38043049fc0249b2f9912bb32729</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm801590u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801590u%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26atitle%3DChalcones%253A%2520A%2520Valid%2520Scaffold%2520for%2520Monoamine%2520Oxidases%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2818%26epage%3D2824%26doi%3D10.1021%2Fjm801590u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Chalcones as Potent Selective Monoamine Oxidase-B Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2016.02.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26974383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=162-169&author=A.+Hammudaauthor=R.+Shalabyauthor=S.+Rovidaauthor=D.+E.+Edmondsonauthor=C.+Bindaauthor=A.+Khalil&title=Design+and+Synthesis+of+Novel+Chalcones+as+Potent+Selective+Monoamine+Oxidase-B+Inhibitors&doi=10.1016%2Fj.ejmech.2016.02.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors</span></div><div class="casAuthors">Hammuda, Arwa; Shalaby, Raed; Rovida, Stefano; Edmondson, Dale E.; Binda, Claudia; Khalil, Ashraf</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">162-169</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of substituted chalcones I (R1 = H, CF3; R2 = H, CF3, OCF3; R3 = H, SO2CH3, SCH3; R4 = R5 = OCH3, OCH2O) were designed and synthesized to be evaluated as selective human MAO-B inhibitors.  A combination of either methylsulfonyl or trifluoromethyl substituents on the arom. ketone moiety with a benzodioxol ring on the other end of the chalcone scaffold was investigated.  The compds. were tested for their inhibitory activities on both human MAO-A and B.  All compds. appeared to be selective MAO-B inhibitors with Ki values in the micromolar to submicromolar range.  Mol. modeling studies have been performed to get insight into the binding mode of the synthesized compds. to human MAO-B active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVIEGMTEF617Vg90H21EOLACvtfcHk0liyMgJJkE25CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gurg%253D&md5=cf213d3c91a3c52175ea29270ec8d8f2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.038%26sid%3Dliteratum%253Aachs%26aulast%3DHammuda%26aufirst%3DA.%26aulast%3DShalaby%26aufirst%3DR.%26aulast%3DRovida%26aufirst%3DS.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DKhalil%26aufirst%3DA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Chalcones%2520as%2520Potent%2520Selective%2520Monoamine%2520Oxidase-B%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D114%26spage%3D162%26epage%3D169%26doi%3D10.1016%2Fj.ejmech.2016.02.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baysal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilapurathu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakasan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Development of Fluorinated Methoxylated Chalcones as Selective Monoamine Oxidase-B Inhibitors: Synthesis, Biochemistry and Molecular Docking Studies</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26189013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=22-29&author=B.+Mathewauthor=G.+E.+Mathewauthor=G.+Ucarauthor=I.+Baysalauthor=J.+Sureshauthor=J.+K.+Vilapurathuauthor=A.+Prakasanauthor=J.+K.+Sureshauthor=A.+Thomas&title=Development+of+Fluorinated+Methoxylated+Chalcones+as+Selective+Monoamine+Oxidase-B+Inhibitors%3A+Synthesis%2C+Biochemistry+and+Molecular+Docking+Studies&doi=10.1016%2Fj.bioorg.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies</span></div><div class="casAuthors">Mathew, Bijo; Mathew, Githa Elizabeth; Ucar, Gulberk; Baysal, Ipek; Suresh, Jerad; Vilapurathu, Jobin Kunjumon; Prakasan, Aneesh; Suresh, Jeethu Kuruppath; Thomas, Anjana</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of methoxylated chalcones with fluoro and trifluoromethyl derivs. were synthesized and investigated for their ability to inhibit human monoamine oxidase A and B.  The chem. structures of the compds. have been characterized by means of their 1H NMR, 13C NMR, Mass spectroscopic datas and elemental anal.  The results demonstrate that these compds. are reversible and selective MAO-B inhibitors with a competitive mode of inhibition.  The most potent compd. (2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl] prop-2-en-1-one showed the best activity and higher selectivity towards hMAO-B with Ki and SI values of 0.22 ± 0.01 μM and 0.05 comparable to that std. drug, Selegiline Ki and SI values were found as 0.33 ± 0.03 μM and 0.04, resp.  Mol. docking studies were carried out to further explain the in vitro results of the new compds., and to identify the hypothetical binding mode for the compds. inside the inhibitor binding cavity of hMAO-B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt6ZptTGtMXbVg90H21EOLACvtfcHk0liyMgJJkE25CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ktLjE&md5=03ebfa985474e683cbc2e89c956d981d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DUcar%26aufirst%3DG.%26aulast%3DBaysal%26aufirst%3DI.%26aulast%3DSuresh%26aufirst%3DJ.%26aulast%3DVilapurathu%26aufirst%3DJ.%2BK.%26aulast%3DPrakasan%26aufirst%3DA.%26aulast%3DSuresh%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Fluorinated%2520Methoxylated%2520Chalcones%2520as%2520Selective%2520Monoamine%2520Oxidase-B%2520Inhibitors%253A%2520Synthesis%252C%2520Biochemistry%2520and%2520Molecular%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Chem.%26date%3D2015%26volume%3D62%26spage%3D22%26epage%3D29%26doi%3D10.1016%2Fj.bioorg.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ucar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purapurath, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moolayil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2655</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fcmdc.201600497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27902880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2649-2655&author=B.+Mathewauthor=G.+Ucarauthor=G.+E.+Mathewauthor=S.+Mathewauthor=P.+K.+Purapurathauthor=F.+Moolayilauthor=S.+Mohanauthor=S.+V.+Gupta&title=Monoamine+Oxidase+Inhibitory+Activity%3A+Methyl-+versus+Chlorochalcone+Derivatives&doi=10.1002%2Fcmdc.201600497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives</span></div><div class="casAuthors">Mathew, Bijo; Ucar, Guelberk; Mathew, Githa Elizabeth; Mathew, Sincy; Kalatharakkal Purapurath, Praseedha; Moolayil, Fasil; Mohan, Smrithy; Varghese Gupta, Sheeba</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2649-2655</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Numerous studies have shown that chalcones are promising scaffolds for the development of new monoamine oxidase-B (MAO-B) inhibitors.  As a continuation of our ongoing research into the development of reversible human MAO-B (hMAO-B) inhibitors, two series of twenty chalcones contg. electron-donating and electron-withdrawing substituents were synthesized.  All compds. were found to be competitive, selective, and reversible inhibitors of hMAO-B except (2E)-1-(4-methylphenyl)-3-(4-nitrophenyl)prop-2-en-1-one (P7) and (2E)-1-(4-chlorophenyl)-3-(4-nitrophenyl)prop-2-en-1-one (P17), which were found to be selective inhibitors of hMAO-A.  The most potent hMAO-B inhibitor, (2E)-1-(4-chlorophenyl)-3-(4-ethylphenyl)prop-2-en-1-one (P16), showed a Ki value of 0.11±0.01 μM.  Mol. docking simulations were carried out to identify the hypothetical binding mode for the most potent compds. in the active sites of hMAO-A and B.  The ability of the compds. to cross the blood-brain barrier was assessed by parallel artificial membrane permeability assay (PAMPA).  Addnl., the most potent hMAO-B inhibitor P16 showed no toxicity in cultured hepatic cells at concns. of 5 and 25 μm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1gWxj-ViSlLVg90H21EOLACvtfcHk0lhcozxzRj7sZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnu77N&md5=43c76cc1c40c6925590995ae03309fcb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600497%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DUcar%26aufirst%3DG.%26aulast%3DMathew%26aufirst%3DG.%2BE.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DPurapurath%26aufirst%3DP.%2BK.%26aulast%3DMoolayil%26aufirst%3DF.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DS.%2BV.%26atitle%3DMonoamine%2520Oxidase%2520Inhibitory%2520Activity%253A%2520Methyl-%2520versus%2520Chlorochalcone%2520Derivatives%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2649%26epage%3D2655%26doi%3D10.1002%2Fcmdc.201600497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parambi, D. G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tondo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Oxygenated Chalcones as Potent and Selective MAO-B Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">103335</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bioorg.2019.103335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31606547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKrs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=103335&author=D.+G.+T.+Parambiauthor=J.+M.+Ohauthor=S.+C.+Baekauthor=J.+P.+Leeauthor=A.+R.+Tondoauthor=O.+Nicolottiauthor=H.+Kimauthor=B.+Mathew&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Oxygenated+Chalcones+as+Potent+and+Selective+MAO-B+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors</span></div><div class="casAuthors">Parambi, Della Grace Thomas; Oh, Jong Min; Baek, Seung Cheol; Lee, Jae Pil; Tondo, Anna Rita; Nicolotti, Orazio; Kim, Hoon; Mathew, Bijo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103335pp.</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study documented the synthesis of oxygenated chalcone derivs. I [R = H, 4-OH, 4-Ph, etc.; n = 1, 2] and their abilities to inhibit monoamine oxidases.  Compd. I [R = 4-F, n = 2] showed the greatest inhibitory activity against MAO-B with an IC50 value of 0.0021 μM, followed by compds. I [R = 4-F, n = 1; R = 4-Me, n = 2] (IC50 = 0.0030 and 0.0034 μM, resp.).  In addn., most of the derivs. potently inhibited MAO-A and I [R = 4-Ph, n = 1] was the most potent inhibitor with an IC50 value of 0.029 μM, followed by I [R = 4-OMe, n = 1; R = 4-Me, n = 1; 4-Br, n = 1; 4-OH, n = 1] (IC50 = 0.035, 0.053, 0.072, and 0.082 μM, resp.).  Compd. I [R = 4-F, n = 2] had a high selectivity index (SI) value for MAO-B of 138.1, and Compd. I [R = 4-NO2, n = 2] (IC50 value for MAO-B = 0.010 μM) had an extremely high SI of >4000.  Kinetic studies revealed that I [R = 4-Ph, 2=1; R = 4-F, n = 2] competitively inhibited MAO-A and MAO-B, resp., with resp. Ki values of 0.016 ± 0.0007 and 0.00050 ± 0.00003 μM.  Lead compd. were also non-toxic at 200 μg/mL in normal rat spleen cells.  Mol. docking simulations and subsequent Mol. Mechanics/Generalized Born Surface Area calcns. provided a rationale that explained exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPZEFZVfdKhLVg90H21EOLACvtfcHk0lhcozxzRj7sZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKrs77O&md5=e0f76ef7520947ec16d94b1b430f92b6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103335%26sid%3Dliteratum%253Aachs%26aulast%3DParambi%26aufirst%3DD.%2BG.%2BT.%26aulast%3DOh%26aufirst%3DJ.%2BM.%26aulast%3DBaek%26aufirst%3DS.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BP.%26aulast%3DTondo%26aufirst%3DA.%2BR.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DMathew%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Oxygenated%2520Chalcones%2520as%2520Potent%2520and%2520Selective%2520MAO-B%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D93%26spage%3D103335%26doi%3D10.1016%2Fj.bioorg.2019.103335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Hydroxypyridinone-Coumarin Hybrids as Multimodal Monoamine Oxidase B Inhibitors and Iron Chelates Against Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.ejmech.2019.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31325784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWltLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2019&pages=367-382&author=C.+Zhangauthor=K.+Yangauthor=S.+Yuauthor=J.+Suauthor=S.+Yuanauthor=J.+Hanauthor=Y.+Chenauthor=J.+Guauthor=T.+Zhouauthor=R.+Baiauthor=Y.+Xie&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Hydroxypyridinone-Coumarin+Hybrids+as+Multimodal+Monoamine+Oxidase+B+Inhibitors+and+Iron+Chelates+Against+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2019.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease</span></div><div class="casAuthors">Zhang, Changjun; Yang, Ke; Yu, Sihang; Su, Jing; Yuan, Shengli; Han, Jiaxin; Chen, Yan; Gu, Jinping; Zhou, Tao; Bai, Renren; Xie, Yuanyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-382</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hydroxypyridinone-substituted coumarins I (R1 = H, Me; R2 = H, Me, Et; R3 = H, R4O; R4 = Me, PhCH2, HC≡CCH2, 3-ClC6H4CH2, 3-FC6H4CH2, 4-FC6H4CH2, 3,5-F2C6H3CH2) were prepd. as dual iron chelators and monoamine oxidase B (MAO-B) inhibitors for potential use in the treatment of Alzheimer's disease.  I (R1 = H; R2 = Me; R3 = 3-FC6H4CH2O) (II) exhibited the most potent activity against MAO-B, with an IC50 value of 14.7 nM.  II protected U251 cells against oxidative stress and ameliorated murine scopolamine-induced cognitive dysfunction in a model for Alzheimer's disease.  Mol. docking calcns. for the binding of II to MAO-B were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgVzvO3fV-0LVg90H21EOLACvtfcHk0lhcozxzRj7sZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWltLvK&md5=422cebd0966ebb383e0e5384e276ea21</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Hydroxypyridinone-Coumarin%2520Hybrids%2520as%2520Multimodal%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%2520and%2520Iron%2520Chelates%2520Against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D180%26spage%3D367%26epage%3D382%26doi%3D10.1016%2Fj.ejmech.2019.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span> <span> </span><span class="NLM_article-title">Novel Isoxazole Derivatives as Potential Antiparkinson Agents: Synthesis, Evaluation of Monoamine Oxidase Inhibitory Activity and Docking Studies</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1501</span>, <span class="refDoi"> DOI: 10.1007/s00044-019-02388-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1007%2Fs00044-019-02388-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yktLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=1488-1501&author=N.+Agrawalauthor=P.+Mishra&title=Novel+Isoxazole+Derivatives+as+Potential+Antiparkinson+Agents%3A+Synthesis%2C+Evaluation+of+Monoamine+Oxidase+Inhibitory+Activity+and+Docking+Studies&doi=10.1007%2Fs00044-019-02388-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies</span></div><div class="casAuthors">Agrawal, Neetu; Mishra, Pradeep</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1488-1501</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Selective monoamine oxidase B inhibitors are potential drug candidates for the treatment of Parkinson's disease.  A series of Ph substituted isoxazole carbohydrazides was designed by structural modification of isocarboxazid, a nonselective MAO inhibitor and evaluated as inhibitors of MAO-A and MAO-B.  The compds. were not able to inhibit MAO-A significantly, but most of the compds. exhibited potent inhibitory activity against MAO-B.  The enzyme kinetic study of the most active compds. 5d, 5-phenyl-N'-(1-(p-tolyl)ethylidene)isoxazole-3-carbohydrazide and 5g, N'-(1-(3,4-dimethoxyphenyl)ethylidene)-5-phenylisoxazole-3-carbohydrazide displayed reversible and competitive MAO-B inhibition.  In mol. modeling studies, compds. 5d and 5g exhibited strong binding affinity on MAO-B active site.  The administration of compds. 5d and 5g exhibited prevention of MPTP-induced Parkinsonism as indicated by footprint anal. and horizontal wire tests.  Further optimization studies are essential to exploit their potential for MAO-B assocd. neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDF_zYt8YmLVg90H21EOLACvtfcHk0lhcozxzRj7sZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yktLvM&md5=a063f977546634efea11a18b94f9e7e9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00044-019-02388-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-019-02388-4%26sid%3Dliteratum%253Aachs%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%26atitle%3DNovel%2520Isoxazole%2520Derivatives%2520as%2520Potential%2520Antiparkinson%2520Agents%253A%2520Synthesis%252C%2520Evaluation%2520of%2520Monoamine%2520Oxidase%2520Inhibitory%2520Activity%2520and%2520Docking%2520Studies%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2019%26volume%3D28%26spage%3D1488%26epage%3D1501%26doi%3D10.1007%2Fs00044-019-02388-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Çevik, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmaniye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saglik, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavusoglu, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozkay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplancikli, Z. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of New Pyrazoline-Thiazole Derivatives as Monoamine Oxidase Inhibitors</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3000</span>– <span class="NLM_lpage">3007</span>, <span class="refDoi"> DOI: 10.1002/jhet.3694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fjhet.3694" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2019&pages=3000-3007&author=U.+A.+%C3%87evikauthor=D.+Osmaniyeauthor=B.+N.+Saglikauthor=S.+Leventauthor=B.+K.+Cavusogluauthor=Y.+Ozkayauthor=Z.+A.+Kaplancikli&title=Synthesis+and+Evaluation+of+New+Pyrazoline-Thiazole+Derivatives+as+Monoamine+Oxidase+Inhibitors&doi=10.1002%2Fjhet.3694"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjhet.3694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.3694%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2587evik%26aufirst%3DU.%2BA.%26aulast%3DOsmaniye%26aufirst%3DD.%26aulast%3DSaglik%26aufirst%3DB.%2BN.%26aulast%3DLevent%26aufirst%3DS.%26aulast%3DCavusoglu%26aufirst%3DB.%2BK.%26aulast%3DOzkay%26aufirst%3DY.%26aulast%3DKaplancikli%26aufirst%3DZ.%2BA.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520New%2520Pyrazoline-Thiazole%2520Derivatives%2520as%2520Monoamine%2520Oxidase%2520Inhibitors%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2019%26volume%3D56%26spage%3D3000%26epage%3D3007%26doi%3D10.1002%2Fjhet.3694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maccioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirilli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleddu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distinto, S.</span></span> <span> </span><span class="NLM_article-title">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: A New Scaffold for the Selective Inhibition of Monoamine Oxidase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6394</span>– <span class="NLM_lpage">6398</span>, <span class="refDoi"> DOI: 10.1021/jm2002876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2002876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6394-6398&author=E.+Maccioniauthor=S.+Alcaroauthor=R.+Cirilliauthor=S.+Vigoauthor=M.+C.+Cardiaauthor=M.+L.+Sannaauthor=R.+Meledduauthor=M.+Yanezauthor=G.+Costaauthor=L.+Casuauthor=P.+Matyusauthor=S.+Distinto&title=3-Acetyl-2%2C5-diaryl-2%2C3-dihydro-1%2C3%2C4-oxadiazoles%3A+A+New+Scaffold+for+the+Selective+Inhibition+of+Monoamine+Oxidase+B&doi=10.1021%2Fjm2002876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: A new scaffold for the selective inhibition of monoamine oxidase B</span></div><div class="casAuthors">Maccioni, Elias; Alcaro, Stefano; Cirilli, Roberto; Vigo, Sara; Cardia, Maria Cristina; Sanna, Maria Luisa; Meleddu, Rita; Yanez, Matilde; Costa, Giosue; Casu, Laura; Matyus, Peter; Distinto, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6394-6398</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles e. g., I were designed, synthesized, and tested as inhibitors against human monoamine oxidase (MAO) A and B isoforms.  Several compds., obtained as racemates, were identified as selective MAO-B inhibitors.  The enantiomers of some derivs. were sepd. by enantioselective HPLC and tested.  The R-enantiomers always showed the highest activity.  Docking study and mol. dynamic simulations demonstrated the putative binding mode.  We conclude that these 1,3,4-oxadiazoles derivs. are promising reversible and selective MAO-B inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9WwTBeNWDFrVg90H21EOLACvtfcHk0lg9sB4LbdcZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7zP&md5=0ebf27c64e591293045768508dd61ef8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm2002876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002876%26sid%3Dliteratum%253Aachs%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DVigo%26aufirst%3DS.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DMeleddu%26aufirst%3DR.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DCasu%26aufirst%3DL.%26aulast%3DMatyus%26aufirst%3DP.%26aulast%3DDistinto%26aufirst%3DS.%26atitle%3D3-Acetyl-2%252C5-diaryl-2%252C3-dihydro-1%252C3%252C4-oxadiazoles%253A%2520A%2520New%2520Scaffold%2520for%2520the%2520Selective%2520Inhibition%2520of%2520Monoamine%2520Oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6394%26epage%3D6398%26doi%3D10.1021%2Fjm2002876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chooaii, H.</span></span> <span> </span><span class="NLM_article-title">Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1519-1529&author=M.-H.+Namauthor=M.+Parkauthor=H.+Parkauthor=Y.+Kimauthor=S.+Yoonauthor=V.+S.+Sawantauthor=J.+W.+Choauthor=J.-H.+Parkauthor=K.+D.+Parkauthor=S.-J.+Minauthor=C.+J.+Leeauthor=H.+Chooaii&title=Indole-Substituted+Benzothiazoles+and+Benzoxazoles+as+Selective+and+Reversible+MAO-B+Inhibitors+for+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.7b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease</span></div><div class="casAuthors">Nam, Min-Ho; Park, Moosung; Park, Hyeri; Kim, Youngjae; Yoon, Seulki; Sawant, Vikram Shahaji; Choi, Ji Won; Park, Jong-Hyun; Park, Ki Duk; Min, Sun-Joon; Lee, C. Justin; Choo, Hyunah</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1529</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivs. with indole moiety were designed and synthesized.  Most of the synthesized compds. showed inhibitory activities against MAO-B and selectivity over MAO-A.  The most active compd. was Compd. 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 29 nM with no apparent effect on MAO-A activity at 10 nM.  Based on the reversibility assay, Compd. 5b turned out to be a fully reversible with over 95% of recovery of enzyme activity after washout of the compd.  Compd. 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isoenzymes, suggesting an absence of high-risk drug-drug interaction.  In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of Compd. 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test.  In summary, the novel, reversible and selective MAO-B inhibitor compd. 5b was synthesized and characterized.  We propose compd. 5b as an effective therapeutic compd. for relieving parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLH2gmh-wolLVg90H21EOLACvtfcHk0lg9sB4LbdcZTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlsrk%253D&md5=e1b9a40a1fd21d03c467463d3c5c773e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00050%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DM.-H.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSawant%26aufirst%3DV.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DK.%2BD.%26aulast%3DMin%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DC.%2BJ.%26aulast%3DChooaii%26aufirst%3DH.%26atitle%3DIndole-Substituted%2520Benzothiazoles%2520and%2520Benzoxazoles%2520as%2520Selective%2520and%2520Reversible%2520MAO-B%2520Inhibitors%2520for%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1519%26epage%3D1529%26doi%3D10.1021%2Facschemneuro.7b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ascenzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zengin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span> <span> </span><span class="NLM_article-title">4-(3-Nitrophenyl)thiazol-2-ylhydrazone Derivatives as Antioxidants and Selective Hmao-B Inhibitors: Synthesis, Biological Activity and Computational Analysis</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1571272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1080%2F14756366.2019.1571272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30727777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFyls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=597-612&author=D.+Secciauthor=S.+Carradoriauthor=A.+Petzerauthor=P.+Guglielmiauthor=M.+D%E2%80%99Ascenzioauthor=P.+Chimentiauthor=D.+Bagettaauthor=S.+Alcaroauthor=G.+Zenginauthor=J.+P.+Petzerauthor=F.+Ortuso&title=4-%283-Nitrophenyl%29thiazol-2-ylhydrazone+Derivatives+as+Antioxidants+and+Selective+Hmao-B+Inhibitors%3A+Synthesis%2C+Biological+Activity+and+Computational+Analysis&doi=10.1080%2F14756366.2019.1571272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis</span></div><div class="casAuthors">Secci, Daniela; Carradori, Simone; Petzer, Anel; Guglielmi, Paolo; D'Ascenzio, Melissa; Chimenti, Paola; Bagetta, Donatella; Alcaro, Stefano; Zengin, Gokhan; Petzer, Jacobus P.; Ortuso, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">597-612</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivs. were designed, synthesized, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms.  Different (un)substituted (hetero)arom. substituents were linked to N1 of the hydrazone in order to establish robust structure-activity relationships.  The results of the biol. testing demonstrated that the presence of the hydrazothiazole nucleus bearing at C4 a Ph ring functionalised at the meta position with a nitro group represents an important pharmacophoric feature to obtain selective and reversible human MAO-B inhibition for the treatment of neurodegenerative disorders.  In addn., the most potent and selective MAO-B inhibitors were evaluated in silico as potential cholinesterase (AChE/BuChE) inhibitors and in vitro for antioxidant activities.  The results obtained from mol. modeling studies provided insight into the multiple interactions and structural requirements for the reported MAO inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVVXzLN6Ry-bVg90H21EOLACvtfcHk0lh1yWEdGydLsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFyls7o%253D&md5=17a294132656b24304b7d597c720ab29</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1571272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1571272%26sid%3Dliteratum%253Aachs%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DPetzer%26aufirst%3DA.%26aulast%3DGuglielmi%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Ascenzio%26aufirst%3DM.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DBagetta%26aufirst%3DD.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DZengin%26aufirst%3DG.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DOrtuso%26aufirst%3DF.%26atitle%3D4-%25283-Nitrophenyl%2529thiazol-2-ylhydrazone%2520Derivatives%2520as%2520Antioxidants%2520and%2520Selective%2520Hmao-B%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Activity%2520and%2520Computational%2520Analysis%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D597%26epage%3D612%26doi%3D10.1080%2F14756366.2019.1571272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer’s Disease Agents</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWhurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=482-496&author=Y.+Xuauthor=J.+Zhangauthor=H.+Wangauthor=F.+Maoauthor=K.+Baoauthor=W.+Liuauthor=J.+Zhuauthor=X.+Liauthor=H.+Zhangauthor=J.+Li&title=Rational+Design+of+Novel+Selective+Dual-Target+Inhibitors+of+Acetylcholinesterase+and+Monoamine+Oxidase+B+as+Potential+Anti-Alzheimer%E2%80%99s+Disease+Agents&doi=10.1021%2Facschemneuro.8b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents</span></div><div class="casAuthors">Xu, Yixiang; Zhang, Jian; Wang, Huan; Mao, Fei; Bao, Keting; Liu, Wenwen; Zhu, Jin; Li, Xiaokang; Zhang, Haiyan; Li, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-496</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multifunctional agents aiming at cholinesterases (ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer's disease (AD).  Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivs. (1-4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD.  Most of these derivs. inhibited ChEs and MAOs with IC50 values in the micro- or nanomolar ranges.  Compd. 1c displayed the dual functional profile of targeting the AChE (IC50 = 0.032 ± 0.007 μM) and MAO-B (IC50 = 2.117 ± 0.061 μM), along with the improved blood-brain barrier (BBB) permeability, antioxidant ability, and good copper chelating property in vitro.  Animal studies showed that compd. 1c·HCl could inhibit the cerebral AChE/MAO-B activities and alleviate scopolamine-induced cognitive impairment in mice.  Combined with good oral bioavailability (F = 45.55%), these findings demonstrated that compd. 1c may be a potent brain permeable multifunctional candidate for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBCWPsXuTCo7Vg90H21EOLACvtfcHk0lh1yWEdGydLsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWhurjL&md5=c72dcad03095270b30de8a72ffe19ea1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00357%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DBao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DRational%2520Design%2520of%2520Novel%2520Selective%2520Dual-Target%2520Inhibitors%2520of%2520Acetylcholinesterase%2520and%2520Monoamine%2520Oxidase%2520B%2520as%2520Potential%2520Anti-Alzheimer%25E2%2580%2599s%2520Disease%2520Agents%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D482%26epage%3D496%26doi%3D10.1021%2Facschemneuro.8b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagide, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavarria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5879</span>– <span class="NLM_lpage">5893</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5879-5893&author=J.+Reisauthor=F.+Cagideauthor=D.+Chavarriaauthor=T.+Silvaauthor=C.+Fernandesauthor=A.+Gasparauthor=E.+Uriarteauthor=F.+Remiaoauthor=S.+Alcaroauthor=F.+Ortusoauthor=F.+Borges&title=Discovery+of+New+Chemical+Entities+for+Old+Targets%3A+Insights+on+the+Lead+Optimization+of+Chromone-Based+Monoamine+Oxidase+B+%28MAO-B%29+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors</span></div><div class="casAuthors">Reis, Joana; Cagide, Fernando; Chavarria, Daniel; Silva, Tiago; Fernandes, Carlos; Gaspar, Alexandra; Uriarte, Eugenio; Remiao, Fernando; Alcaro, Stefano; Ortuso, Francesco; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5879-5893</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of new chem. entities endowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clin. relevant subject.  Therefore, a small library of chromone derivs. was synthesized and screened toward human monoamine oxidase isoforms (hMAO-A and hMAO-B).  The structure-activity relationships studies strengthen the importance of the amide spacer and the direct linkage of carbonyl group to the γ-pyrone ring, along with the presence of meta and para substituents in the exocyclic ring.  The most potent MAO-B inhibitors were N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide (20) (IC50 = 403 pM) and N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide (27) (IC50 = 669 pM), acting as competitive and noncompetitive reversible inhibitors, resp.  Computational docking studies provided insights into enzyme-inhibitor interactions and a rationale for the obsd. selectivity and potency.  Compd. 27 stands out due to its favorable toxicol. profile and physicochem. properties, which pointed toward blood-brain barrier permeability, thus being a valid candidate for subsequent animal studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWONk5yTkyN7Vg90H21EOLACvtfcHk0lh1yWEdGydLsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVWksb8%253D&md5=361d3dde07c197e2bdc41d08746a35f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00527%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DCagide%26aufirst%3DF.%26aulast%3DChavarria%26aufirst%3DD.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DFernandes%26aufirst%3DC.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DRemiao%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520New%2520Chemical%2520Entities%2520for%2520Old%2520Targets%253A%2520Insights%2520on%2520the%2520Lead%2520Optimization%2520of%2520Chromone-Based%2520Monoamine%2520Oxidase%2520B%2520%2528MAO-B%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5879%26epage%3D5893%26doi%3D10.1021%2Facs.jmedchem.6b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colettis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovino, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pislar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamecki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangialavori, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolsak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakelj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trontelj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01886</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01886" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVCqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1361-1387&author=D.+Knezauthor=N.+Colettisauthor=L.+G.+Iacovinoauthor=M.+Sovaauthor=A.+Pislarauthor=J.+Koncauthor=S.+Lesnikauthor=J.+Higgsauthor=F.+Kameckiauthor=I.+Mangialavoriauthor=A.+Dolsakauthor=S.+Zakeljauthor=J.+Tronteljauthor=J.+Kosauthor=C.+Bindaauthor=M.+Marderauthor=S.+Gobec&title=Stereoselective+Activity+of+1-Propargyl-4-styrylpiperidine-like+Analogues+That+Can+Discriminate+between+Monoamine+Oxidase+Isoforms+A+and+B&doi=10.1021%2Facs.jmedchem.9b01886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B</span></div><div class="casAuthors">Knez, Damijan; Colettis, Natalia; Iacovino, Luca G.; Sova, Matej; Pislar, Anja; Konc, Janez; Lesnik, Samo; Higgs, Josefina; Kamecki, Fabiola; Mangialavori, Irene; Dolsak, Ana; Zakelj, Simon; Trontelj, Jurij; Kos, Janko; Binda, Claudia; Marder, Mariel; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1361-1387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymic activity with cardiovascular, neurol., and oncol. disorders.  This has promoted increased research into selective MAO-A and MAO-B inhibitors.  Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis- and trans-1-propargyl-4-styrylpiperidines.  While the cis isomers are potent human MAO-A inhibitors, the trans analogs selectively target only the MAO-B isoform.  The inhibition was studied by kinetic anal., UV-vis spectrum measurements, and X-ray crystallog.  The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and addnl. in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders.  This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYa4wKcyp0JrVg90H21EOLACvtfcHk0ljOuDqYiBEEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVCqtg%253D%253D&md5=0a5e378381f1f72bf7624c5670d5a47c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01886%26sid%3Dliteratum%253Aachs%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DColettis%26aufirst%3DN.%26aulast%3DIacovino%26aufirst%3DL.%2BG.%26aulast%3DSova%26aufirst%3DM.%26aulast%3DPislar%26aufirst%3DA.%26aulast%3DKonc%26aufirst%3DJ.%26aulast%3DLesnik%26aufirst%3DS.%26aulast%3DHiggs%26aufirst%3DJ.%26aulast%3DKamecki%26aufirst%3DF.%26aulast%3DMangialavori%26aufirst%3DI.%26aulast%3DDolsak%26aufirst%3DA.%26aulast%3DZakelj%26aufirst%3DS.%26aulast%3DTrontelj%26aufirst%3DJ.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DMarder%26aufirst%3DM.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DStereoselective%2520Activity%2520of%25201-Propargyl-4-styrylpiperidine-like%2520Analogues%2520That%2520Can%2520Discriminate%2520between%2520Monoamine%2520Oxidase%2520Isoforms%2520A%2520and%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1361%26epage%3D1387%26doi%3D10.1021%2Facs.jmedchem.9b01886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gidaro, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Human Monoamine Oxidase: Biological and Molecular Modeling Studies on Selected Natural Flavonoids</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">9004</span>– <span class="NLM_lpage">9011</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.6b03529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.6b03529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=9004-9011&author=S.+Carradoriauthor=M.+C.+Gidaroauthor=A.+Petzerauthor=G.+Costaauthor=P.+Guglielmiauthor=P.+Chimentiauthor=S.+Alcaroauthor=J.+P.+Petzer&title=Inhibition+of+Human+Monoamine+Oxidase%3A+Biological+and+Molecular+Modeling+Studies+on+Selected+Natural+Flavonoids&doi=10.1021%2Facs.jafc.6b03529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Human Monoamine Oxidase: Biological and Molecular Modeling Studies on Selected Natural Flavonoids</span></div><div class="casAuthors">Carradori, Simone; Gidaro, Maria Concetta; Petzer, Anel; Costa, Giosue; Guglielmi, Paolo; Chimenti, Paola; Alcaro, Stefano; Petzer, Jacobus P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">9004-9011</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Naturally occurring flavonoids display a plethora of different biol. activities, but emerging evidence suggests that this class of compds. may also act as antidepressant agents endowed with multiple mechanisms of action in the central nervous system, increasing central neurotransmission, limiting the reabsorption of bioamines by synaptosomes, and modulating the neuroendocrine and GABAA systems.  Due to their presence in foods, food-derived products, and nutraceuticals, we established their role and structure-activity relationships as reversible and competitive human monoamine oxidase (MAO) inhibitors.  In addn., mol. modeling studies, which evaluated their modes of MAO inhibition, are presented.  These findings could provide pivotal implications in the quest of novel drug-like compds. and for the establishment of harmful drug-dietary supplement interactions commonly reported in the therapy with antidepressant agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Xs8oOeyyqrVg90H21EOLACvtfcHk0ljOuDqYiBEEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmsrzK&md5=67ed28b3e4c59474c165d5c0a9cd2706</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.6b03529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.6b03529%26sid%3Dliteratum%253Aachs%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DGidaro%26aufirst%3DM.%2BC.%26aulast%3DPetzer%26aufirst%3DA.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DGuglielmi%26aufirst%3DP.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26atitle%3DInhibition%2520of%2520Human%2520Monoamine%2520Oxidase%253A%2520Biological%2520and%2520Molecular%2520Modeling%2520Studies%2520on%2520Selected%2520Natural%2520Flavonoids%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2016%26volume%3D64%26spage%3D9004%26epage%3D9011%26doi%3D10.1021%2Facs.jafc.6b03529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Applications of Selective and Non-Selective Inhibitors of Monoamine Oxidase A and B That Do Not Cause Significant Tyramine Potentiation</span>. <i>Neurotoxicology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/S0161-813X(03)00103-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS0161-813X%2803%2900103-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=14697899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=243-250&author=M.+B.+H.+Youdimauthor=M.+Weinstock&title=Therapeutic+Applications+of+Selective+and+Non-Selective+Inhibitors+of+Monoamine+Oxidase+A+and+B+That+Do+Not+Cause+Significant+Tyramine+Potentiation&doi=10.1016%2FS0161-813X%2803%2900103-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation</span></div><div class="casAuthors">Youdim, Moussa B. H.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">243-250</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The major side effect with the use of first generation of non selective monoamine oxidase (MAO) inhibitors as neuropsychiatric drugs was what became known as the "cheese reaction".  Namely, potentiation of sympathomimetic activity of ingested tyramine present in cheese and other food stuff, resulting from its ability to release noradrenaline, when prevented from metab. by MAO.  The identification of two forms of MAO, termed types A and B and their selective irreversible inhibitors resolved some of this problems.  However irreversible MAO-A inhibitors continue to induce a cheese reaction, whereas MAO-B inhibitors at their selective dosage did not and led to introduction of L-deprenyl (selegiline) as an anti-Parkinson drug, since dopamine is equally well metabolized by both enzyme forms.  The cheese reaction is a consequence of inhibition of MAO-A, the enzyme responsible for metab. of noradreanline and serotonin, located in peripheral adrenergic neurons.  The consequence of these findings were the development of reversible MAO-A inhibitors (RIMA), moclobemide and brofaromin, as antidepressants and possible anti-Parkinson activity, with limited tyramine potentiation, since the amine can displace the inhibitor from its binding site on the enzyme.  It has always been deemed a greater pharmacol. advantage to inhibit both forms of the enzymes to get the full functional activities of the amine neurotransmitters, and without inducing a "cheese reaction".  This was not possible until recently, with the development of the novel cholinesterase-brain selective MAO-AB inhibitor, TV3326 (N-propargyl-(3R)-aminoindan-5-yl-Et methylcarbamte hemitartate), a carbamte deriv. of the irreversible MAO-B inhibitor anti-Parkinson drug, rasagiline.  This drug is a brain selective MAO-A and B inhibitor, with little inhibition of liver and small intestine enzymes.  Pharmacol. it has limited tyramine potentiation, very similar to moclobemide and being a MAO-AB inhibitor it has the antidepressant, anti-Parkinson and anti-Alzheimer activities in the resp. models used to develop such drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa20KLpFvMErVg90H21EOLACvtfcHk0li7M6ZLY_4Qcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLjM&md5=d360334303dbe2d40879c68a3b4098c5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0161-813X%2803%2900103-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-813X%252803%252900103-7%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DTherapeutic%2520Applications%2520of%2520Selective%2520and%2520Non-Selective%2520Inhibitors%2520of%2520Monoamine%2520Oxidase%2520A%2520and%2520B%2520That%2520Do%2520Not%2520Cause%2520Significant%2520Tyramine%2520Potentiation%26jtitle%3DNeurotoxicology%26date%3D2004%26volume%3D25%26spage%3D243%26epage%3D250%26doi%3D10.1016%2FS0161-813X%2803%2900103-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Twenty Years On: The Impact of Fragments on Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd.2016.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27417849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=605-619&author=D.+A.+Erlansonauthor=S.+W.+Fesikauthor=R.+E.+Hubbardauthor=W.+Jahnkeauthor=H.+Jhoti&title=Twenty+Years+On%3A+The+Impact+of+Fragments+on+Drug+Discovery&doi=10.1038%2Fnrd.2016.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years on: the impact of fragments on drug discovery</span></div><div class="casAuthors">Erlanson, Daniel A.; Fesik, Stephen W.; Hubbard, Roderick E.; Jahnke, Wolfgang; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">605-619</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream.  More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials.  FBDD has been widely applied in both academia and industry, as evidenced by the large no. of papers from universities, non-profit research institutions, biotechnol. companies and pharmaceutical companies.  Moreover, FBDD draws on a diverse range of disciplines, from biochem. and biophysics to computational and medicinal chem.  As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future.  This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them.  It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrXQhFttydkrVg90H21EOLACvtfcHk0li7M6ZLY_4Qcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gisb%252FE&md5=fc2bcf0da6b7b1083a5ff263057cfa80</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.109%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DTwenty%2520Years%2520On%253A%2520The%2520Impact%2520of%2520Fragments%2520on%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D605%26epage%3D619%26doi%3D10.1038%2Fnrd.2016.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4990</span>– <span class="NLM_lpage">5003</span>, <span class="refDoi"> DOI: 10.1021/bi3005126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi3005126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=4990-5003&author=D.+E.+Scottauthor=A.+G.+Coyneauthor=S.+A.+Hudsonauthor=C.+Abell&title=Fragment-Based+Approaches+in+Drug+Discovery+and+Chemical+Biology&doi=10.1021%2Fbi3005126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Approaches in Drug Discovery and Chemical Biology</span></div><div class="casAuthors">Scott, Duncan E.; Coyne, Anthony G.; Hudson, Sean A.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4990-5003</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fragment-based approaches to finding novel small mols. that bind to proteins are now firmly established in drug discovery and chem. biol.  Initially developed primarily in a few centers in the biotech and pharma industry, this methodol. has now been adopted widely in both the pharmaceutical industry and academia.  After the initial success with kinase targets, the versatility of this approach has now expanded to a broad range of different protein classes.  Herein we describe recent fragment-based approaches to a wide range of target types, including Hsp90, β-secretase, and allosteric sites in human immunodeficiency virus protease and fanesyl pyrophosphate synthase.  The role of fragment-based approaches in an academic research environment is also examd. with an emphasis on neglected diseases such as tuberculosis.  The development of a fragment library, the fragment screening process, and the subsequent fragment hit elaboration will be discussed using examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2ry6mWC83bVg90H21EOLACvtfcHk0li7M6ZLY_4Qcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosV2qsLY%253D&md5=39a6f0f741e711fd572e24c95142f55d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi3005126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi3005126%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DCoyne%26aufirst%3DA.%2BG.%26aulast%3DHudson%26aufirst%3DS.%2BA.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DFragment-Based%2520Approaches%2520in%2520Drug%2520Discovery%2520and%2520Chemical%2520Biology%26jtitle%3DBiochemistry%26date%3D2012%26volume%3D51%26spage%3D4990%26epage%3D5003%26doi%3D10.1021%2Fbi3005126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span> <span> </span><span class="NLM_article-title">The ‘Rule of Three’ for Fragment-Based Drug Discovery: Where Are We Now?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd3926-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd3926-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=23845999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ks7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=644&author=H.+Jhotiauthor=G.+Williamsauthor=D.+C.+Reesauthor=C.+W.+Murray&title=The+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Drug+Discovery%3A+Where+Are+We+Now%3F&doi=10.1038%2Fnrd3926-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The 'rule of three' for fragment-based drug discovery: where are we now?</span></div><div class="casAuthors">Jhoti, Harren; Williams, Glyn; Rees, David C.; Murray, Christopher W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The value of using the RO3 in FBDD is being (correctly) challenged as many useful fragment hits do not adhere to its restrictions (see the Practical Fragments blog website).  We have always believed that the RO3 concept has limitations and, like other rules related to desirable physicochem. properties, such as the 'rule of five' guidelines, it is simply a guideline that should not be overemphasized.  Nevertheless, we believe that the RO3 has been useful in ensuring that fragment libraries really do consist of compds. with fragment-like properties, although reports of 'fragment' hits that actually resemble lead-like compds. - particularly considering their substantial mol. mass - do still appear.  The fundamental concept of fragment screening is to use simpler mols. so that the chem. space can be sampled much more efficiently than is possible when using mols. of greater complexity.  One consequence of screening smaller, simpler fragments is that their affinity is expected to be relatively low (>1 mM), given the limited nos. of potential interactions that they can make with the protein.  Although weak in potency, fragment hits make high-quality interactions with the protein as they must overcome a substantial entropic barrier to binding, relative to their size.  The detection of low-potency fragment hits presents substantial tech. challenges, but to avoid these challenges and succumb to the temptation to screen larger, more complex mols. runs counter to the whole raison d'être of fragment screening.  We now have experience of over 30 fragment screens against a broad range of protein classes, and our results support the view that less complex mols. give a higher hit rate.  Consequently, our fragment library now almost exclusively contains mols. with fewer than 17 non-hydrogen atoms (mol. mass <230 Da).  As such, we believe the RO3 concept has assisted in limiting the mol. complexity in our fragment libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Jd0pJhvtnbVg90H21EOLACvtfcHk0li7M6ZLY_4Qcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ks7zP&md5=36ee69ae9c183b59da9afb8cb07c2c48</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd3926-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3926-c1%26sid%3Dliteratum%253Aachs%26aulast%3DJhoti%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26atitle%3DThe%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Drug%2520Discovery%253A%2520Where%2520Are%2520We%2520Now%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D644%26doi%3D10.1038%2Fnrd3926-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Experiences in Fragment-Based Drug Discovery</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.tips.2012.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=22459076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslejsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=224-232&author=C.+W.+Murrayauthor=M.+L.+Verdonkauthor=D.+C.+Rees&title=Experiences+in+Fragment-Based+Drug+Discovery&doi=10.1016%2Fj.tips.2012.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Experiences in fragment-based drug discovery</span></div><div class="casAuthors">Murray, Christopher W.; Verdonk, Marcel L.; Rees, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">224-232</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chem. leads for drug targets.  In FBDD, specialised detection methods are used to identify small chem. compds. (fragments) that bind to the drug target, and structural biol. is usually employed to establish their binding mode and to facilitate their optimization.  In this article, we present three recent and successful case histories in FBDD.  We then re-examine the key concepts and challenges of FBDD with particular emphasis on recent literature and our own experience from a substantial no. of FBDD applications.  Our opinion is that careful application of FBDD is living up to its promise of delivering high quality leads with good phys. properties and that in future many drug mols. will be derived from fragment-based approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUzcsuUdmx4bVg90H21EOLACvtfcHk0lg9zV396141Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslejsLs%253D&md5=c97b6b84a4afeadb87ee7d46e6d2bb91</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DExperiences%2520in%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D224%26epage%3D232%26doi%3D10.1016%2Fj.tips.2012.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Computational Discovery of Picomolar Q(o) Site Inhibitors of Cytochrome bc(1) Complex</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">11168</span>– <span class="NLM_lpage">11176</span>, <span class="refDoi"> DOI: 10.1021/ja3001908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja3001908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlemtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=11168-11176&author=G.-F.+Haoauthor=F.+Wangauthor=H.+Liauthor=X.-L.+Zhuauthor=W.-C.+Yangauthor=L.-S.+Huangauthor=J.-W.+Wuauthor=E.+A.+Berryauthor=G.-F.+Yang&title=Computational+Discovery+of+Picomolar+Q%28o%29+Site+Inhibitors+of+Cytochrome+bc%281%29+Complex&doi=10.1021%2Fja3001908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Discovery of Picomolar Qo Site Inhibitors of Cytochrome bc1 Complex</span></div><div class="casAuthors">Hao, Ge-Fei; Wang, Fu; Li, Hui; Zhu, Xiao-Lei; Yang, Wen-Chao; Huang, Li-Shar; Wu, Jia-Wei; Berry, Edward A.; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11168-11176</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. challenge to the fragment-based drug discovery (FBDD) is its low-throughput nature due to the necessity of biophys. method-based fragment screening.  Herein, a method of pharmacophore-linked fragment virtual screening (PFVS) was successfully developed.  Its application yielded the first picomolar-range Qo site inhibitors of the cytochrome bc1 complex, an important membrane protein for drug and fungicide discovery.  Compared with the original hit compd. 4 (Ki = 881.80 nM, porcine bc1), the most potent compd. 4f displayed 20 507-fold improved binding affinity (Ki = 43.00 pM).  Compd. 4f was proved to be a noncompetitive inhibitor with respect to the substrate cytochrome c, but a competitive inhibitor with respect to the substrate ubiquinol.  Addnl., the crystal structure of compd. 4e (Ki = 83.00 pM) bound to the chicken bc1 was detd. at 2.70 Å resoln., providing a mol. basis for understanding its ultrapotency.  To the authors' knowledge, this study is the first application of the FBDD method in the discovery of picomolar inhibitors of a membrane protein.  This work demonstrates that the novel PFVS approach is a high-throughput drug discovery method, independent of biophys. screening techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFot0FjSNmbVg90H21EOLACvtfcHk0lg9zV396141Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlemtLo%253D&md5=23821de7aaecdbcb8aa513a05fd5bc87</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fja3001908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja3001908%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DYang%26aufirst%3DW.-C.%26aulast%3DHuang%26aufirst%3DL.-S.%26aulast%3DWu%26aufirst%3DJ.-W.%26aulast%3DBerry%26aufirst%3DE.%2BA.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DComputational%2520Discovery%2520of%2520Picomolar%2520Q%2528o%2529%2520Site%2520Inhibitors%2520of%2520Cytochrome%2520bc%25281%2529%2520Complex%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D11168%26epage%3D11176%26doi%3D10.1021%2Fja3001908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">ACFIS: A Web Server for Fragment-Based Drug Discovery</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">W550</span>– <span class="NLM_lpage">W556</span>, <span class="refDoi"> DOI: 10.1093/nar/gkw393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fnar%2Fgkw393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27150808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2itrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=W550-W556&author=G.-F.+Haoauthor=W.+Jiangauthor=Y.-N.+Yeauthor=F.-X.+Wuauthor=X.-L.+Zhuauthor=F.-B.+Guoauthor=G.-F.+Yang&title=ACFIS%3A+A+Web+Server+for+Fragment-Based+Drug+Discovery&doi=10.1093%2Fnar%2Fgkw393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">ACFIS: a web server for fragment-based drug discovery</span></div><div class="casAuthors">Hao, Ge-Fei; Jiang, Wen; Ye, Yuan-Nong; Wu, Feng-Xu; Zhu, Xiao-Lei; Guo, Feng-Biao; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">W1</span>),
    <span class="NLM_cas:pages">W550-W556</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In order to foster innovation and improve the effectiveness of drug discovery, there is a considerable interest in exploring unknown 'chem. space' to identify new bioactive compds. with novel and diverse scaffolds.  Hence, fragment-based drug discovery (FBDD) was developed rapidly due to its advanced expansive search for 'chem. space', which can lead to a higher hit rate and ligand efficiency (LE).  However, computational screening of fragments is always hampered by the promiscuous binding model.  In this study, we developed a new web server Auto Core Fragment in silico Screening (ACFIS).  It includes three computational modules, PARA_GEN, CORE_GEN and CAND_GEN.  ACFIS can generate core fragment structure from the active mol. using fragment deconstruction anal. and perform in silico screening by growing fragments to the junction of core fragment structure.  An integrated energy calcn. rapidly identifies which fragments fit the binding site of a protein.  We constructed a simple interface to enable users to view top-ranking mols. in 2D and the binding mode in 3D for further exptl. exploration.  This makes the ACFIS a highly valuable tool for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7MTRU-oeBvrVg90H21EOLACvtfcHk0lg9zV396141Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2itrjF&md5=3d0086f13fb247d6735fb29568d2ee04</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkw393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkw393%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DY.-N.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DGuo%26aufirst%3DF.-B.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DACFIS%253A%2520A%2520Web%2520Server%2520for%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3DW550%26epage%3DW556%26doi%3D10.1093%2Fnar%2Fgkw393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Phylogenetic and Structural Analysis Reveals the Molecular Evolution of the ABA Receptor Gene Family</span>. <i>J. Exp. Bot.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1322</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1093/jxb/erz511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fjxb%2Ferz511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=31740933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKmtr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=1322-1336&author=J.-F.+Yangauthor=M.-X.+Chenauthor=J.-H.+Zhangauthor=G.-F.+Haoauthor=G.-F.+Yang&title=Genome-Wide+Phylogenetic+and+Structural+Analysis+Reveals+the+Molecular+Evolution+of+the+ABA+Receptor+Gene+Family&doi=10.1093%2Fjxb%2Ferz511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide phylogenetic and structural analysis reveals the molecular evolution of the ABA receptor gene family</span></div><div class="casAuthors">Yang, Jing-Fang; Chen, Mo-Xian; Zhang, Jian-Hua; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Botany</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1322-1336</span>CODEN:
                <span class="NLM_cas:coden">JEBOA6</span>;
        ISSN:<span class="NLM_cas:issn">1460-2431</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The plant hormone abscisic acid (ABA) plays a crucial role during the plant life cycle as well as in adaptive responses to environmental stresses.  The core regulatory components of ABA signaling in plants are the pyrabactin resistance1/PYR1- like/regulatory component of ABA receptor family (PYLs), which comprise the largest plant hormone receptor family known.  They act as neg. regulators of members of the protein phosphatase type 2C family.  Due to the biol. importance of PYLs, many researchers have focused on their genetic redundancy and consequent functional divergence.  However, little is understood of their evolution and its impact on the generation of regulatory diversity.  In this study, we identify pos. selection and functional divergence in PYLs through phylogenetic reconstruction, gene structure and expression pattern anal., pos. selection anal., functional divergence anal., and structure comparison.  We found the correlation of desensitization of PYLs under specifi modifiations in the mol. recognition domain with functional diversifiation.  Hence, an interesting antagonistic co-evolutionary mechanism is proposed for the functional diversifiation of ABA receptor family proteins.  We believe a compensatory evolutionary pathway may have occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptlFHeUobbcbVg90H21EOLACvtfcHk0lg43iy4UA0Mxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKmtr%252FE&md5=d76ab7d89d37634d46f934a9f57b996f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjxb%2Ferz511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjxb%252Ferz511%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DM.-X.%26aulast%3DZhang%26aufirst%3DJ.-H.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DGenome-Wide%2520Phylogenetic%2520and%2520Structural%2520Analysis%2520Reveals%2520the%2520Molecular%2520Evolution%2520of%2520the%2520ABA%2520Receptor%2520Gene%2520Family%26jtitle%3DJ.%2520Exp.%2520Bot.%26date%3D2020%26volume%3D71%26spage%3D1322%26epage%3D1336%26doi%3D10.1093%2Fjxb%2Ferz511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserue, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keserueauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lg43iy4UA0Mxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeserue%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=1725-1730&author=J.-F.+Yangauthor=F.+Wangauthor=W.+Jiangauthor=G.-Y.+Zhouauthor=C.-Z.+Liauthor=X.-L.+Zhuauthor=G.-F.+Haoauthor=G.-F.+Yang&title=PADFrag%3A+A+Database+Built+for+the+Exploration+of+Bioactive+Fragment+Space+for+Drug+Discovery&doi=10.1021%2Facs.jcim.8b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery</span></div><div class="casAuthors">Yang, Jing-Fang; Wang, Fan; Jiang, Wen; Zhou, Guang-You; Li, Cheng-Zhang; Zhu, Xiao-Lei; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1725-1730</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural analyses of drugs and pesticides can enable the identification of new bioactive compds. with novel and diverse scaffolds as well as improve our understanding of the bioactive fragment space.  The Pesticide And Drug Fragments (PADFrag) database is a unique bioinformatic-cheminformatic cross-referencing resource that combines detailed bioactive fragment data and potential targets with a strong focus on quant., analytic, and mol.-scale information for the exploration of bioactive fragment space for drug discovery (http://chemyang.ccnu.edu.cn/ccb/database/PADFrag/).  The main applications of PADFrag are the anal. of the privileged structures within known bioactive mols., ab initio mol. library design, and core fragment discovery for fragment-based drug design.  Other potential applications include prediction of fragment interactions and general pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoF3PkNXTMkrVg90H21EOLACvtfcHk0lg43iy4UA0Mxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGru7fE&md5=c434a56ca94611f6e004daa8e28518cd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00285%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.-Y.%26aulast%3DLi%26aufirst%3DC.-Z.%26aulast%3DZhu%26aufirst%3DX.-L.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DPADFrag%253A%2520A%2520Database%2520Built%2520for%2520the%2520Exploration%2520of%2520Bioactive%2520Fragment%2520Space%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D1725%26epage%3D1730%26doi%3D10.1021%2Facs.jcim.8b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">AIMMS Suite: A Web Server Dedicated for Prediction of Drug Resistance on Protein Mutation</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1093/bib/bbz092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbz092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2nsbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=318-328&author=F.-X.+Wuauthor=F.+Wangauthor=J.-F.+Yangauthor=W.+Jiangauthor=M.-Y.+Wangauthor=C.-Y.+Jiaauthor=G.-F.+Haoauthor=G.-F.+Yang&title=AIMMS+Suite%3A+A+Web+Server+Dedicated+for+Prediction+of+Drug+Resistance+on+Protein+Mutation&doi=10.1093%2Fbib%2Fbbz092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">AIMMS suite: a web server dedicated for prediction of drug resistance on protein mutation</span></div><div class="casAuthors">Wu, Feng-Xu; Wang, Fan; Yang, Jing-Fang; Jiang, Wen; Wang, Meng-Yao; Jia, Chen-Yang; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Briefings in Bioinformatics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">318-328</span>CODEN:
                <span class="NLM_cas:coden">BBIMFX</span>;
        ISSN:<span class="NLM_cas:issn">1477-4054</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug resistance is one of the most intractable issues for successful treatment in current clin. practice.  Although many mutations contributing to drug resistance have been identified, the relationship between the mutations and the related pharmacol. profile of drug candidates has yet to be fully elucidated, which is valuable both for the mol. dissection of drug resistance mechanisms and for suggestion of promising treatment strategies to counter resistant.  Hence, effective prediction approach for estg. the sensitivity of mutations to agents is a new opportunity that counters drug resistance and creates a high interest in pharmaceutical research.  However, this task is always hampered by limited known resistance training samples and accurately estn. of binding affinity.  Upon this challenge, we successfully developed Auto In Silico Macromol. Mutation Scanning (AIMMS), a web server for computer-aided de novo drug resistance prediction for any ligand-protein systems.  AIMMS can qual. est. the free energy consequences of any mutations through a fast mutagenesis scanning calcn. based on a single mol. dynamics trajectory, which is differentiated with other web services by a statistical learning system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8wUPr9bt9LVg90H21EOLACvtfcHk0liuj5KW4fq6Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2nsbbL&md5=c70fc164b4a18985cd921e5496bcdd63</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbz092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbz092%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.-Y.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DAIMMS%2520Suite%253A%2520A%2520Web%2520Server%2520Dedicated%2520for%2520Prediction%2520of%2520Drug%2520Resistance%2520on%2520Protein%2520Mutation%26jtitle%3DBriefings%2520Bioinf.%26date%3D2020%26volume%3D21%26spage%3D318%26epage%3D328%26doi%3D10.1093%2Fbib%2Fbbz092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carradori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardia, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orallo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirilli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Semipreparative HPLC Separation, Biological Evaluation, and 3D-QSAR of Hydrazothiazole Derivatives as Human Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5063</span>– <span class="NLM_lpage">5070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bmc.2010.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=20579890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5063-5070&author=F.+Chimentiauthor=D.+Secciauthor=A.+Bolascoauthor=P.+Chimentiauthor=A.+Graneseauthor=S.+Carradoriauthor=E.+Maccioniauthor=M.+C.+Cardiaauthor=M.+Yanezauthor=F.+Oralloauthor=S.+Alcaroauthor=F.+Ortusoauthor=R.+Cirilliauthor=R.+Ferrettiauthor=S.+Distintoauthor=J.+Kirchmairauthor=T.+Langer&title=Synthesis%2C+Semipreparative+HPLC+Separation%2C+Biological+Evaluation%2C+and+3D-QSAR+of+Hydrazothiazole+Derivatives+as+Human+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bmc.2010.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors</span></div><div class="casAuthors">Chimenti, Franco; Secci, Daniela; Bolasco, Adriana; Chimenti, Paola; Granese, Arianna; Carradori, Simone; Maccioni, Elias; Cardia, M. Cristina; Yanez, Matilde; Orallo, Francisco; Alcaro, Stefano; Ortuso, Francesco; Cirilli, Roberto; Ferretti, Rosella; Distinto, Simona; Kirchmair, Johannes; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5063-5070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study reports on synthesis in high yields (70-99%), HPLC enantiosepn., inhibitory activity against human monoamino oxidases, and mol. modeling including 3D-QSAR studies, of a large series of (4-aryl-thiazol-2-yl)hydrazones (1-45).  Most of the synthesized compds. proved to be potent and selective inhibitors of hMAO-B isoform in the micromolar or nanomolar range, thus demonstrating that hydrazothiazole could be considered a good pharmacophore to design new hMAO-B inhibitors.  Due to the presence in some derivs. of a chiral center, we also performed a semipreparative chromatog. enantiosepn. of these compds. obtained by a stereoconservative pattern.  The sepd. enantiomers were submitted to in vitro biol. evaluation to point out the stereorecognition of the active site of the enzyme towards these structures.  Finally, a 3D-QSAR study was carried out using Comparative Mol. Field Anal. (CoMFA), aiming to deduce rational guidelines for the further structural modification of these lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1QZPBAeaYGLVg90H21EOLACvtfcHk0liuj5KW4fq6Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslagtbs%253D&md5=7f4a33195161dccff09e9f98321249b9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DGranese%26aufirst%3DA.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DFerretti%26aufirst%3DR.%26aulast%3DDistinto%26aufirst%3DS.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520Semipreparative%2520HPLC%2520Separation%252C%2520Biological%2520Evaluation%252C%2520and%25203D-QSAR%2520of%2520Hydrazothiazole%2520Derivatives%2520as%2520Human%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5063%26epage%3D5070%26doi%3D10.1016%2Fj.bmc.2010.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morissette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Sweidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcangi, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, T.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice</span>. <i>Neuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1159/000438789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1159%2F000438789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=26227546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=300-314&author=M.+Bourqueauthor=M.+Morissetteauthor=S.+Al+Sweidiauthor=D.+Carusoauthor=R.+C.+Melcangiauthor=T.+Di+Paolo&title=Neuroprotective+Effect+of+Progesterone+in+MPTP-Treated+Male+Mice&doi=10.1159%2F000438789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice</span></div><div class="casAuthors">Bourque, Melanie; Morissette, Marc; Al Sweidi, Sara; Caruso, Donatella; Melcangi, Roberto C.; Di Paolo, Therese</div><div class="citationInfo"><span class="NLM_cas:title">Neuroendocrinology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">300-314</span>CODEN:
                <span class="NLM_cas:coden">NUNDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0028-3835</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Numerous studies have reported on the neuroprotective activity of estradiol, whereas the effect of the other ovarian steroid, progesterone, is much less documented.  Methods: This study sought to investigate neuroprotection with a low dose of progesterone (1 μg) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated male mice to model Parkinson's disease and compare it to the effect of this steroid in intact mice (expt. 1).  We also investigated if high doses of progesterone could protect dopaminergic neurons already exposed to MPTP (expt. 2).  We measured progesterone effects on various dopaminergic markers [dopamine and its metabolites, dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2)] and on neuroactive steroids in both plasma and the brain.  Results: For expt. 1, our results showed that progesterone completely prevented the effect of MPTP toxicity on dopamine concns., on the increase in the 3-methoxytyramine/dopamine ratio, as well as on VMAT2-specific binding in the striatum and the substantia nigra.  Progesterone decreased MPTP effects on 3,4-dihydroxyphenylacetic acid concns. and DAT-specific binding in the lateral part of the anterior striatum and in the middle striatum (medial and lateral parts).  Progesterone treatment of intact mice had no effect on the markers investigated.  For expt. 2, measures of dopaminergic markers in the striatum showed that 8 mg/kg of progesterone was the most ED to reduce MPTP effects, and more limited effects were obsd. with 16 mg/kg.  We found that progesterone treatment increases the levels of brain progesterone itself as well as of its metabolites.  Conclusion: Our result showed that progesterone has neuroprotective effects on dopaminergic neurons in MPTP-treated male mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2qq343wfbEbVg90H21EOLACvtfcHk0liuj5KW4fq6Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFWisrc%253D&md5=6e61cc79a0865453cf1177be32591850</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1159%2F000438789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000438789%26sid%3Dliteratum%253Aachs%26aulast%3DBourque%26aufirst%3DM.%26aulast%3DMorissette%26aufirst%3DM.%26aulast%3DAl%2BSweidi%26aufirst%3DS.%26aulast%3DCaruso%26aufirst%3DD.%26aulast%3DMelcangi%26aufirst%3DR.%2BC.%26aulast%3DDi%2BPaolo%26aufirst%3DT.%26atitle%3DNeuroprotective%2520Effect%2520of%2520Progesterone%2520in%2520MPTP-Treated%2520Male%2520Mice%26jtitle%3DNeuroendocrinology%26date%3D2016%26volume%3D103%26spage%3D300%26epage%3D314%26doi%3D10.1159%2F000438789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faravelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fariello, R. G.</span></span> <span> </span><span class="NLM_article-title">Safinamide - From Molecular Targets To A New Anti-Parkinson Drug</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">S18</span>– <span class="NLM_lpage">S23</span>, <span class="refDoi"> DOI: 10.1212/WNL.67.7_suppl_2.S18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1212%2FWNL.67.7_suppl_2.S18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=17030736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVeqsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=S18-S23&author=C.+Cacciaauthor=R.+Majauthor=M.+Calabresiauthor=S.+Maestroniauthor=L.+Faravelliauthor=L.+Curatoloauthor=P.+Salvatiauthor=R.+G.+Fariello&title=Safinamide+-+From+Molecular+Targets+To+A+New+Anti-Parkinson+Drug&doi=10.1212%2FWNL.67.7_suppl_2.S18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Safinamide: From molecular targets to a new anti-Parkinson drug</span></div><div class="casAuthors">Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7, Suppl. 2</span>),
    <span class="NLM_cas:pages">S18-S23</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Ideal treatment in Parkinson's disease (PD) aims at relieving symptoms and slowing disease progression.  Of all remedies, levodopa remains the most effective for symptomatic relief, but the medical need for neuroprotectant drugs is still unfulfilled.  Safinamide, currently in phase III clin. trials for the treatment of PD, is a unique mol. with multiple mechanisms of action and a very high therapeutic index.  It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na and Ca channels and inhibition of glutamate release.  Safinamide has neuroprotective and neuro rescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.  Safinamide potentiates levodopa-mediated increase of DA levels in DA-depleted mice and reverses the waning motor response after prolonged levodopa treatment in 6-OHDA-lesioned rats.  Safinamide has excellent bioavailability, linear kinetics, and is suitable for once-a-day administration.  Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyY9RqTsiL5LVg90H21EOLACvtfcHk0lhEwJbK-gqZ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVeqsLfL&md5=51e4743fd40d5a177ebd2e7f14c7cd4d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1212%2FWNL.67.7_suppl_2.S18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.67.7_suppl_2.S18%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DMaj%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DM.%26aulast%3DMaestroni%26aufirst%3DS.%26aulast%3DFaravelli%26aufirst%3DL.%26aulast%3DCuratolo%26aufirst%3DL.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%2520-%2520From%2520Molecular%2520Targets%2520To%2520A%2520New%2520Anti-Parkinson%2520Drug%26jtitle%3DNeurology%26date%3D2006%26volume%3D67%26spage%3DS18%26epage%3DS23%26doi%3D10.1212%2FWNL.67.7_suppl_2.S18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Lewis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przedborski, S.</span></span> <span> </span><span class="NLM_article-title">Protocol for the MPTP Mouse Model of Parkinson’s Disease</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1038/nprot.2006.342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1038%2Fnprot.2006.342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=17401348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGntb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=141-151&author=V.+Jackson-Lewisauthor=S.+Przedborski&title=Protocol+for+the+MPTP+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1038%2Fnprot.2006.342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Protocol for the MPTP mouse model of Parkinson's disease</span></div><div class="casAuthors">Jackson-Lewis, Vernice; Przedborski, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol describes our method of producing a reliable mouse model of Parkinson's disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  We discuss the particulars of the model, provide key refs. and outline what investigators need to know to develop the MPTP mouse model of PD safely and successfully.  Completion of this protocol depends on the regimen of MPTP used and on the actual planned studies, which often range from 7 to 30 d.  This protocol calls for implementation of safety measures and for the acquisition of several pieces of equipment, which are a one-time investment worth making if one elects to use this model on a regular basis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq4GX2AMcV_LVg90H21EOLACvtfcHk0lhEwJbK-gqZ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGntb3N&md5=19737029e8ea7ab7626172d29daf8678</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.342%26sid%3Dliteratum%253Aachs%26aulast%3DJackson-Lewis%26aufirst%3DV.%26aulast%3DPrzedborski%26aufirst%3DS.%26atitle%3DProtocol%2520for%2520the%2520MPTP%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D141%26epage%3D151%26doi%3D10.1038%2Fnprot.2006.342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouradian, M. M.</span></span> <span> </span><span class="NLM_article-title">Protection Against Acute MPTP-Induced Dopamine Depletion in Mice by Adenosine A1 Agonist</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">768</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1993.tb03215.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1111%2Fj.1471-4159.1993.tb03215.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=8419552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFymsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=768-771&author=Y.+S.+Lauauthor=M.+M.+Mouradian&title=Protection+Against+Acute+MPTP-Induced+Dopamine+Depletion+in+Mice+by+Adenosine+A1+Agonist&doi=10.1111%2Fj.1471-4159.1993.tb03215.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist</span></div><div class="casAuthors">Lau, Yuen Sum; Mouradian, M. Maral</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">768-71</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">The effects of the adenosine A1 agonist N6-cyclohexyladenosine (CHA) on MPTP-induced dopamine (DA) depletion in the striatum of C57BL/6 mice were studied.  Twenty hours after a single injection of MPTP (30 mg/kg, s.c.), the toxin caused 62% depletion of striatal DA.  CHA (0.2-3 mg/kg, s.c.), when given together with MPTP, prevented the toxin-induced DA depletion in a dose-dependent manner.  This protective action was apparently mediated by the A1 receptors, because this effect was selectively antagonized by pretreating the animals with the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (25 mg/kg, i.p.).  When CHA (3 mg/kg) was injected 5 h after MPTP administration, at which point striatal DA levels were already reduced significantly, a rapid and complete recovery of the striatal DA levels occurred.  These neurochem. data suggest that the A1 agonist CHA is potentially useful as a neuroprotective agent against MPTP-induced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObJxurREH4LVg90H21EOLACvtfcHk0lhEwJbK-gqZ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFymsrg%253D&md5=1f61f347ea64790b75fbd36924f9ac6c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1993.tb03215.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1993.tb03215.x%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DY.%2BS.%26aulast%3DMouradian%26aufirst%3DM.%2BM.%26atitle%3DProtection%2520Against%2520Acute%2520MPTP-Induced%2520Dopamine%2520Depletion%2520in%2520Mice%2520by%2520Adenosine%2520A1%2520Agonist%26jtitle%3DJ.%2520Neurochem.%26date%3D1993%26volume%3D60%26spage%3D768%26epage%3D771%26doi%3D10.1111%2Fj.1471-4159.1993.tb03215.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span> <span> </span><span class="NLM_article-title">Resveratrol Synergizes with Low Doses of L-DOPA To Improve MPTP-Induced Parkinson Disease in Mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2019.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.bbr.2019.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=30922940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVWhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2019&pages=10-18&author=Q.+Liuauthor=D.+Zhuauthor=P.+Jiangauthor=X.+Tangauthor=Q.+Langauthor=Q.+Yuauthor=S.+Zhangauthor=Y.+Cheauthor=X.+Feng&title=Resveratrol+Synergizes+with+Low+Doses+of+L-DOPA+To+Improve+MPTP-Induced+Parkinson+Disease+in+Mice&doi=10.1016%2Fj.bbr.2019.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice</span></div><div class="casAuthors">Liu, Qianqian; Zhu, Dashuai; Jiang, Peien; Tang, Xinyu; Lang, Qiuhan; Yu, Qinyi; Zhang, Shaozhi; Che, Yongzhe; Feng, Xizeng</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">L-DOPA (L-3,4-dihydroxyphenylalanine) relieves symptoms of Parkinson disease (PD), but long-term use can cause serious side effects.  Resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV), a polyphenolic compd. derived from grapes and red wine that has antioxidant activity, has been shown to have neuroprotective effects.  RV was investigated to enhance the therapeutic effect of L-DOPA in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson disease.  Mice received a saline or RV injection (10 mg/kg/day), then 2 h later, saline or MPTP (15 mg/kg/day) was administered for 7 consecutive days.  Saline or L-DOPA (5 or 8 mg/kg/day) was injected post-administration of MPTP for the last 2 consecutive days.  Our results indicated that RV alleviated MPTP-induced loss of dopaminergic neurons and attenuated astroglial activation in the nigrostriatal pathway.  In parallel, RV reduced the expression of α-synuclein in the striatum.  In addn., RV also increased levels of the anti-apoptotic signalling mol. Bcl-2, reduced levels of the pro-apoptotic signalling mol. Bax, and reduced activation of caspase-3 in the striatum.  Specifically, RV significantly reduced motor dysfunction in MPTP-treated mice.  Furthermore, the RV-treated group showed less IL-1β and an enhanced pAkt/Akt ratio, which promoted dopamine neuron survival in the striatum.  We found that the effects of co-administration of RV with L-DOPA (5 mg/kg) were equiv. to those of administration of 8 mg/kg L-DOPA in MPTP-induced PD mice.  Therefore, with fewer side effects, L-DOPA can be effectively used in the treatment of PD over a long period of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyUVrCpxuWbVg90H21EOLACvtfcHk0lhEwJbK-gqZ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVWhtLs%253D&md5=3558fd48197b6564863adac9b6223008</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2019.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2019.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DLang%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DX.%26atitle%3DResveratrol%2520Synergizes%2520with%2520Low%2520Doses%2520of%2520L-DOPA%2520To%2520Improve%2520MPTP-Induced%2520Parkinson%2520Disease%2520in%2520Mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2019%26volume%3D367%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.bbr.2019.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stichel-Gunkel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luebbert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenscroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Effects of Rotigotine in the Acute MPTP-Lesioned Mouse Model of Parkinson’s Disease</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2007.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.neulet.2007.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=18162314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2008&pages=30-34&author=D.+Schellerauthor=C.+Stichel-Gunkelauthor=H.+Luebbertauthor=G.+Porrasauthor=P.+Ravenscroftauthor=M.+Hillauthor=E.+Bezard&title=Neuroprotective+Effects+of+Rotigotine+in+the+Acute+MPTP-Lesioned+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.neulet.2007.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease</span></div><div class="casAuthors">Scheller, Dieter; Stichel-Gunkel, Christine; Luebbert, Hermann; Porras, Gregory; Ravenscroft, Paula; Hill, Michael; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-34</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dopamine agonists used to manage Parkinsonian motor symptoms have been suggested to be neuroprotective.  The study was designed to assess the neuroprotective potential of the D3/D2/D1 dopamine receptor agonist rotigotine in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned (MPTP) mouse model of Parkinson's disease by measuring mesencephalic degenerating neurons using FluoroJade staining and the remaining dopaminergic nerve endings in the striatum using dopamine transporter binding.  Continuous administration of rotigotine at a dose of 3 mg/kg significantly attenuated MPTP-induced acute cell degeneration in the FluoroJade-staining paradigm.  Rotigotine (0.3-3 mg/kg) partially protected dopamine nerve endings from MPTP-induced degeneration in a dose-dependent manner.  These data suggest that rotigotine, at the doses employed, significantly protected dopamine neurons from degeneration in an acute mouse model of MPTP intoxication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIBulvYTClObVg90H21EOLACvtfcHk0ljjzuUmHhirvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslaqtLs%253D&md5=04e756a9bed937879dc2cb5c515c1a83</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2007.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2007.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DScheller%26aufirst%3DD.%26aulast%3DStichel-Gunkel%26aufirst%3DC.%26aulast%3DLuebbert%26aufirst%3DH.%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DRavenscroft%26aufirst%3DP.%26aulast%3DHill%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DNeuroprotective%2520Effects%2520of%2520Rotigotine%2520in%2520the%2520Acute%2520MPTP-Lesioned%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeurosci.%2520Lett.%26date%3D2008%26volume%3D432%26spage%3D30%26epage%3D34%26doi%3D10.1016%2Fj.neulet.2007.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heikkila, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvoisin, R. C.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1126/science.6610213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1126%2Fscience.6610213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=6610213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVertr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1984&pages=1451-1453&author=R.+E.+Heikkilaauthor=A.+Hessauthor=R.+C.+Duvoisin&title=Dopaminergic+Neurotoxicity+of+1-Methyl-4-Phenyl-1%2C2%2C5%2C6-Tetrahydropyridine+in+Mice&doi=10.1126%2Fscience.6610213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice</span></div><div class="casAuthors">Heikkila, Richard E.; Hess, Arthur; Duvoisin, Roger C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">4656</span>),
    <span class="NLM_cas:pages">1451-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)(I)  [28289-54-5] is known to cause an irreversible destruction of the dopaminergic nigrostriatal pathway and symptoms of parkinsonism in humans and in monkeys.  However, MPTP has been reported to act only minimally or not at all in several other animal species.  When MPTP (30 mg/kg) was administered parenterally to mice, a decrease in concns. of neostriatal dopamine and its metabolites, a decrease in the capacity of neostriatal synaptosomal prepns. to accumulate [3H]dopamine, and a disappearance of nerve cells in the zona compacta of the substantia nigra were obsd.  In contrast, MPTP administration had no effect on neostriatal concns. of serotonin and its metabolites.  MPTP administration thus results in biochem. and histol. changes in mice similar to those reported in humans and monkeys and similar to those seen in Parkinson's disease in humans.  The mouse should prove to be a useful small animal with which to study the mode of action of MPTP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwJkIdGXUurVg90H21EOLACvtfcHk0ljjzuUmHhirvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVertr0%253D&md5=cf0098a4c243c87e35af0380ad3b6145</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscience.6610213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6610213%26sid%3Dliteratum%253Aachs%26aulast%3DHeikkila%26aufirst%3DR.%2BE.%26aulast%3DHess%26aufirst%3DA.%26aulast%3DDuvoisin%26aufirst%3DR.%2BC.%26atitle%3DDopaminergic%2520Neurotoxicity%2520of%25201-Methyl-4-Phenyl-1%252C2%252C5%252C6-Tetrahydropyridine%2520in%2520Mice%26jtitle%3DScience%26date%3D1984%26volume%3D224%26spage%3D1451%26epage%3D1453%26doi%3D10.1126%2Fscience.6610213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michimata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, T.</span></span> <span> </span><span class="NLM_article-title">Role of Dopamine Transporter Against MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Neurotoxicity in Mice</span>. <i>Metab. Brain Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1023/A:1023863003093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1023%2FA%3A1023863003093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=12822832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvVagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=139-146&author=R.+Kurosakiauthor=Y.+Muramatsuauthor=H.+Watanabeauthor=M.+Michimataauthor=M.+Matsubaraauthor=Y.+Imaiauthor=T.+Araki&title=Role+of+Dopamine+Transporter+Against+MPTP+%281-Methyl-4-Phenyl-1%2C2%2C3%2C6-Tetrahydropyridine%29+Neurotoxicity+in+Mice&doi=10.1023%2FA%3A1023863003093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Dopamine Transporter Against MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Neurotoxicity in Mice</span></div><div class="casAuthors">Kurosaki, R.; Muramatsu, Y.; Watanabe, H.; Michimata, M.; Matsubara, M.; Imai, Y.; Araki, T.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-146</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">We investigated the alterations of dopamine transporter (DAT)-immunopos. cells against MPTP neurotoxicity, in comparison with tyrosine hydroxylase (TH)- immunopos. neurons and glial fibrillary acidic protein (GFAP)-immunopos. cells.  This study showed that DAT and TH immunoreactivity was decreased gradually in the striatum and substantia nigra of mice after MPTP treatment.  The patterns of the intense TH-immunoreactive fibers and cell bodies were similar to those of DAT-immunoreactive fibers and cell bodies in the striatum and substantia nigra of mice after MPTP treatment.  In contrast, GFAP immunoreactivity was increased gradually in the striatum and substantia nigra after MPTP treatment.  In our double-labeled immunostaining with anti-DAT and anti-GFAP antibodies, DAT immunoreactivity was obsd. only in the nigral dopaminergic neurons, but not in the reactive astrocytes.  The present results provide further evidence that the functional damage of DAT may precede dopaminergic neuronal death after MPTP treatment, although the decrease in the no. of TH-immunopos. neurons was more pronounced than that in the no. of DAT-immunopos. neurons.  Furthermore,these findings demonstrate that MPTP can selectively injure the dopaminergic neurons which DAT proteins are predominantly distributed on the striatum and substantia nigra.  The results provide beneficial information for MPTP-induced neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLdLa0x3LbvLVg90H21EOLACvtfcHk0ljjzuUmHhirvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvVagsbs%253D&md5=80cb584593e77b029cb09d0efba35486</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023863003093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023863003093%26sid%3Dliteratum%253Aachs%26aulast%3DKurosaki%26aufirst%3DR.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMichimata%26aufirst%3DM.%26aulast%3DMatsubara%26aufirst%3DM.%26aulast%3DImai%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26atitle%3DRole%2520of%2520Dopamine%2520Transporter%2520Against%2520MPTP%2520%25281-Methyl-4-Phenyl-1%252C2%252C3%252C6-Tetrahydropyridine%2529%2520Neurotoxicity%2520in%2520Mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2003%26volume%3D18%26spage%3D139%26epage%3D146%26doi%3D10.1023%2FA%3A1023863003093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span> <span> </span><span class="NLM_article-title">MAO-B Inhibitors: Multiple Roles in the Therapy of Neurodegenerative Disorders?</span>. <i>Parkinsonism Relat. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/S1353-8020(99)00043-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2FS1353-8020%2899%2900043-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=18591148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A280%3ADC%252BD1cvitFyrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=25-47&author=P.+Foleyauthor=M.+Gerlachauthor=M.+B.+Youdimauthor=P.+Riederer&title=MAO-B+Inhibitors%3A+Multiple+Roles+in+the+Therapy+of+Neurodegenerative+Disorders%3F&doi=10.1016%2FS1353-8020%2899%2900043-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?</span></div><div class="casAuthors">Foley P; Gerlach M; Youdim M B; Riederer P</div><div class="citationInfo"><span class="NLM_cas:title">Parkinsonism & related disorders</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-47</span>
        ISSN:<span class="NLM_cas:issn">1353-8020</span>.
    </div><div class="casAbstract">Monoamine oxidases play a central role in catecholamine catabolism in the central nervous system.  The biochemical and pharmacological properties of inhibitors of the monoamine oxidase type B are reviewed.  The evidence for biochemical activities distinct from their ability to inhibit MAO-B is discussed, including possible antioxidative and antiapoptotic activities of these agents.  The significance of these properties for the pharmacological management of Parkinson's disease and the evidence for a neuroprotective effect of one such agent (selegiline) is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZCSetTAu6zNbHMBt0mMIXfW6udTcc2eaarvcetPtzaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvitFyrtQ%253D%253D&md5=aa64555d2fd4bbd0b9d748ce8ad1a1e1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1353-8020%2899%2900043-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1353-8020%252899%252900043-7%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGerlach%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DRiederer%26aufirst%3DP.%26atitle%3DMAO-B%2520Inhibitors%253A%2520Multiple%2520Roles%2520in%2520the%2520Therapy%2520of%2520Neurodegenerative%2520Disorders%253F%26jtitle%3DParkinsonism%2520Relat.%2520Disord.%26date%3D2000%26volume%3D6%26spage%3D25%26epage%3D47%26doi%3D10.1016%2FS1353-8020%2899%2900043-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">LARMD: Integration of Bioinformatic Resources to Profile Ligand-Driven Protein Dynamics With a Case on the Activation of Estrogen Receptor</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1093/bib/bbz141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbz141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.-F.+Yangauthor=F.+Wangauthor=Y.-Z.+Chenauthor=G.-F.+Haoauthor=G.-F.+Yang&title=LARMD%3A+Integration+of+Bioinformatic+Resources+to+Profile+Ligand-Driven+Protein+Dynamics+With+a+Case+on+the+Activation+of+Estrogen+Receptor&doi=10.1093%2Fbib%2Fbbz141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbz141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbz141%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-F.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.-Z.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DLARMD%253A%2520Integration%2520of%2520Bioinformatic%2520Resources%2520to%2520Profile%2520Ligand-Driven%2520Protein%2520Dynamics%2520With%2520a%2520Case%2520on%2520the%2520Activation%2520of%2520Estrogen%2520Receptor%26jtitle%3DBriefings%2520Bioinf.%26date%3D2019%26doi%3D10.1093%2Fbib%2Fbbz141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lgqXo_lvJiWzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">ACID: A Free Tool for Drug Repurposing Using Consensus Inverse Docking Strategy</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">73</span> <span class="refDoi"> DOI: 10.1186/s13321-019-0394-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1186%2Fs13321-019-0394-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=F.+Wangauthor=F.-X.+Wuauthor=C.-Z.+Liauthor=C.-Y.+Jiaauthor=S.-W.+Suauthor=G.-F.+Haoauthor=G.-F.+Yang&title=ACID%3A+A+Free+Tool+for+Drug+Repurposing+Using+Consensus+Inverse+Docking+Strategy&doi=10.1186%2Fs13321-019-0394-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs13321-019-0394-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-019-0394-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DLi%26aufirst%3DC.-Z.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DSu%26aufirst%3DS.-W.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DACID%253A%2520A%2520Free%2520Tool%2520for%2520Drug%2520Repurposing%2520Using%2520Consensus%2520Inverse%2520Docking%2520Strategy%26jtitle%3DJ.%2520Cheminf.%26date%3D2019%26volume%3D11%26doi%3D10.1186%2Fs13321-019-0394-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, T. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swails, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitberg, A. E.</span></span> <span> </span><span class="NLM_article-title">MMPBSA.py: An Efficient Program for End-State Free Energy Calculations</span>. <i>J. Chem. Theory. Comput.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3321</span>, <span class="refDoi"> DOI: 10.1021/ct300418h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300418h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2gtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=3314-3321&author=B.+R.+Millerauthor=T.+D.+McGeeauthor=J.+M.+Swailsauthor=N.+Homeyerauthor=H.+Gohlkeauthor=A.+E.+Roitberg&title=MMPBSA.py%3A+An+Efficient+Program+for+End-State+Free+Energy+Calculations&doi=10.1021%2Fct300418h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">MMPBSA.py: An Efficient Program for End-State Free Energy Calculations</span></div><div class="casAuthors">Miller, Bill R., III; McGee, T. Dwight, Jr.; Swails, Jason M.; Homeyer, Nadine; Gohlke, Holger; Roitberg, Adrian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3314-3321</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MM-PBSA is a post-processing end-state method to calc. free energies of mols. in soln.  MMPBSA.py is a program written in Python for streamlining end-state free energy calcns. using ensembles derived from mol. dynamics (MD) or Monte Carlo (MC) simulations.  Several implicit solvation models are available with MMPBSA.py, including the Poisson-Boltzmann Model, the Generalized Born Model, and the Ref. Interaction Site Model.  Vibrational frequencies may be calcd. using normal mode or quasi-harmonic anal. to approx. the solute entropy.  Specific interactions can also be dissected using free energy decompn. or alanine scanning.  A parallel implementation significantly speeds up the calcn. by dividing frames evenly across available processors.  MMPBSA.py is an efficient, user-friendly program with the flexibility to accommodate the needs of users performing end-state free energy calcns.  The source code can be downloaded at http://ambermd.org/ with AmberTools, released under the GNU General Public License.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZK3C1jqiSULVg90H21EOLACvtfcHk0liUO5CmWmUUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2gtrzP&md5=cc4148bd8f70c7cad94fd3ec6f580e52</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fct300418h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300418h%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DMcGee%26aufirst%3DT.%2BD.%26aulast%3DSwails%26aufirst%3DJ.%2BM.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DRoitberg%26aufirst%3DA.%2BE.%26atitle%3DMMPBSA.py%253A%2520An%2520Efficient%2520Program%2520for%2520End-State%2520Free%2520Energy%2520Calculations%26jtitle%3DJ.%2520Chem.%2520Theory.%2520Comput.%26date%3D2012%26volume%3D8%26spage%3D3314%26epage%3D3321%26doi%3D10.1021%2Fct300418h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">FungiPAD: A Free Web Tool for Compound Property Evaluation and Fungicide-Likeness Analysis</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.8b06596</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.8b06596" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsleqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=1823-1830&author=M.-y.+Wangauthor=F.+Wangauthor=G.-F.+Haoauthor=G.-F.+Yang&title=FungiPAD%3A+A+Free+Web+Tool+for+Compound+Property+Evaluation+and+Fungicide-Likeness+Analysis&doi=10.1021%2Facs.jafc.8b06596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">FungiPAD: A Free Web Tool for Compound Property Evaluation and Fungicide-Likeness Analysis</span></div><div class="casAuthors">Wang, Meng-yao; Wang, Fan; Hao, Ge-Fei; Yang, Guang-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1823-1830</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing prevalence of fungal diseases, continual development of resistance, and stringent environmental regulation have revealed an urgent need to develop more selective, safer, resistance-breaking, and cost-effective fungicides.  However, most new fungicidal lead compds. fail in their late stages of development due to poor soly. or permeability, meaning they have suboptimal physicochem. properties.  Hence, the exploration of advanced technologies for compds. 'fungicide-likeness' assessment might overcome these obstacles and bring more chem. entities to market.  FungiPAD (http://chemyang.ccnu.edu.cn/ccb/database/FungiPAD/) is a free platform employed to predict physicochem. properties, bioavailability and fungicide-likeness swiftly and powerfully by using comprehensive approaches, such as physicochem. radars, qual. and quant. anal.  This platform contains data for over 16000 physicochem. descriptors, the results of 2200 qual. and 1100 quant. analyses of marketed fungicides, and provides comprehensive fungicide-likeness anal. for different compds.  The user-friendly interface facilitates interpretation and manipulation by non-computational scientist in support of fungicide discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRz5rSPirfu7Vg90H21EOLACvtfcHk0liUO5CmWmUUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsleqtL4%253D&md5=4b50ef4d1f1e38c520616c54977c5db2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.8b06596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.8b06596%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.-y.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DFungiPAD%253A%2520A%2520Free%2520Web%2520Tool%2520for%2520Compound%2520Property%2520Evaluation%2520and%2520Fungicide-Likeness%2520Analysis%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2019%26volume%3D67%26spage%3D1823%26epage%3D1830%26doi%3D10.1021%2Facs.jafc.8b06596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujahid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukrishnan, M.</span></span> <span> </span><span class="NLM_article-title">A New Enantioselective Synthesis of the Anti-Parkinson Agent Safinamide</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1756</span>, <span class="refDoi"> DOI: 10.1055/s-0033-1341104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1055%2Fs-0033-1341104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1amtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=1751-1756&author=A.+Reddiauthor=M.+Mujahidauthor=M.+Sasikumarauthor=M.+Muthukrishnan&title=A+New+Enantioselective+Synthesis+of+the+Anti-Parkinson+Agent+Safinamide&doi=10.1055%2Fs-0033-1341104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A new enantioselective synthesis of the anti-Parkinson agent safinamide</span></div><div class="casAuthors">Reddi, Anjaneyulu; Mujahid, Mohammad; Sasikumar, Murugesan; Muthukrishnan, Murugan</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1751-1756, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An alternative highly enantioselective synthesis of the anti-Parkinson agent safinamide from simple, com. available, starting materials is described.  The protocol might also be useful in the synthesis of structural variants of safinamide, such as ralfinamide or related analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf19y3UMaUILVg90H21EOLACvtfcHk0liUO5CmWmUUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1amtbbJ&md5=31d4bde2667bcd4ec1d724bac8927a96</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1341104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1341104%26sid%3Dliteratum%253Aachs%26aulast%3DReddi%26aufirst%3DA.%26aulast%3DMujahid%26aufirst%3DM.%26aulast%3DSasikumar%26aufirst%3DM.%26aulast%3DMuthukrishnan%26aufirst%3DM.%26atitle%3DA%2520New%2520Enantioselective%2520Synthesis%2520of%2520the%2520Anti-Parkinson%2520Agent%2520Safinamide%26jtitle%3DSynthesis%26date%3D2014%26volume%3D46%26spage%3D1751%26epage%3D1756%26doi%3D10.1055%2Fs-0033-1341104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, G.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-F.</span></span> <span> </span><span class="NLM_article-title">Cloud 3D-QSAR: A Web Tool for the Development of Quantitative Structure-Activity Relationship Models in Drug Discovery</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1093/bib/bbaa276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1093%2Fbib%2Fbbaa276" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Y.-L.+Wangauthor=F.+Wangauthor=X.-X.+Shiauthor=C.-Y.+Jiaauthor=F.-X.+Wuauthor=G.-F.+Haoauthor=G.-F.+Yang&title=Cloud+3D-QSAR%3A+A+Web+Tool+for+the+Development+of+Quantitative+Structure-Activity+Relationship+Models+in+Drug+Discovery&doi=10.1093%2Fbib%2Fbbaa276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbaa276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbaa276%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DX.-X.%26aulast%3DJia%26aufirst%3DC.-Y.%26aulast%3DWu%26aufirst%3DF.-X.%26aulast%3DHao%26aufirst%3DG.-F.%26aulast%3DYang%26aufirst%3DG.-F.%26atitle%3DCloud%25203D-QSAR%253A%2520A%2520Web%2520Tool%2520for%2520the%2520Development%2520of%2520Quantitative%2520Structure-Activity%2520Relationship%2520Models%2520in%2520Drug%2520Discovery%26jtitle%3DBriefings%2520Bioinf.%26date%3D2020%26doi%3D10.1093%2Fbib%2Fbbaa276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y.-K.</span></span> <span> </span><span class="NLM_article-title">Hederagenin and Alpha-Hederin Promote Degradation of Proteins in Neurodegenerative Diseases and Improve Motor Deficits in MPTP-Mice</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=10.1016%2Fj.phrs.2016.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=27838509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2017&pages=25-44&author=A.-G.+Wuauthor=W.+Zengauthor=V.+K.-W.+Wongauthor=Y.-Z.+Zhuauthor=A.+C.+Y.+Loauthor=L.+Liuauthor=B.+Y.-K.+Law&title=Hederagenin+and+Alpha-Hederin+Promote+Degradation+of+Proteins+in+Neurodegenerative+Diseases+and+Improve+Motor+Deficits+in+MPTP-Mice&doi=10.1016%2Fj.phrs.2016.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice</span></div><div class="casAuthors">Wu, An-Guo; Zeng, Wu; Wong, Vincent Kam-Wai; Zhu, Yi-Zhun; Lo, Amy C. Y.; Liu, Liang; Law, Betty Yuen-Kwan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-44</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pathogenesis of neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's disease (HD) are closely related to the formation of protein aggregates and inclusion body.  For instance, active autophagic components from Chinese herbal medicines (CHMs) are highlighted to modulate neurodegeneration via degrdn. of disease proteins.  In this study, the neuroprotective effect of the purified Hedera helix (HH) fraction contg. both hederagenin and α-hederin, is confirmed by the improvement of motor deficits in PD mice model.  Furthermore, hederagenin and α-hederin derived from HH are confirmed as novel autophagic enhancers.  Both compds. reduce the protein level of mutant huntington with 74 CAG repeats and A53T α-synuclein, and inhibit the oligomerization of α-synuclein and inclusion formation of huntington, via AMPK-mTOR dependent autophagy induction.  Both hederagenin and α-hederin induce autophagy and promote the degrdn. of neurodegenerative mutant disease proteins in vitro, suggesting the therapeutic roles of HH in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH-LNj0NxMXrVg90H21EOLACvtfcHk0lg16FOfI9eZSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjtb7K&md5=09222a752ae8a3621374a239c9aed87c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.-G.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DWong%26aufirst%3DV.%2BK.-W.%26aulast%3DZhu%26aufirst%3DY.-Z.%26aulast%3DLo%26aufirst%3DA.%2BC.%2BY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLaw%26aufirst%3DB.%2BY.-K.%26atitle%3DHederagenin%2520and%2520Alpha-Hederin%2520Promote%2520Degradation%2520of%2520Proteins%2520in%2520Neurodegenerative%2520Diseases%2520and%2520Improve%2520Motor%2520Deficits%2520in%2520MPTP-Mice%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D115%26spage%3D25%26epage%3D44%26doi%3D10.1016%2Fj.phrs.2016.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5Y','PDB','2Z5Y'); return false;">PDB: 2Z5Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5Z','PDB','2V5Z'); return false;">PDB: 2V5Z</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01663">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16888"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01663?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01663</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C NMR spectra of all new compounds; HPLC traces of final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_001.pdf">jm0c01663_si_001.pdf (3.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01663/suppl_file/jm0c01663_si_002.csv">jm0c01663_si_002.csv (1.86 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01663&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01663%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01663" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991b56e83f124c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
